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Trauma-induced secondary cardiac injury (TISCI) represents an under recognised 
complication of severe injury with haemorrhage. A limited number of clinical studies have 
supported the development of adverse cardiac events, such as arrhythmia, in association with 
biomarker proven TISCI. Pre-clinical studies using small animal models have provided 
insights into potential mechanisms and key effector molecules involved in the development 
of TISCI, but there remains a general lack of understanding regarding the in vivo functional 
implications of this indirect cardiac injury resulting from trauma-haemorrhage.  
This project aimed to investigate the implications of cardiac injury on myocardial systolic 
function. A robust, translatable model of TISCI was developed, which reflected the cardiac 
biomarker profile identified in clinical studies and, for the first time, demonstrated a 
significant, dose-dependent rise in Heart-type Fatty Acid Binding Protein (H-FABP) in 
response to trauma-haemorrhage. Non-invasive echocardiography was used to determine the 
acute myocardial response to injury and haemorrhage and also to assess the response of the 
left ventricle to resuscitation after an antecedent 60-minute period of trauma-haemorrhage.  
The functional studies presented here have enabled real time visualisation of the impact of 
trauma-haemorrhage upon systolic left ventricular function over 1 to 6 hours, both with and 
without resuscitation. Having established the trends in in vivo systolic function over time, 
further studies were then conducted to test the combination of adenosine, lidocaine and 
magnesium (ALM) as a cardiovascular rescue agent in TISCI. ALM, as an adjunct to fluid 
resuscitation, has shown great promise as a therapeutic agent which improves haemodynamic 
outcomes, reduces the volume of resuscitation fluid required and favours survival in the 
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1.1 Trauma: The Nature of the Disease 
Trauma is a globally prevalent, common disease with a wide severity spectrum, which 
typically, but not exclusively, afflicts the young. Injury is the predominant cause of death in 
adolescence to middle age with trauma being the leading cause of death in the 15 to 44 year 
old age group. Given the disease’s propensity to affect the young, trauma is the leading cause 
of life years lost worldwide (WHO 2017).  
Physical trauma results from penetrating or blunt injury sustained due to inter-personal 
violence, such as assault and stabbing, falls and more commonly, road traffic collisions 
(RTC). Major (sometimes referred to as complex) trauma, can be defined as serious injuries, 
affecting a number of body systems, which pose a significant risk of death or disability.  
As with other common diseases, prevention is preferable to cure; however the nature of 
traumatic injury means that although there are opportunities to limit severity, such as 
legislative changes such as the introduction of laws relating to seat-belts and workplace 
health and safety initiatives, we are unlikely to eradicate the condition.  
There are multiple phases in the progression of this disease, commencing at the scene of 
injury. These phases can be regarded as offering different points of opportunity where 
appropriate intervention is vital in limiting severity and ensuring improved patient outcomes.  
Clinical management of trauma patients aims to restore meaningful life after injury. Trauma 
research is vital to equip clinicians with the techniques and expertise required to manage 
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complex patients with life-threatening physiological derangement in order to optimise patient 
outcomes. 
1.1.1 Epidemiology 
Trauma is the causative factor in millions of deaths annually internationally and is the sixth 
leading cause of death worldwide (Soreide K, 2009). In England and Wales, 12,500 people 
die due to physical injury every year according to data released by TARN in 2016 (Trauma 
Audit and Research Network, UK). The magnitude of the public health challenge becomes 
clearer when one considers that for every death due to trauma, there are two survivors left 
with life-changing disability (NICE 2013). 
1.25 million deaths annually worldwide are attributable to RTCs and road traffic injuries are 
the leading cause of death in the 15-29 year old age group. Males are more likely to be 
involved and 73% of all RTC related deaths occur in men under the age of 25 (WHO 2017).  
Death related to road traffic collisions remains the leading cause of death in the people aged 
between 15 and 44 years of age in the United States and the fourth leading cause of death 
overall when all ages are considered (CDC 2015). In 1990, road injuries and interpersonal 
violence claimed 73,680 lives in the U.S. There has however been a decline in these figures 
with 12,650 fewer deaths due to these modes of injury (GBD 2013, published in The Lancet).  
The trends seen in the U.S may point to improvement, but regardless of these figures, injury 
still kills significant numbers of people annually and survivors face challenges relating to 
morbidity. Globally, deaths resulting from injury represent 8.8% of all mortality; a figure 
which, incidentally, has not changed since 2000. Road traffic collisions are the leading cause 
of deaths when unintentional injury is considered (WHO 2015).  
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The WHO reports on the burden of diseases globally. The mortality and morbidity related to 
disease is quantified in terms of Disability-adjusted life years (DALYs) and RTCs were the 
leading cause of DALYs lost in 15 to 19 year old males (WHO 2015). 
1.1.2 Death due to injury 
Death as a result of injury can be defined as an acute, early or late event. Advances in the 
care of injured patients mean that more patients are surviving to reach hospital. Some deaths, 
however, remain sadly inevitable. Central nervous system (CNS) injury, such as catastrophic 
brain or spinal cord injury, obviously lead to rapid, predictable fatality. 
Uncontrolled haemorrhage with resultant exsanguination is also a cause of acute and ‘early’ 
death (defined as being within 3 to 7 days of sustaining injuries) and CNS injury, not severe 
enough to cause instant death, along with uncontrolled bleeding, represents another cause of 
early deaths (Sauaia et al 1995 and Kauvar et al 2006).  
A prospective study carried out by 22 major trauma centres and smaller trauma units in the 
United Kingdom demonstrated the prevalence and outcomes associated with trauma and 
major haemorrhage (Stanworth et al 2016). Over the duration of the study, 442 patients had 
injuries severe enough to trigger the activation of a massive haemorrhage protocol. Patient 
outcomes were poor with high early mortality. Two thirds died within 24-hours and of these, 
50% did not survive beyond 4 hours of their arrival to the emergency department. The death 
rates were highest for those patients requiring a ‘massive’ blood transfusion (defined as being 
the administration of 10 or more units of packed red blood cells over the first 24 hours of 









Figure 1.1. Mortality associated with major and massive haemorrhage.  
A. Mortality with major and massive haemorrhage at 3 hours, 24 hours, in-hospital and at 1 
year. B. Mortality within the first 24 hours of presentation with major haemorrhage. Patients 
receiving at least 4 units of packed red blood cells (PRBC) were eligible and defined as 
experiencing ‘major’ haemorrhage. Massive transfusion was defined as 10 or more units of 
PRBC being administered within the first 24 hours (Figure adapted from Stanworth et al, 
2016 and used with permission).  
 
Study data was used to estimate the national incidence of major trauma-haemorrhage and 
associated mortality. England and Wales were estimated to have 5000 patients with major 
trauma-haemorrhage annually and one third of these will die as a result of their injuries.  
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Life-threats change over the hours and days of a patient’s admission. Multiple organ failure 
(MOF) after trauma has been shown to occur in a bimodal distribution in survivors. The first 
peak is seen in the 1st 3 days after injury with the second being seen at 5-7 days. (Durham et 
al 2003). MOF is the most common cause of late (after 7 days) deaths after trauma (Sauaia et 
al 1995).  
A study by Probst et al in 2009 analysed patient records spanning up to 3 decades after initial 
injury. Cardiovascular disease (including arrhythmia) accounted for the majority (37%) of 
late deaths and trauma survivors had a significantly higher mortality compared to an age and 
gender matched cohort during the first 12 months after injury. This study gives some insight 
into the cause of death in trauma patients in the months and years following injury, but this is 
otherwise a relatively overlooked area of research. 
1.1.3 The impact upon the individual 
Personal health and well-being may be affected in ways apart from the more obvious 
outcomes of death and disability. Exposure to violence for example, can increase the risk of 
smoking, illicit substance abuse, mental illness and suicidality (WHO 2017). The health 
implications associated with trauma can therefore be wide ranging and chronic. There is also 
an association with crime and importantly, further acts of violence thereby creating a cycle of 
violence which generates further victims. In a retrospective study of trauma survivors, 19% 
of those surviving to be discharged later died due to a second major trauma (Probst et al 
2009).  
Trauma survivors have experienced significant psychological as well as physical upset. They 
may face significant changes in their social standing and personal relationships due to their 
loss of ‘health’. Scarring and loss of limbs may result in issues surrounding self-image 
(perhaps particularly relevant in societies which place a great emphasis on physical 
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appearance). Self-esteem may also be negatively affected if survivors are unable to return to 
work or follow career paths which had been previously open to them before their injury.  
A study of functional outcomes after trauma used standard measures of functional well-being 
and found that 16% of the trauma survivors questioned reported a reduction in well-being 
after hospital discharge (Kauvar et al 2006). 
A study by Probst et al in 2009 looked at late deaths after severe trauma (ISS of 16 or more) 
and reported that 10% patients surviving to be discharged from hospital subsequently went on 
to commit suicide.  
The American Trauma Recovery Project (TRP) was a prospective study which evaluated 
multiple factors, including functional and psychological outcomes up to 18 months after 
severe injury. The study employed a standardised quality of life measure (QWB scale) and 
revealed that at the 12-month follow up point, only 18% of patients questioned reported 
restoration of normal functional outcomes and when reassessed at 18 months, there had been 
no significant improvement in their situation. The length of admission to critical care as a 
consequence of injury was identified, along with post-injury depression and emergence of a 
post-traumatic stress disorder, as an independent predictor of outcome (Holbrook et al 1999).  
As survival after injury improves, the physical and psychological sequelae of trauma and its 
impact upon rehabilitation and restoration of an acceptable quality of life should not be 
underestimated. 
1.1.4 The impact upon society 
Caring for injured patients is expensive. RTCs alone are estimated to cost most countries 3% 
of their gross domestic product (WHO 2017). Lengthy hospital admissions, critical care, 
surgery and rehabilitation are associated with significant costs to health services.  
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Trauma is, as discussed, a disease of the young and as such, injury can impact upon the 
financial contribution that younger citizens are able to make which can be thought of as 
‘productive years lost’.  Family members may have to leave work in order to become carers. 
Other financial implications to society include costs related to legal considerations such as 
prosecutions and imprisonment. The Morgan-Jones report (2011) states that complex trauma 
costs the NHS £0.3 to £0.4m per annum with a long-term cost to the UK economy of in 
excess of £3.5 billion pounds per annum. European studies published in the 1990s reported 
that only 42 to 50% of trauma survivors were back in employment at 2 years. (Holbrook 1999 
and Vasquez 1996).  
The ability to restore meaningful, fulfilling, productive life after injury has important 
benefits, not just for the individual, but for society as a whole. 
1.2 Trauma Research in the United Kingdom 
In 1988 a working party chaired by Professor Sir Miles Irving at the Royal College of 
Surgeons of England concluded that a significant proportion of trauma deaths were 
preventable and related to inadequate delivery of medical care. A number of 
recommendations were made based upon this including improvement of pre-hospital care, 
rapid transfer of patients with the use of air ambulances and the auditing and research of 
injury and trauma systems.  
By 1992, 33 UK hospitals had, by using an agreed methodology, analysed the effectiveness 
of their trauma facilities (TARN 2016). Results were published in the British Medical 
Journal, thereby disseminating the information to a wider audience and generating further 
interest in improving the management of trauma patients.  
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The Rand report (Morgan-Jones et al 2011) identified that trauma was an important but 
relatively poorly funded area when allocation of research funding in the UK was assessed. 
Less than 1% of total UK funding of health research was allocated to trauma research.  
This relative underfunding by no means reflects the substantial need for improvement in the 
care of injured patients in the U.K. There is a need to broaden the horizons of trauma research 
in order to address the current issues in both the pre-hospital and in-patient settings and 
identify those points within the patient’s journey where novel treatments and interventions 
can improve clinical outcomes. 
1.2.1 Recent advances in the care of the injured patient 
Improvements in trauma care can be regarded as clinical and organisational and the success 
of one is dependent upon success of the other. The Rand report (Morgan-Jones et al 2011) 
commissioned by the U.K’s Department of Health, stated that there were ‘fewer than five, 
and possibly no more than two, centres in the UK capable of handling major trauma cases’. 
There was a recommendation that the field was under-resourced, translational research was 
not occurring quickly enough, and ‘clinical gaps’ needed review and an assessment of 
whether current research were addressing these gaps.  
The key findings of this report have been, in part, addressed and as of October 2016, the UK 
has 27 hospitals with major trauma centre status; 4 in London alone and a number 
specialising in paediatric trauma (www.nhs.uk). Major trauma centres offer 24 hour dedicated 
trauma teams, led by senior clinicians. An integrated, multidisciplinary approach involving 
departments as diverse as radiology and the blood transfusion laboratory, offers a co-
ordinated approach to the management of the patient.  
There is an emphasis on a protocol led approach to trauma patients with triage aimed at 
ensuring an appropriate response. An example of this is the declaration of a ‘code red’ in 
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response to on scene physiological derangement and preparation to transfer the patient to 
theatre as soon as possible after arrival. Cole et al in 2017 reported that the introduction of a 
co-ordinated trauma system in London had resulted in vast improvements in terms of access 
to hospital trauma specialists on arrival with higher rates of senior clinician involvement and 
improved rates of survival in critically ill trauma patients (Cole et al 2017). 
There are many points on the trauma patient’s journey which can be viewed as opportunities 
to intervene to limit mortality and morbidity.  This starts at the scene of the injury. A 
retrospective analysis at a single centre over the course of 3 decades reported a significant 
reduction in transfer times of patients from scene to the definitive care centre with the use of 
helicopters (Probst et al 2009). The use of air ambulances such as the Helicopter Emergency 
Medical Services (HEMS) in the U.K, has led to swifter arrival of specialist teams with 
trauma-specific expertise with notable successes. The personnel on board the helicopters has 
not been the only positive factor; the availability of blood on board has allowed for newer 
strategies of initial fluid resuscitation of bleeding patients to be implemented in the first hour 
after injury.  
The use of tranexamic acid represents another success story in trauma research. The CRASH-
2 trial concluded that early administration of tranexamic acid significantly reduced all-cause 
mortality when given to bleeding trauma patients and tranexamic acid is currently included in 
code red protocols in the UK.  
Transfusion protocols including high-dose fresh frozen plasma for major haemorrhage have 
been shown to confer survival benefit to patients, even within the first 3 hours of presentation 
to the emergency department when mortality rates are high (Stanworth et al 2016).  
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Identification of the major barriers to delivering effective trauma care and an appreciation of 
the need for research have been instrumental in making demonstrable improvements in the 
U.K’s delivery of these services. 
1.3 Organ Dysfunction after Trauma 
Improvements in the acute management of injured patients have however been associated 
with a shift in the development of complications and associated mortality and morbidity. 
Improvements in pre-hospital care for example, mean that more people are surviving injuries 
which would have previously resulted in swift death at the scene. Such patients however have 
experienced severe physiological derangement necessitating aggressive treatment strategies. 
More may be surviving to reach a definitive care centre however, the majority will require 
prolonged resuscitation, immediate surgery, and critical care.  
The patient may have survived the acute phase, but the issues may be best demonstrated with 
the finding that the incidence of multiple organ failure (MOF) after trauma rose over a period 
of 3 decades with improvement in acute and early pre-hospital and inpatient care (Probst et al 
2009). Gains on one hand can be associated with losses on the other in the context of the 
physiological maelstrom of severe trauma. 
Organ dysfunction and failure after trauma is a significant problem and multiple organ failure 
(MOF) is the leading cause of late deaths (Frohlich et al 2014). The incidence of MOF after 
trauma follows a bimodal pattern with the first peak occurring in the first 3 days, and the 






Multiple organ failure (MOF) is currently thought to affect 15 – 40% of severely injured 
patients, the incidence may vary in part due to the use of different assessment and scoring 
systems across centres and, perhaps more fundamentally, a lack of a single, accepted 
definition (Dewar 2014). A study of adult trauma patients admitted to intensive care revealed 
that 47% developed failure of multiple organ systems (with cardiovascular failure featuring in 
85% of cases). Whereas failure of a single organ was associated with low mortality, MOF 
was shown to be associated with a 6-fold overall increased risk of death (27% of patients 
admitted who developed MOF died). MOF survivors had a nearly 4 times greater risk for 
requiring long-term assistance with personal care and daily activities on discharge from 
hospital (Ulvik et al 2007). The importance therefore of early recognition and prompt 
treatment to prevent and / or limit organ dysfunction and failure cannot be overemphasised.  
Multi-organ dysfunction syndrome (MODS) is a newer term which recognises a continuous 
process of organ dysfunction in which the contribution of each organ can be variable rather 
than the ‘all-or-nothing’ model of multi-organ failure described in the 1970s.  
It is important to recognise that failure of organs in this way after trauma is not a direct result 
of injury; acute kidney injury for example does not refer to direct renal injury with resultant 
loss of function. Visceral dysfunction after injury is not necessarily a consequence of 
mechanical disruption sustained by the organ but rather due to a culmination of physiology 
related to injury and the interventions undertaken to resuscitate and stabilise the patient. The 
precise pathophysiology of organ dysfunction after trauma remains poorly understood. There 
is evidence for the involvement of pro-inflammatory pathways, initiated at the time of injury 
to promote survival, becoming self-harming and mediating organ damage in the later stages 
(Tsukamoto et al 2010). The exact contribution of inflammation to organ dysfunction 
syndromes is a widely researched area and much remains unclear.  
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It is perhaps not heresy to speculate that trauma survivorship will plateau when the acute and 
early, preventable deaths are all but prevented but the organ failure and dysfunction 
experienced whilst on critical care and beyond contribute to later morbidity. There needs to 
be more focus therefore, on strategies to identify, prevent and treat organ injury occurring 
indirectly as a result of trauma. 
1.3.1 Organ failure scoring systems and measures of cardiac outcome 
Similarly to the adoption of scoring systems to grade injury severity (such as the Injury 
Severity Score or ISS), a number of scoring systems exist in critical care and indeed trauma 
research to identify and monitor organ outcomes after injury. Scoring systems have been in 
use for decades to study and predict patient outcomes. The Acute Physiology and Chronic 
Health Evaluation (APACHE) II and III, the Simplified Acute Physiology Score (SAPS) II 
have been widely adopted in critical care. The Sequential Organ Failure Assessment (SOFA) 
is a more recent, validated addition and the Denver Post-injury Multiple Organ Failure Score 
is also used to grade severity of MOF after trauma.  
Different centres employ different scoring systems and each has its strengths and limitations. 
The basic premise however remains largely the same. Physiological parameters from the 
different organ systems are used to generate cumulative scores which indicate severity of 
organ dysfunction and associated mortality. Cardiovascular parameters are scored in each of 
the systems with heart rate and blood pressure recordings contributing to the scoring. The use 
of cardiovascular drugs such as noradrenaline also featuring as an indicator of severity of 
cardiovascular dysfunction and the level of organ support that is required by the patient.  
1.4  Direct Cardiac Injury 
When the heart is wounded directly, be it with a knife or as a result of an unrestrained driver 
accelerating forwards into a steering wheel, this is regarded as direct cardiac injury. Incised 
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wounds to the heart, such as would be experienced with a sharp, penetrating object, carry a 
high mortality rate and will require immediate surgical intervention in most cases. 
1.4.1 Blunt cardiac injury 
Direct, blunt cardiac injury (BCI) results from the transfer of energy to the thorax, of a 
magnitude that will deliver an impact to the myocardium. Such an injury may be ‘silent’ with 
no clinically appreciable outcome. In some cases however, the impact is enough to cause 
myocardial bruising (contusion), and more serious injury however may induce arrhythmia 
(Guan et al 2007, Ismailov 2007) which can lead to sudden cardiac death as in the case of 
commotio cordis. In some cases, the impact and energy transfer is enough to result in 
mechanical disruption of the heart with muscle rupture (Maron & Estes 2010).  
Blunt cardiac injury has been demonstrated to be associated in a 2.6 fold increase in AMI in 
trauma patients aged 46 or younger and the development of AMI was independent of pre-
existing coronary artery disease (Ismailov et al 2005). 
In such cases, there is a suggestion that the acceleration-deceleration forces and direct blunt 
chest trauma experienced leads to damage to the intima of coronary arteries and, even in the 
absence of atherosclerosis, could precipitate clot formation and resultant myocardial 
ischaemia.  
The treatment of blunt cardiac injury is mainly aimed at the complications which may arise. 
Mild contusions may instigate serial electrocardiograms (ECGs) and cardiac biomarker 
assessment with little else and generally are not a cause for immediate concern. Arrhythmia 





1.5 Indirect, Secondary Cardiac Injury 
There is a relative paucity of clinical research into the trauma-induced secondary cardiac 
injury (TISCI) that occurs as an indirect consequence of injury. Most of the evidence for this 
organ injury and dysfunction has been reported from pre-clinical studies. Studies related to 
TISCI generally speaking investigate how the condition manifests clinically (for example the 
development of arrhythmia), how the myocardium demonstrates injury with the release of 
cardiac specific biomarkers or how cardiomyocyte damage is apparent on histological and 
post-mortem studies. 
1.5.1 Autopsy and histology of cardiac injury after trauma 
A number of studies have been conducted investigating the clinicopathological correlation 
between cardiac lesions and shock. Left ventricular abnormalities found at autopsy include 
sub-endocardial haemorrhages and the term ‘shock lesion’ has been applied to these in the 
past due to the association with shock states (Sevitt. 1970).  
A retrospective study of 15 patients who had been subjected to physical assault and died 
during their original inpatient admission, was conducted in order to investigate any link 
between sudden death and the ‘stress’ associated with violence. Myofibrillar degeneration 
and contraction band necrosis was seen in 11 out of the 15 cases when cardiac histology was 
performed. This was interpreted as evidence for ‘stress cardiomyopathy’ and no similar 
histological finding was seen when compared with a cohort of age and cardiac disease 
matched controls. In 1 case, there was evidence that the patient had experienced arrhythmia 
during their admission. The researchers concluded that the findings were similar to those seen 
in animal models and represented catecholamine-mediated cellular changes initiated due to 
the assault (Cebelin et al 1980).  
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Despite the small size of the study by Cebelin et al, more recent work has also reported 
similar microscopic changes in the myocardium of trauma patients. After demonstrating the 
presence of calmodulin in myocardial tissue taken from a canine model of regional 
ischaemia, Yoshida et al went on to demonstrate that this early indicator of cardiac ischaemia 
and necrosis was also present in human tissue after death due to a variety of trauma 
mechanisms. They also supported the previous work of Cebelin et al with the identification 
of contraction band formation and myofibrillar degeneration, interpreted as being related to 
trauma rather than pre-existing cardiac disease. The most severe microscopic abnormalities 
were seen in a patient after RTC who was shocked and required ‘intense resuscitation for 2 
hours’ before death. In this case, subendocardial haemorrhages were also noted (Yoshida et 
al, 1992).  
The development of sub-endocardial haemorrhages in association with a number of 
conditions including trauma and haemorrhage have been recognised for some time. In the 
1970s, a paper published in Forensic Science journal reported that particular areas of the 
heart, such as the sub-endocardium and papillary muscles, appeared to be at particular risk for 
the development of lesions. A ‘general hypoxic cardiovascular injury’ was described as 
occurring as a result of acute blood loss and progressing to cause complications in the longer 
term (Rajs. 1977).  
A more contemporary, prospective post-mortem study has also reported the finding of sub-
endocardial haemorrhage in victims of trauma. 125 hearts were assessed grossly and 
microscopically with the aim of determining the incidence and significance of myocardial 
lesions resulting from trauma (including burns). Patient survival ranged from 4 to 12 hours, to 
over 1 month. None of the hearts showed evidence of coronary pathology grossly, however a 
variety of microscopic abnormalities were noted in 25 of the hearts. These ranged from 
interstitial oedema and mononuclear cell infiltrates, to fibrosis and hypertrophy. 13.6% of 
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hearts examined demonstrated microscopic changes consistent with sub-endocardial 
haemorrhage with the vast majority of these being seen in patients who had experienced 
‘mechanical trauma’ rather than burns. The development of sub-endocardial changes 
occurred early (nearly half of hearts examined in cases where the patient had died within 12 
hours featured these changes) and in almost all of the cases where the heart had myocardial 
changes, hypotension had been a feature of the patients’ clinical presentation (Gawande et al 
2014).  
The development of sub-endocardial haemorrhage, in the absence of direct thoracic trauma, is 
particularly interesting as it is the sub-endocardium that contains the specialised 
cardiomyocytes that form the Purkinje fibres of the heart’s conduction system. One may 
speculate that the early onset of histological changes reported in this anatomical region may 
contribute to the development of later aberrant conduction. Unfortunately, the study had 
significant limitations, including the absence of data regarding severity of injury grade and 
incidence of arrhythmia and it is therefore difficult to fully establish the clinical relevance of 
the microscopic lesions detected. It is also unclear whether the development of sub-
endocardial lesions in these cases were due to the initial injury or subsequent resuscitation 
attempts.  
Post mortem studies such as the ones discussed here have considerable limitations. Firstly, 
they are typically retrospective and of small size. Post mortem histology can be difficult to 
interpret given tissue degradation and the clinical significance of any histological changes 
seen is of uncertain significance clinically. They often lack the details relating to severity of 
injury (such as ISS) and other clinical considerations and therefore it is more difficult to draw 
conclusions about the risks for the development of myocardial injury and how this manifests 
clinically. The administration of vasopressors, such as noradrenaline, may also contribute to 
ischaemic lesions due to coronary arterial constriction, but it is difficult to establish the role 
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of exogenous catecholamines in the development of these cardiac lesions.  The limited 
number of studies however, report mutually supportive findings and do shed some light onto 
the timing and nature of the cellular damage experienced by the left ventricle as a result of 
trauma and haemorrhage. 
1.5.2 Clinical manifestations of TISCI 
One of the earliest studies relating to cardiac outcomes was performed retrospectively and 
took the form of a patient record and ECG review of patients admitted to critical care. It 
included 107 injured patients out of a population of 2,820 intensive care patients. 
Approximately 10% of the injured developed atrial tachyarrhythmias (Artucio et al 1990). A 
significant association between arrhythmia and mortality was not proven.  
In 2011, Hadjizacharia et al reported the findings from a retrospective study spanning 7 years 
and designed to investigate incidence of and outcomes from atrial arrhythmias (including 
fibrillation, flutter and supraventricular tachycardia (SVT)) after trauma and in the critical 
care setting. 3499 patients were admitted over the study period and 6% developed an atrial 
arrhythmia (AA). The development of an AA was associated with older age, female gender 
injury severity and blunt trauma. AA was found to be an independent risk factor for mortality 
and if beta-blockers were administered to treat the AA, this was associated with a reduced 
mortality (Hadjizacharia et al 2011).  
As well as arrhythmia, a link between injury and acute myocardial infarction (AMI) had 
previously been proposed. In a retrospective study of over 11,000 trauma patients, 19 
developed an AMI and 5 were identified as experiencing an AMI truly related to injury. If 
AMI developed, it tended to be in older patients with previous comorbidities which 
predisposed to infarction (Moosikasuwan et al 2000).  
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The studies outlined above lend some support to the association between trauma and the 
development of adverse cardiac events (ACE) such as arrhythmia and MI but they do have 
significant limitations. Firstly, they are retrospective and involve a very small number of 
patients who actually developed the cardiac complication in question. Both studies focus on 
one specific ACE only and in the case of the 2000 study, patients who had experienced direct 
thoracic trauma were not excluded. Hadjizacharia’s study included patients admitted to 
critical care for a variety of reasons and the trauma patients only represented a proportion of 
patients studied. The lack of detail including injury severity score and comorbidity for 
example also limits the utility of these studies in drawing conclusions about the association 
between non-cardiac trauma and incidence of ACE.  
A larger study, although still retrospective, was published in 2005 and, involving more than 1 
million American trauma patients, makes for more convincing reading (Ismailov et al, 2005). 
The risk of AMI after trauma was greatest in patients who had suffered direct, blunt cardiac 
injury (independent of pre-existing coronary artery disease) but injury to sites distant from 
the thorax such as the pelvis, was also associated with the development of ACE such as 
infarction. Coronary angiography findings confirmed that AMI was occurring via a non-
atherosclerotic mechanism.  The authors suggest that blunt trauma to the lower abdomen and 
pelvis may exert abnormal hydrostatic pressures leading to an increase in shear stresses 
which could potentially damage endothelium and in some cases, rupture coronary arteries.  
The study was the first to give evidence for trauma as a risk factor for AMI but did not 
comment on outcomes, incidence of other forms of ACE and, as a retrospective study, is 
subject to some of the limitations encountered in other clinical studies already discussed. 
The following year, another study looking at atrial arrhythmia in critically ill trauma patients 
was published (Seguin et al 2006). The design of the study addressed some of the limitations 
of preceding work; namely that it was carried out prospectively, it looked specifically at 
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trauma patients rather than intensive care admissions as a whole, and more clinical 
information was available (such as injury severity and organ dysfunction scores). Some 
important findings were reported. These were that AA occurrence could be an indicator of the 
overall illness severity after injury and that the presence of systemic inflammatory response 
syndrome (SIRS), a recognised physiological occurrence after severe injury, was a risk factor 
for the development of atrial fibrillation (AF) in these patients. The severity of injury was 
also linked to the development of AF (over half of the patients who developed AF had 2 or 
more body regions injured).  
Mortality rates have not been proven to be associated with the development of arrhythmia in 
the studies discussed. Despite this, the development of such a cardiac complication has 
significance clinically as it results in administration of drugs such as beta blockers, and could 
potentially lengthen a patient’s stay in a critical care setting due to the need for continuous 
cardiac monitoring and treatment.  
What is striking about the studies previously discussed here is that although functional 
cardiac outcomes were investigated following trauma, biochemical indicators of 
cardiomyocyte injury were not analysed as a method by which to detect and characterise 
cardiac injury and adverse events. Cardiac specific biomarkers have been an integral part of 
the work-up and monitoring of patients with acute cardiac events for decades. Point of care 
testing of troponins for example have provided a rapid, sensitive and specific means of 
stratifying risk of acute myocardial infarction for many years. An appreciation of the risk for 
cardiac injury in trauma has existed for a while and some critical care units routinely screen 
trauma patients for troponin rises in the 1st 24 hours after injury (Martin et al 2005).  
In 2012 however, De’ath et al. conducted a retrospective study aiming to lend support to the 
existence of TISCI and investigate associated outcomes. 135 trauma patients requiring 
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intensive care admission were included. Data regarding injury severity, mechanism of injury, 
daily physiological data and survival were analysed.  
The development of arrhythmia, AMI, angina, cardiogenic and cardiac shock were regarded 
as ACE. The study found that 13.3% of patients recruited developed ACE (most often SVT, 
with atrial fibrillation included within this classification) and these outcomes were more 
common in patients over 50 and those with pre-existing cardiac diagnoses. There was also an 
association between severity of injury and subsequent development of cardiac complications. 
Interestingly, 5 out of the 18 patients who developed ACE were under 50 years old and had 
no pre-existing cardiac history and were on no medication. This study also supported earlier 
studies with the observation that ACE could occur in the absence of direct thoracic injury. It 
was the first to perform biochemical analysis of well characterised cardiac biomarkers 
troponin I (TnI), brain natriuretic peptide (BNP) and heart fatty acid binding protein (H-
FABP).  Significantly higher admission biomarker levels were seen in those patients who 
developed ACE and in these patients, H-FABP and BNP remained elevated compared to 
patients without ACE at 24 and 72 hours. Patients who developed an ACE were more than 
twice as likely to die.  
An association between the pro-inflammatory cytokine IL-6 and H-FABP was noted lending 
support for the previously postulated link between inflammation and secondary cardiac 
injury.  
Following on from this study, De’Ath et al investigated the association between TISCI and 
inflammation in an attempt to elucidate some of the mechanisms underlying the cardiac 
injury previously reported to be associated with ACE and mortality. Cardiac biomarkers and 
cytokine levels were assessed at admission, 24 and 72 hours. They concluded that even at this 
acute stage after injury, there is an association between inflammation, cardiac injury and 
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ACE. Moreover, if cytokine levels AND cardiac biomarkers were both elevated on 
admission, there was a higher in-patient mortality rate. Therefore, this study lends support to 
the mechanistic theories regarding the contribution of post-traumatic inflammation to the 
development of TISCI which is associated with poorer clinical outcomes.  
Naganathar et al in 2015 published the first prospective study investigating Trauma-
Associated Cardiac Injury and Dysfunction, (TACID). This study confirmed the earlier 
findings from retrospective work regarding admission cardiac biomarker profiles and 
subsequent ACE development and increased mortality (Naganathar et al 2015). Again, 13% 
of trauma patients recruited developed an ACE with SVT (including atrial fibrillation) being 
the most frequent manifestation. Older patients tended to be at higher risk for experiencing an 
ACE but 50% of the ACE ‘positive’ patients were younger than 45 and with no history of 
cardiac disease.  Nearly a third of those developing ACE were below 30 years of age. Patients 
with thoracic injury however were not excluded and indeed over half (59%) of the ACE 
group had experienced chest trauma.  
Many of the studies discussed did not assess the clinical outcomes relating to ACE 
development. Naganathar et al however reported that there was an association between 
development of a cardiac complication and a longer critical care and overall hospital stay. 
The association between admission catecholamine levels and cardiac injury was also 
investigated and suggested that adrenaline (epinephrine) concentrations on admission were 
strongly associated with TISCI development.  
Questions still remain regarding the underlying pathophysiology of TISCI and functional 
implications associated with the development of this complication; both in the acute and early 
stages after injury, longer term consequences and how cardiac injury and dysfunction actually 
contribute to the increased associated mortality and morbidity. 
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1.5.3 Cardiac biomarkers in TISCI 
Cardiac specific biomarkers have been an integral part of the work-up and monitoring of 
patients with acute cardiac events for decades. Point of care testing of troponins for example 
have provided a rapid, sensitive and specific means of stratifying risk of acute myocardial 
infarction. An appreciation of the risk for cardiac injury in trauma has existed for a while and 
some critical care units routinely screen trauma patients for troponin rises in the 1st 24 hours 
after injury (Martin et al 2005).  
It has been recognised for some time that cardiac biomarkers can be elevated in critically ill 
patients and this is not always a result of acute myocardial infarction resulting from coronary 
artery occlusion. (Lim et al 2006).  A study involving 1081 trauma patients showed that 
Troponin I was elevated in 29% and a ‘high’ TnI (>5μg/L) was associated with a 44% 
mortality rate. Direct myocardial, or indeed thoracic injury however was not an independent 
predictor of raised TnI concentration. The authors concluded that elevated TnI post injury 
was related to overall burden of physiological disruption and not necessarily due to direct 
cardiac injury (Martin et al 2005). In another study, 35% of trauma patients admitted to 
critical care had elevated TnI in the absence of chest injury and elevated TnI was associated 
with hypotension and the development of MODS (Edouard et al 1998).  
The development of cardiac complications after trauma-haemorrhage has been shown to be 
associated with blood levels of well recognised cardiac biomarkers such as H-FABP and 
troponin. De’ath et al in 2012 reported that serum biomarkers were elevated at point of 
admission to hospital and were associated with the subsequent development of ACE. For 
example, H-FABP was found to be 3 times higher in patients who later developed an ACE 
when compared to the levels of those who did not. H-FABP and BNP were detected early on 
in the admission of trauma patients with troponin rising later. 12 and 24 hour troponin levels 
were significantly higher in patients suffering an ACE compared to those who did not 
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experience cardiac complications. Not only was H-FABP found to be an early indicator of the 
risk of subsequent ACE, it was also found to correlate with the severity of injury with the 
highest levels being seen in those with the highest ISS. In 2015, Naganathar et al also 
reported the results of Trauma Associated Cardiac Injury and Dysfunction (TACID) study, a 
prospective study involving 300 trauma patients admitted to an urban major trauma centre. 
TACID echoed some of the findings from earlier work regarding biomarker levels and ACE 
incidence but also found that the development of ACE was associated with longer critical 
care and hospital admission and a 3-fold increase in hospital mortality rate (Naganathar et al 
2015).  
There are of course multiple factors to be considered when interpreting these results but these 
findings do lend weight to the argument regarding early development of cardiac injury and 
ACE after TH and also the utility of cardiac biomarkers in the both detection and risk 
stratification of patients for cardiac injury and dysfunction after TH. 
1.5.4 H-FABP as a biomarker of TISCI 
H-FABP is a small protein located in the cytosol of cardiomyocytes. It has a low plasma 
concentration under normal circumstances and it was first recognised as a marker of 
myocardial injury by Glatz et al in 1988. It is released rapidly during periods of cardiac 
ischaemia and has been demonstrated to identify AMI within 4 hours of symptom onset 
(McCann et al 2008).  Immunohistochemistry studies demonstrated rapid decline in H-FABP 
from cardiomyocytes with reduced or absent immunoreactivity detected at 60 minutes of 
ischaemia (Watanabe et al 2003).   
An autopsy study demonstrated that H-FABP was depleted from the myocardium of patients 
with sudden cardiac death (Kilcullen et al 2007), but the corresponding electron microscopy 
studies did not show features of myocyte necrosis. It can therefore be regarded as an early 
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indicator of cardiac ischaemia, even in the absence of established myocyte necrosis and in 
this way, can be regarded as superior to troponin in the detection of early myocardial 
ischaemia. 
H-FABP is therefore particularly relevant as a biomarker in TISCI studies where regional 
ischaemia secondary to coronary occlusion is no necessarily present and therefore the 
associated myocyte damage may be more subtle. H-FABP has been described as an 
“excellent early marker” of myocardial injury in the context of heart failure and unstable 
angina in particular (Pelsers et al 2005).  
H-FABP has utility not only in detecting acute episodes of ischaemia, but there is also 
evidence that it has a role in prognostication after cardiac ischaemia, being predictive of 
mortality post MI across a range of troponin concentrations (Kilcullen 2007). H-FABP has 
also been shown to identify patients at high risk of MI who were troponin negative 
(O’Donoghue et al 2006). H-FABP has also been demonstrated to significantly correlate with 
the development of adverse cardiac events and cardiac mortality (Nakata et al 2003). 
Another potential advantage of H-FABP over troponin is the association of troponin with 
head injury. In a 2005 study, Martin et al assessed troponin levels in trauma patients admitted 
to critical care. They reported that patients with traumatic brain injury were more likely to 
have elevated TnI when compared to the remainder of the non-brain injured cohort (Martin et 
al 2005). This association with brain injury has not been demonstrated with H-FABP. A 
raised troponin level in a polytrauma patient with head injury may therefore be more 
complicated to interpret whereas an elevated H-FABP is less likely to be a result of brain 
injury.  
Another potential benefit of H-FABP compared to troponins lies in the rapidity of its 
clearance after myocardial ischaemia. Levels typically normalise within 24 hours compared 
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to troponins which take longer to return to within reference range. H-FABP therefore would 
be useful in the early detection of subsequent episodes of myocardial ischaemia whereas 
these may be ‘masked’ by continuously high troponin levels (Pelsers & Glatz 2005).  
There are some however some potential drawbacks to the use of H-FABP as a biomarker of 
TISCI. H-FABP has been shown to be expressed to a lesser extent by skeletal muscle (Pelsers 
et al 2005). Caution has to be taken therefore in interpreting the results when injuries include 
fractures and associated soft tissue damage are present as is indeed frequently the case in 
polytrauma patients.  
Despite this potential limitation, H-FABP has shown real promise as an early biomarker of 
cardiomyocyte injury with resultant cardiac dysfunction after trauma-haemorrhage. This 
evidence however has remained largely in the clinical setting and there is a need for this to be 
validated in animal models of trauma-haemorrhage which could be used to further our 
knowledge regarding the functional implications of TISCI. 
1.6 The Experimental Evidence for Trauma-Induced Secondary 
Cardiac Injury 
There is a growing body of clinical evidence that supports the development of an indirect 
cardiac injury, occurring after a period of haemorrhagic shock and trauma, which culminates 
in impaired cardiac function and contributes to poorer outcomes and mortality after trauma.  
Conditions of reduced tissue perfusion with subsequent reperfusion as well as the 
upregulation of inflammatory pathways are likely to coexist after severe injury and 
resuscitated blood loss. A combination of biological and physiological factors therefore, is 
likely to contribute to the development of this secondary cardiac injury. However, much 
remains unknown about the key mechanistic pathways in the development of this important 
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clinical outcome. The development of robust, translatable pre-clinical models of secondary 
cardiac injury will be critically important in the characterisation and treatment of the cardiac 
consequence of trauma and haemorrhagic shock. 
1.6.1 Contemporary pre-clinical models of TISCI; methodology, mechanistic insights 
& limitations 
A literature search was performed for studies relevant to cardiac dysfunction following 
trauma, haemorrhage or the combination of the two. A PubMed search was performed in 
2013 using the search details ((“injuries” [subheading] OR “injuries” [All Fields] OR 
“trauma” [All Fields] OR “wounds and injuries” [MeSH Terms] OR (“wounds” [All Fields] 
AND “injuries” [All Fields] AND “haemorrhage” [MeSH Major Topic]) AND “heart” 
[MeSH Major Topic].  
Applying these search criteria returned 205 abstracts. Abstracts published within the last 20 
years were selected in order to capture a good range of studies and to gain an understanding 
of how models have changed and developed over time, particularly in a relatively rapidly 
evolving clinical setting. Studies investigating isolated brain or spinal injury were excluded, 
as were studies relating to burn injury. Each of the remaining abstracts were screened and 
only those deemed to be relevant were retrieved as full text articles. Publications not captured 
by the search criteria outlined above but having relevance to the scope of this literature 
review were also reviewed.  
A search of the online database retrieved 205 abstracts, after screening, 31 of these were 
regarded to be relevant to this review. A further 21 abstracts were identified as having 
relevance to this topic and therefore have also been included. Certain authors have 
contributed several studies (for example I.R Chaudry’s team in the US) and there is therefore 
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a significant degree of overlap in terms of methodology and protocol design across the 
literature reviewed.  
 
Species 
The studies reviewed described the use of five species of animal, the largest animal used was 
a pig.  The vast majority of the studies used a rat model. The availability of genetically 
modified mouse strains may have prompted the use of this species in studies investigating the 
mechanistic basis of cardiac injury, but mice were used in a minority of cases. Li et al in 
2007 reported findings using a TNF-α “knock-out” strain to investigate the role of 
inflammation in the development of cardiac injury. 2 years earlier, Meng et al also used a 
genetically modified strain in order to demonstrate pro-inflammatory signalling pathways 
acting via toll-like receptor-4.  
Rodent models dominate the literature. There is only one porcine model (Granfeldt et al 
2012).  The availability of genetically modified strains is one reason why these smaller 
animals are preferred and despite the genomic differences, smaller animals are invaluable in 
gaining insights into molecular and cellular mechanisms of trauma haemorrhage related 
cardiac pathophysiology. There are however, a number of limitations when using a mouse or 
rat when investigating cardiac dysfunction after trauma haemorrhage.  
Technically, surgery and instrumentation are challenging in a small animal model requiring 
vessel cannulation. Blood volume is limited and this will influence the number of tests 
possible in a single animal. The small volumes available may also preclude repeat testing in 
the same animal over time making assessment of temporal trends difficult.  
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Baseline mean arterial blood pressure is similar across the species but resting heart rate is 
much higher in rats and mice and there are some structural differences in the cardiovascular 
systems of rodents compared to larger animals and humans who share similar anatomy and 
haemodynamic responses to blood loss. The small heart size and increased heart rate poses 
technical challenges for cardiac imaging such as echocardiography but the differences do not 
just impact on a technical front. Rodents are most active during the night and as such, their 
circadian rhythms are different to humans with higher nocturnal blood pressure during their 
active hours. There are differences in the action potential in rodents compared to humans 
with a lack of the plateau phase leading to a shorter action potential in rodents. There are 
differences in calcium flux with less reliance on the Na+/Ca2+ exchanger playing less of a role 
in rodents compared to humans and there are also differences in cardiac myosin isoforms 
with rodent hearts demonstrating a preferential shift towards the beta-myosin isoform under 
conditions of load change and / or hormonal influence (Hasenfuss. 1998). These 
physiological differences also need to be considered when selecting the most suitable species 
to answer the cardiovascular research question being posed but these differences, although 
important, have not been a barrier to using rodents in this type of research.  
Animal models have been used to assess therapeutics with potential to prevent cardiac injury 
and / or dysfunction. In terms of therapeutic studies, due to the genomic differences between 
rodents and human, additional experiments in a larger animal may be required before 
conclusions about efficacy and safety can be made and this represents a drawback in the use 
of the smaller animals in therapeutic studies and as cardiac specific research moves forwards, 






There were a number of different anaesthesia strategies used in the papers reviewed here. 19 
of the references implemented a protocol where a combination of inhalational and injectable 
agents were used for induction and maintenance of anaesthesia. In 16 of the references, 
intravenous or intraperitoneal drugs alone were used and 13 used inhaled gases. In one of the 
studies reviewed, it was unclear which anaesthesia strategy had been used. Isoflurane was the 
inhalational agent of choice in the majority of the studies. If an injectable agent was used 
alone, or in combination with, the inhaled agent, this tended to be pentobarbital. 
A potential limitation of using an anaesthetic regimen which includes a short-acting 
barbiturate such as pentobarbitone relates to its relatively short half-life. As the drug is 
eliminated, ‘top-up’ doses may be required during the experiment. This has the draw-back of 
a variable and relatively uncontrolled depth of anaesthesia and, as a consequence, fluctuations 
in haemodynamic status and catecholamine release.  
Isoflurane is a halogenated ether used for anaesthesia alone, or in combination with an 
injectable agent. As well as anaesthesia, it also has analgesic properties which make it an 
attractive choice for the injury models. The route of administration and short half-life mean 
that isoflurane can be easily titrated to produce a stable surgical plane of anaesthesia. 
Isoflurane can induce hypotension but is less cardio-depressive than other anaesthetic agents 
used in these models. This is obviously one potential benefit when conducting studies relating 
to cardiac performance.  
Zou et al use ketamine as an anaesthetic agent in their rat trauma haemorrhage model. 
Ketamine has been deemed a favourable choice when anaesthetising trauma patients as it is 
less likely to cause hypotension. The addition of ketamine into the trauma models therefore 
may improve the translational potential. In the studies to date, ketamine is not used widely.  
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Another limitation of the animal models generally is the lack of medications routinely seen in 
clinical management of injured patients such as opiate analgesia. The inclusion of relevant 
drugs such as ketamine therefore, may answer such criticism.  
Pre-Clinical Models of Trauma / Trauma-haemorrhage / Haemorrhage 
Trauma is a complex, multi-modal disease. Pre-clinical models therefore have been designed 
in order to reproduce the complex physiology and biological conditions of haemorrhagic 
shock, injury or a combination of the two.  
Trauma 
In the majority of the experiments, injury took the form of soft tissue injury by means of a 
laparotomy. Guan et al in 2002 however, used a different approach and combined multiple 
fractures with blood loss in order to generate conditions of tissue ischaemia and 
inflammation. The fractures created varied in severity with the heaviest injury load 
comprising of bilateral femoral, tibial and humeral fracture in the same animal.  
A modified Noble-Collip drum was used in a number of the studies (Wang et al 2013, Feng 
et al 2013, Yan et al 2010 and Tao et al 2005). This method was adopted when blunt, whole 
body trauma in the absence of haemorrhagic shock was being investigated. (Briefly, 
anaesthetised animals are placed in a rotating drum and the drum turned at a defined rate per 
minute in order inflict multiple, blunt force injuries on unrestrained animals as they 
repeatedly fall. Sham control animals are also placed in the drum but restrained to the inner 
wall so experience the revolution but without injury). The aim is to produce non-lethal 
mechanical trauma without concomitant circulatory compromise. Not all of the groups 
however, report on the appearance of the heart after the experiment and therefore it is not 
clear if direct cardiac trauma was sustained as a consequence of the technique used. None of 
the studies using this technique report any post mortem analysis being performed on the rest 
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of the cadaver and, apart from the information that the animals were alive at 24 hours, it 
therefore it is difficult to determine the exact injury severity and how reproducible this 
technique was.  
As the purpose of the non-lethal trauma studies outlined above was to investigate secondary 
cardiac injury, thoracic trauma was avoided. Many investigators used laparotomy for the 
trauma component of the model. In a primate model designed to induce secondary lung injury 
however, a combination of tissue trauma, fracture and haemorrhagic shock were required 
(Pretorius et al 1987). Only 1 of the studies reviewed here included limb fractures in the 
protocol. A potential limitation of including fractures however, is the ability to recover the 
animal from anaesthesia and the addition of fracture to the study protocol can therefore limit 
the duration of the observation period. In the UK, animals are generally not recovered from 
anaesthesia if limb fracture without fixation has been performed. This type of model would 
require intensive animal monitoring and follow up and potentially additional home office 
approval. The addition of fractures to a protocol, although possible, will increase the severity 
of the injury and resultant inflammation, arguably increasing the translational potential for 
the model but, this will have its own challenges and limitations.  
Haemorrhage 
None of the studies adopt an uncontrolled bleeding protocol and there are two strategies used 
in order to induce haemorrhagic shock in the studies, namely, fixed pressure or fixed volume 
haemorrhage with controlled withdrawal of blood via an indwelling vascular catheter. Only 3 
of the studies reviewed adopted a volume-controlled protocol (Meng et al 2005, Yang et al 
2007 and Nachuraju et al 2011). In these experiments 30, 50 and 60% of estimated total 
blood volume was drawn respectively after performing a weight calculation in order to 
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estimate total blood volume. The remaining experiments, where blood loss was included in 
the study design, used a pressure-dependent protocol.  
The most-severe form of haemorrhagic shock was described in the protocol of 4 studies 
reviewed (Granfeldt et al 2012, Sambol et al 2009 & 2011 and Yao et al 2006). In the 4 
studies conducted by these 3 groups, blood was withdrawn until a target mean arterial 
pressure of 30 – 35mmHg was achieved. Kapoor et al in 1997 presented the results of 
experiments conducted in dogs with pressure-dependent haemorrhage to 50 ±5mmHg. The 
haemorrhagic shock induced in this study therefore represents the least severe (in terms of 
target MABP achieved) amongst the references presented in this review.  
The majority of the studies adopted a fixed-pressure haemorrhage protocol with blood loss 
performed over a defined time-frame in order to achieve a pre-determined target blood 
pressure. The depth of hypotension is therefore well defined and haemodynamic responses 
can be characterised. A limitation of this approach, however, is that it is tightly controlled and 
therefore does not accurately reflect what happens clinically. The main advantage over the 
fixed-volume method is that the degree of hypotension can be tightly controlled and is 
reproducible. Small animal work using rodents tends to preclude the use of uncontrolled 
bleeding in the form of liver laceration etc due to technical considerations relating to the 
animals’ size and total blood volume. Compensatory mechanisms may vary between 
controlled and uncontrolled bleeding and it has been demonstrated previously that indices of 
shock severity are lower in pressure-controlled bleeding compared to uncontrolled 
haemorrhage protocols. (Sondeen et al 2007). It may be argued that an uncontrolled 
haemorrhage protocol may be superior in terms of translational potential, but in mechanistic 





Only 4 of the combined trauma / haemorrhage studies reviewed did not include a 
resuscitation phase in the experimental design (Nachuraju et al 2011, Sato et al 2007, 
Gonzales et al 2006 and Meng et al 2005). In some cases, such as Granfeldt et al 2012, the 
impact of resuscitation strategy upon cardiac injury was one of the study aims. In the majority 
of studies however, the rationale for including a resuscitation phase is not implicitly stated 
and therefore one must deduce that it is performed in order to restore intravascular volume 
and blood pressure with the aim of monitoring cardiac function and the temporal patterns of 
the inflammatory response over the longer term. The introduction of a resuscitation phase 
also allows for the development of an ischaemia / reperfusion injury which has been 





Table 1.1 Protocols for Inducing Haemorrhagic Shock With, or Without Trauma in 
Pre-Clinical Models.  
(Reference ranges for mice, rats, hamsters and dogs are taken from Wolfensohn & Lloyd 
(2013). Ranges for pigs are taken from Hannon et al 1989). SBP = systolic blood pressure.  








References    
Haemorrhage only     
Mouse 133 - 160  30% Meng ‘05    
Rat 84 - 134 35 ± 5mmHg 
50mmHg 
35 – 40mmHg 
40mmHg 
 Yao ‘96, M Shahani ‘01 
Yang ‘04, Sato ‘07  
Soliman ’12  
Meldrum ‘97 
 
   
Rat   60% 
 
Gonzales ‘06, Letson ‘11 
 
   
Hamster 150  50% Nachuraju ‘11    
Dog 100 - 178 50 ± 5mmHg 
40mmHg 
 Kapoor ‘97 
Sato ‘00, Coimbra ‘04 
   
Pig 120 - 134 30 – 35mmHg  Granfeldt ‘12    
Trauma - Haemorrhage     
Mouse  35 ± 5mmHg  Zhang ‘12, Nickel ‘09    





 Remmers ‘97&’98 
Robinson ‘97, Angele' 98, 
Jarrar ‘00 (x2), Mizushima 
‘00, Guan ‘02, Hsieh ‘06, 
Yu ‘07, Zou ‘07, Ba ‘08, 
Kan ‘08, Hsu ‘09, Tsai ‘12 
Kuebler ‘03 
   
Rat  35 – 40mmHg  Hsieh ‘05, Szalay ‘05, 
Hsieh ‘06, Yang ‘06, Hsu 
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The choice of resuscitation fluid varies amongst the studies. 25 of the studies out of the 36 
which include a resuscitation phase, report the use of crystalloid solutions intravenously. 
Ringer’s lactate is the fluid of choice in these references and a fixed volume of 4 times the 
shed blood volume is used in each case. A protocol using twice the volume of shed blood in 
Ringer’s was implemented in 3 studies (Coimbra et al 2004, Meldrum et al 1997 and Yao et 
al 1996).  
Shed blood was reinfused after a period of haemorrhagic shock in 5 of the studies reviewed 
and in the remaining 3, shed blood and crystalloid were administered after the haemorrhage 
and shock phase (Granfeldt et al 2012, Guan et al 2002 and Shahani et al 2001).  
Apart from the publications from Soliman et al, Granfeldt et al and Shahani et al, 
resuscitation fluids are administered in the absence of a pre-defined resuscitation end-point. 
For example, the majority of the studies relating to the investigation of the role of the sex 
hormones in the development of cardiac dysfunction, use a fixed volume resuscitation 
protocol where 4 times the volume of shed blood is returned to the animal in the form of 
lactated Ringer’s solution. Guan et al in 2002 outline that shed blood is returned along with a 
fixed volume of 0.9% saline. In 2012, Soliman et al outline in their methodology that shed 
blood alone was returned with the aim of reaching a target mean arterial blood pressure of 
50mmHg. Granfeldt et al and Shahani et al also targeted MAP and after blood was 
administered, crystalloid boluses were given to meet a pre-defined target blood pressure.  
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Fluid resuscitation was included in the protocol of most of the studies where animals had 
suffered blood loss. Lactated Ringer’s solution was the commonest resuscitation fluid of 
choice and was used in isolation or in combination with blood.  
The inclusion of a resuscitation phase in the models adds another level of technical difficulty, 
with insertion of a greater number of indwelling vascular catheters (if blood is to be returned 
via the intravenous route rather than through the arterial catheter), blood storage and the 
requirement for anti-coagulation to prevent coagulation of drawn blood and occlusion of 
multiple in-dwelling catheters.   
In terms of translational potential, resuscitation of the animal will cause organ reperfusion, 
which in itself may contribute to pathophysiology in the form of ischaemia-reperfusion 
injury, and this is more likely to reflect the clinical scenario. The majority of the studies 
reviewed here employed a clear fluid resuscitation strategy with crystalloid solutions 
administered on the basis of the shed blood volume. For the majority of the studies, fluid is 
returned at a set volume. Shahani et el, Soliman et al and Granfeldt et al however target 
resuscitation in terms of mean arterial pressure. The latter 2 groups also administered a 
combination of shed blood and crystalloid. As clinical resuscitation practice moves away 
from the use of large volume crystalloid resuscitation in trauma, contemporary animal models 
of trauma haemorrhage would be expected to modify accordingly in order to optimise their 
translational potential. There appears to be a lack of emphasis upon targeted resuscitation, 
with a lack of pre-defined end-points of resuscitation. This approach could add another level 
of complexity to already challenging models, but it may be required to develop standardised, 
robust models in which to characterise the functional cardiac response. 
 
Table 1.2 Protocols for Resuscitation in Pre-Clinical Models of H and THS. 
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SB = Shed blood, 4x refers to 4 times the volume of shed blood, 2x refers to twice the 
volume of shed blood. 
Species Shed blood Crystalloid Blood & Crystalloid 
Mouse  4 x SB volume 
(Nickel ‘09) 
 
Rat (Sambol ’09 &‘11, 
Soliman ’12) 
2 x SB volume 
 (Yao ‘96,  
Meldrum) 





Hsieh, Szalay, Yang, 
Hsu, Yu, Zou, Ba, 
Kan, Tsai) 
(Guan ’02) 
Dog (Kapoor ‘97, Sato 
’00) 
2 x SB volume 
(Coimbra ’04) 
(Shahani ’01) 





Diagnosis and Manifestations of Cardiac Injury in pre-clinical models 
Rodent models have repeatedly demonstrated that cardiac function is depressed following 
trauma (Li et al 2007), (Li et al 2007), (Feng et al 2013), (Wang et al 2013), (Tao et al 2005), 
(Yan et al 2010), haemorrhagic shock (Shahani et al 2001), Meldrum et al 1997), Nachuraju 
et al 2011), (Yao et al 1996), (Soliman et al 2012), (Sato et al 2000) and trauma-
haemorrhage (Zhang et al 2014), (Zhang et al 2012), (Kan et al 2008), (Liu et al 2012), 
(Sambol et al 2009), (Sambol et al 2011), (Yang et al 2004 & 2006), (Zou et al 2009), 
(Remmers et al 1998), (Hsu et al 2008), (Mizushima et al 2000), (Hsieh et al 2006), (Kuebler 
et al  2003), (Hsu et al 2009), (Yu et al 2007), (Yu et al 2008), (Yu et al 2005), (Tsai et al 
2012) and (Szalay et al 2005).  
Cardiac dysfunction has been demonstrated both in-vivo and ex-vivo using invasive and non-
invasive haemodynamic monitoring. The most commonly adopted method involved the use 
of a heart performance analyser with or without a dilution technique to assess cardiac 
performance. Stroke volume was seen to decline, maximum rates of rise (+dP/dtmax) fell 
along with a decline on ventricular pressure (-dP/dtmax) and left ventricular developed 
pressures (LVDP). Ventricular peak systolic pressures, cardiac output, cardiac index and the 
delivery of oxygen (DO2) were all reported to decline after trauma with or without 
accompanying haemorrhagic shock.  
Both systolic and diastolic dysfunction has been reported (Shahani et al 2001). 
Electrocardiogram (ECG) assessment has also allowed for the monitoring of rhythm 
disturbance and electrophysiological abnormalities have been reported (Sato et al 2007, 
Sambol et al 2009 and Letson & Dobson 2011).  
Only 1 study elected to use well characterised cardiac specific biomarkers to diagnose cardiac 
injury for the purposes of their study. This group published experimental data regarding the 
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role of TNF- α and ROS in the development of cardiac injury and dysfunction in rats after 
mechanical trauma. They demonstrated that troponin I levels  and Creatinine kinase (CK) 
activity were elevated in trauma rats when compared to sham controls at time-points up to 2 
hours after injury (Feng et al 2013).  
Human cardiovascular disease has been modelled in small animals for decades (Russell & 
Proctor 2006) and characterisation of left ventricular pressure-volume relationships, and the 
construction of pressure-volume loops, have been widely used in pre-clinical rodent models 
of cardiovascular disease. The miniaturisation of technology has allowed for the development 
of high-fidelity micro-manometers which can be used in small-animal studies and real-time 
generation of pressure-volume loops, have proven to be a valuable tool in characterisation of 
cardiovascular dynamics.   
The use of sophisticated, invasive cardiac assessment has therefore been successfully 
employed in models of cardiac injury to demonstrate the functional implications of trauma-
haemorrhage. These techniques are highly specialised and require a great deal of skill to 
perform in a robust fashion. There are also a number of limitations to be considered when 
using these techniques in rodent models of trauma-haemorrhage. Their placement is highly 
invasive and challenging requiring microsurgery and monitoring to ensure that the catheters 
remain in the correct place. There may also be issues in the placement of these micro-
manometers into a cardiovascular system which has been subject to severe haemorrhage and 
is therefore ‘shut-down’. Appropriate calibration of these systems may also be difficult as 
viscosity changes with haemorrhage and then subsequent resuscitation. The use of these 
systems in small animals may be limited by the need for frequent recalibration. Greatly 
reduced circulating volumes may preclude frequent blood taking for recalibration, 
particularly in models with severely shocked animals who are already very unstable.   
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Ex vivo heart systems such as the isolated retrograde-perfused Langendorff heart were also 
used by a number of the researchers (Sambol et al 2009, Sambol et al 2011, Du et al 2015, 
Wang et al 2013 and Tao et al 200). They have proved useful in studies of ischaemia / 
reperfusion and cardiac disease such as heart failure and have been a useful piece of the 
cardiovascular researcher’s toolkit when assessing the impact of therapeutics upon cardiac 
physiology. The addition of a pressure transducing system allows for the measurement of 
indices of ventricular performance.  
The use of these apparatus however poses significant technical challenges to the researcher 
particularly when using small, delicate murine hearts. Crystalloid perfusion of the heart may 
cause tissue oedema and due to its low oncotic pressure, coronary artery flow rates are much 
higher than in vivo. Removing the heart from the body will also remove important neuro-
hormonal influences and therefore reduce translational potential and retrograde perfusion of 
the heart with clear fluid is obviously far removed from the in vivo situation.  
The timing of onset of cardiac dysfunction has been, in the majority of studies, reported as 
occurring between 2 and 5 hours after injury (Yang et al 2006, Yang et al 2004, Mizushima 
et al 2000, Meng et al 2005 and Szalay et al 2005). Feng et al in 2013 reported a ‘hyper-
acute’ onset of dysfunction of within 60-minutes of trauma but this is not typical. Longer 
studies have been performed with animals being recovered from anaesthesia and then 
undergoing cardiac functional assessment at a later stage. Cardiac dysfunction onset has been 
demonstrated to occur up to 48-hours post injury (Remmers et al 1998, Kuebler et al 2003, 
Tao et al 2005, Liu et al 2012 and Wang et al 2013).  
While the identification of molecules and biomarkers relevant to the development of 
secondary cardiac injury can be easily taken into the clinical setting, investigating cardiac 
dysfunction with the use of functional assessment in trauma patients is more challenging. 
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There is therefore a need to take the research presented here forward. To develop models 
which encompass the ischaemia, inflammation, reperfusion which contribute to organ 
dysfunction and to develop ways of characterising cardiac function in this setting which are 
relevant clinically.   
Pathophysiology 
Identification of the key effector molecules and pathways involved in the development of this 
specific type of cardiac injury was the aim in the majority of the research studies presented 
here. As such, small animal models feature most frequently.  
Endocrine function 
Gender differences in the inflammatory and immune responses in general have been well 
documented. 16 of the studies reviewed, many of which have been conducted by I.H. 
Chaudry’s research team in the US, characterise the contribution of gender-specific endocrine 
signalling to the inflammatory response after trauma-haemorrhage specifically. Because 
many of these studies were performed by the same group, there is significant overlap in terms 
of species chosen and other aspects of the methodology such as resuscitation strategy and 
burden of injury. In the majority of these studies therefore, rats are the species used, 
haemorrhage takes the form of controlled, pressure - dependent bleeding to a MAP of 35-
40mmHg and soft tissue injury in the form of a laparotomy. Broadly speaking, the aims of 
these studies include the elucidation of key endocrine pathways that confer immunological 
benefit and cardioprotection to females compared to males after trauma haemorrhage and to 
identify therapeutic agents that have the ability to provide males with these benefits or 




Shahani et al in 2001 published the only study investigating the role of adrenergic signalling 
in the development of cardiac inflammation and dysfunction after haemorrhagic shock.  They 
concluded that the α1-adrenergic pathway was initiated in response to haemorrhage and this 
was associated with depressed myocardial function. This effect was partially blocked with the 
use of a TNF-α blocking antibody and, in another experimental group, with the 
administration of prazosin hydrochloride before the onset of haemorrhage (Shahani et al 
2001).  
Apoptosis & Autophagy 
The role of apoptotic and autophagy pathways specifically have been investigated in a 
smaller number of these references with 8 studies focussing upon relevant pathways and 
molecules. Of these, Guan et al in 2002 and Tsai et al in 2012 investigated the development 
of cardiomyocyte apoptosis in response to the combination of trauma and haemorrhagic 
shock while the remainder (Wang et al 2013, Feng et al 2013, Yan et al 2010, Li et al 2007 
and Tao et al 2005) subjected animals to blunt trauma (most often in the form of the modified 
Noble-Collip drum whole body trauma, which has been described earlier) in the absence of 
haemorrhage. Broadly speaking, the hypothesis being that injury at sites other than the heart 
set into motion inflammatory cascades culminating in cardiomyocyte cell death which was 
demonstrated in these studies in injured animals when compared to sham controls.  
Pro-Inflammatory Pathways & Cytokines 
Pro-inflammatory mediators such as TNF- α and the interleukins feature frequently in the 
body of literature reviewed here. There is also significant overlap with studies elucidating the 
role of the sex hormones as these inflammatory cytokines are downstream effectors of the 
pathways involved. 6 of the studies investigate the role of signalling via NF-KB and the 
production of TNF – α on the development of cardiac injury and dysfunction.  
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Investigators have measured levels of these cytokines most frequently in plasma of animals 
after haemorrhage and / or trauma but there are a number of studies where levels of cytokine 
expression within the myocardial tissue itself has been performed.  
The toll-like receptor (TLR) pathways have drawn much interest in trauma research due to 
their role in damage-associated molecular pattern (DAMP) signalling. TLRs such as TLR-4 
are regulators of pro-inflammatory signalling cascades and as such, investigators have been 
keen to identify their role in organ dysfunction after trauma-haemorrhage and identify pivotal 
molecules which could provide therapeutic targets. In order to investigate the relationship 
between TLR-4 and TNF- α as a downstream effector in haemorrhagic shock and cardiac 
dysfunction, Meng et al haemorrhaged mice with a defective TLR-4 receptor and compared 
the TNF- α response and cardiac function with wild-type. The group also used genetic strains 
to investigate TNF receptor signalling. They reported that TLR-4 signalling was involved in 
generating TNF - α in haemorrhagic shock and that depression of myocardial function was 
modulated via the p55 TNF – α receptor specifically.  
Li et al in 2007 also took advantage of the availability of genetically modified strains to 
investigate inflammatory signalling pathways in the development of cardiomyocyte injury 
when they developed their mouse trauma model. Serum from TNF – α knock-out mice was 
used to demonstrate the role of this cytokine in the development of cardiomyocyte apoptosis 
after non-lethal mechanical injury. Healthy cardiomyocytes cultured with plasma taken from 
the TNF- α deficient strain did not develop the higher incidence of apoptosis that was 
demonstrated in cadiomyocytes cultured in plasma removed from injured wild-type mice.      
In 2013, Feng et al observed that mechanical trauma led to an increase in myocardial and 
serum TNF- α concentrations which was associated with cardiac dysfunction. The group went 
on to demonstrate that serum from trauma animals, when incubated with cardiomyocytes 
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from a control group, decreased contractile amplitude. This outcome, however, was less 
pronounced if a TNF – α antagonist was also applied supporting their hypothesis that TNF- α 
has a role in the development of cardiac dysfunction after trauma.  
Reactive Oxygen Species 
The earliest study investigating the role of oxidative stress and free radical production in the 
development of cardiac dysfunction after haemorrhage was published in 1997 by Kapoor et 
al. Another 3 studies have focussed upon contribution of the oxidative pathways (Feng et al 
2013, Li et al 2007 and Tao et al 2005), but always in the context of isolated trauma. 
Lymphatics 
The gut represents an organ which is vulnerable to ischaemia in haemorrhagic shock as 
remaining blood is diverted in order to maintain circulation to other organs. The potential for 
ischaemia, coupled with the huge surface area that the intestinal organ possesses has raised 
the possibility that the gut may be involved in the development of organ dysfunction after 
haemorrhage. Specifically in relation to this review, Sambol et al published the only study 
investigating the role of mesenteric lymph in the development of cardiac dysfunction 
secondary to trauma and haemorrhagic shock. The group hypothesise that lymph, in 
conditions of trauma and shock, contains factors which have a negatively inotropic effect on 
the heart. One group of animals was treated with LDL with the intention of preventing 
intestinal lymph from entering the bloodstream. Cardiac function was analysed using an ex 
vivo isolated heart system.  The group report that this was protective and infer that 
myocardial dysfunction after trauma and shock is likely related to factors present in 





Trauma and haemorrhage represent a spectrum of pathophysiological states in humans. Mild 
injury without accompanying blood loss will not be expected to instigate the same degree of 
inflammatory response and physiological derangement as the polytrauma patient with soft 
tissue and bony injury, severe blood loss, haemorrhagic shock, organ ischaemia and 
subsequent resuscitation and reperfusion.  
This review demonstrates the variability amongst animal models which have been developed 
to investigate cardiac sequelae of trauma and haemorrhage. Protocols which have separated 
bleeding from injury have provided mechanistic insights into cardiac injury and dysfunction 
but it may be said that the ideal model would be one in which both conditions are present. 
Injury in isolation may be enough to precipitate cardiac injury, however, the absence of shock 
in these models may offer too simplistic a view. To optimise the translational potential of 
these models to the severely injured patient in the resuscitation room, hypoperfusion and all 
the cellular implications that it brings should ideally be acting in parallel with injury and 
inflammation.  
This review of contemporary animal models in published work, has identified common 
methodological approaches used in the detection and characterisation of trauma-induced 
secondary cardiac injury. In vivo studies have already yielded important insights into the 
cellular and molecular mechanisms driving cardiac injury and dysfunction, but the 
understanding of the pathophysiology underpinning TISCI remains relatively poorly 
understood. There is a relative paucity of knowledge regarding clinically-relevant biomarkers 
and how these relate to the development of cardiac injury and dysfunction in the pre-clinical 
models. As we better understand the temporal patterns of biomarker release in humans, this 
70 
 
needs to be validated in the animal models to facilitate development of relevant models of 
injury and haemorrhage.  
A significant limitation of the small animal studies is the lack of uncontrolled haemorrhage 
protocols. It can be argued that controlled bleeding does not accurately reflect the clinical 
situation and this therefore limits the translational potential. That being said, the 
reproducibility and standardisation gained with the use of a controlled haemorrhage model 
may represent a significant advantage, particularly perhaps when designing a model in which 
to assess therapeutic agents. This issue has to be considered however when drawing 
conclusions from studies designed in this way.  It is vitally important, however, that the 
model is designed carefully in order to appropriately address the question being posed and 
allow for successful translation into human studies.  
This review has highlighted some of the limitations associated with widely used models. 
Although there has to be an acceptance that no one model will perfectly recreate the complex 
pathophysiology associated with injury and shock, there is no doubt that animal models still 
have much to offer us in our quest to understand how cardiac injury and dysfunction occurs 
and ultimately, how this can be limited or prevented. There is a need for in vivo models 
capable of comprehensively characterising cardiac functional outcomes in the context of 
TISCI. Such models will be particularly critical for the development of therapeutics. 
 
1.7 Proposed Therapeutic Strategies to Treat TISCI 
No clinical studies have been undertaken to identify drugs which could specifically prevent 
or limit the cardiac injury which develops as a consequence of trauma-haemorrhage (TH). A 
great number of studies have focussed upon aspects of resuscitation such as prevention of 
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coagulopathy, however there is a relative paucity of research investigating prevention of 
TISCI specifically with ‘cardio-protective’ resuscitation strategies.  
It can of course be said that any improvement in overall haemodynamic status will have the 
presumed beneficial effect of improving myocardial blood flow, but, as previously discussed, 
restoration of blood flow to the myocardium after an antecedent period of ischaemia, as with 
other organs, can potentiate changes in cellular and tissue homeostasis (ischaemia-
reperfusion injury) which can instigate organ failure and contributes to high morbidity and 
mortality at a later stage. The heart could be regarded to be especially at risk due to its 
inherent inability to reduce its workload during acute hypotension; in fact, the metabolic 
demands placed on the organ during this time of physiological stress is even greater as the 
work rate must increase in order to maintain cardiac output. Whereas the cerebrovascular and 
renovascular circulations for example may benefit as the heart increases its work rate to raise 
cardiac output, the coronary circulation is compromised further with a reduction in diastolic 
filling time as heart rate increases. The myocardium therefore rapidly accrues a metabolic 
deficit under these circumstances with associated cellular derangement and this is also 
accompanied by the inflammatory consequences of shock and injury during ischaemia and 
upon reperfusion (Kalogeris et al 2012).  
As knowledge regarding the pathophysiological processes behind the development of 
secondary cardiac injury is gained the focus shifts onto potential ways to modulate these key 
pathways in order to ameliorate the cardiac injury resulting from trauma-haemorrhage. A 
small number of pre-clinical studies have investigated therapeutic agents with the potential to 
provide cardio-protection after haemorrhage or combined trauma-haemorrhage.  
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Interventions investigated have included the use of strategies as diverse as whole body 
hypothermia to protect ‘key’ organs including the heart (Alam et al 2010) to targeting 
specific molecules with monoclonal antibodies (Yang et al 2006). 
1.7.1 Vascular endothelium and microcirculation 
The importance of protecting the endothelium from the effects of ischaemia and reperfusion 
injury, such as the situation of coronary artery occlusion followed by revascularisation, has 
long been appreciated.  
Endothelial injury has been observed as an indirect consequence of blood loss and injury. It is 
thought that this may contribute to impaired perfusion and cellular homeostasis and this was 
the rationale behind the use of the amino acid L-arginine in these studies. L-arginine is a 
substrate for the production of cNOS, levels of which had been observed to fall after trauma-
haemorrhage. In 1998, Angele et al employed a rat model of TH and administered L-arginine 
as an adjuvant to fluid resuscitation. They reported improved cardiac output and organ blood 
flow (measured using thermodilution technique) compared to a control group (Angele et al 
1998).  
Pentoxyfilline was administered at resuscitation to haemorrhaged dogs with subsequent 
improvements in cardiac function, cardiac index and a reduction in inflammation. This study 
was limited by the small number of animals and the relatively short period of observation, 
however, this demonstrated how targeting the microcirculation by altering red blood cell 
morphology could be another aspect of the vascular system to investigate (Coimbra et al 
2004). 
1.7.2 Hormonal therapies 
Irshad Chaudry’s team in the United States have undertaken a number of studies investigating 
the role of sex hormones in the development of cardiac dysfunction after TH and have 
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offered evidence that progesterone (Kuebler et al 2003) and oestrogen therapy may reduce 
the severity of cardiovascular injury when used in their rat model of TH. They have 
demonstrated a dose-dependent improvement in left ventricular performance when oestrogen 
and oestrogen receptor agonists, including diarylpropinonitrile (DPN), were administered 2 
hours after the onset of TH and the beneficial cardiac effects persisted for more than 6 hours. 
There have been a number of studies reporting the beneficial effects of oestrogens after T-H, 
but this study provided insights into both the specific receptor sub-types involved in 
mediating this cardio-protection as well as demonstrating a dose-response (Ba et al 2008).   
It is not only oestrogens and testosterone which have been investigated in the context of 
trauma and injury mediated organ injury. The administration of metoclopramide was shown 
to improve cardiac and hepatocellular outcomes and reduce inflammation (as measured by 
IL-6 production) due to its effect of increasing prolactin secretion from the anterior pituitary 
of rats subjected to TH (Jarrar et al 2000). 
1.7.3 Regulation of metabolic function 
An end-point of the cellular consequences of ischaemia involves the mitochondrial 
generation of adenosine triphosphate (ATP). Enzymes including pyruvate dehydrogenase 
(PDH) are essential for ATP generation and during periods of hypoxia, activity of this 
enzyme is reduced (Andersen et al 2015).  
This observation was the basis of a 2015 study which used a rat model of 55% blood loss to 
investigate the potential beneficial effects of a drug which restored the balance of enzyme 
acetylation and therefore improved the availability of the functional enzyme needed for ATP 
generation during ischaemia. Administration of a deacetylase inhibitor was shown to enhance 
cardiac PDH and reduce mortality from 75% - 37.5%. There was also an observed reduction 
in the expression of pro-apoptotic caspase-3 as well as pro-inflammatory mediators. PDH 
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activity was the only measured component of the electron transport chain and the mechanism 
by which the effects were mediated however remain unclear (Chang et al 2015). Similar 
improvements in haemodynamics and survival had been previously reported in 2006 with the 
use of the histone deacetylase inhibitor valproic acid, but this had been given as a pre-
treatment hours before the onset of haemorrhagic shock (Gonzales et al 2006).   
1.7.4 Targeting inflammation and oxygen species generation 
Strategies employed to modulate the generation of reactive oxygen species (ROS) and their 
impact upon cardiac function have included the administration of exogenous nitric oxide 
(Nachuraju et al 2011) and modulation of immune-mediated ROS generation. Insulin has 
recognised anti-inflammatory and anti-oxidant properties and as such this has been 
investigated as a therapeutic agent in TISCI. Animals that received insulin 10 minutes after 
injury was sustained were observed to generate less ROS, have lower serum troponin levels 
and demonstrated better cardiac function when compared to controls. Insulin therapy was 
therefore identified as having anti-inflammatory and anti-oxidant properties which would be 
beneficial in limiting cardiac dysfunction (Feng et al 2013).  
The administration of hydrogen sulphide (H2S) was demonstrated to be of benefit in terms of 
survival, haemodynamic outcomes and organ injury after haemorrhage. The improvements in 
haemodynamic function reported were attributed to the anti-inflammatory properties of H2S 
(although it has also been reported as having pro-inflammatory activity under certain 
conditions (Szabo 2007) and this therefore may be a dose-related response). A single bolus of 
H2S improved blood pressure and was associated with reduced generation of reactive oxygen 
species and a down-regulation of pro-inflammatory mediators (Ganster et al 2010).  
The use of the anti-oxidant resveratrol was investigated as a potential adjunct to fluid 
resuscitation. 10-minutes after resuscitation after T-H, a single bolus of resveratrol was 
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administered to rats and left ventricular contractility was assessed using an intra-ventricular 
pressure transducer. Rats treated with the agent showed improved LV performance and 
reduced heart rates compared to controls at 2 hours. There was also an associated reduction in 
inflammation (plasma TNF-α assay) and when cardiac tissue ATP levels were compared, T-H 
controls were found to have significantly reduced levels. Reduced levels of ATP were 
restored however with treatment (this improvement was not seen in animals pre-treated with 
the Sirt-1 inhibitor suggesting that resveratrol mediated its cardio-protective effects via a Sirt-
1-dependent pathway (Jian et al 2012). This study therefore identifies a potential 
cardioprotective agent and also describes its mechanism of action in bringing about its 
cardioprotective effects.  
Anti-inflammatory agents have also been identified for the prevention of TISCI in trauma 
without haemorrhage. Quercetin is an anti-oxidant found in fruit and vegetables and this was 
administered as a pre-treatment before injury was induced. In-vivo cardiac assessment at 12 
hours post trauma revealed improved left ventricular performance when treatment animals 
were compared to controls. Heart tissue analysis determined that there was a reduction in 
both cardiomyocyte apoptosis and circulating TNF-α in treated animals (Jing et al., 2016). 
This was the first time that this dietary flavonoid was tested in this context and the results are 
encouraging. However, there are limitations in terms of the methodology; a Noble-Collip 
drum was used to induce mechanical, non-lethal injury and, as previously discussed, there are 
issues regarding standardisation of injury and therefore inflammation with the use of this 
technique. Quercetin was also given before trauma and this therefore has implications for 
translational potential.  
Another naturally occurring anti-oxidant found in plants, resveratrol, has also been identified 
as an anti-inflammatory, anti-oxidant agent with potential applications in trauma-
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haemorrhage as a cardio-protective agent with additional benefits for other organs including 
the gut as well (Liu et al 2015).  
The platelet inhibitor dipyridamole is also known to have anti-inflammatory effects and this 
commonly used cardiovascular drug was identified as a potential therapeutic agent by 
Soliman et al in 2012. When administered to rats after haemorrhage, there was a reduction in 
the size of the inflammatory infiltrate into the myocardium. Cardiac performance measured in 
isolated hearts was improved and plasma TNF – α levels were noted to be lower in the 
treatment group compared to controls (Soliman et al 2012). A possible limitation of this use 
of this drug however lies with its anti-platelet effect. It is unclear how the use of this 
therapeutic would contribute to bleeding and the development or potentiation of 
coagulopathy when used in an uncontrolled haemorrhage setting.  
Research using transgenic mouse strains have provided insights into key molecules and 
effectors involved in the development of TISCI. The pro-inflammatory signalling pathways 
in particular have been investigated (Zhang et al 2012 and Meng et al 2005). The 
development of monoclonal antibodies has allowed for the selective blockade of molecules 
and therefore pathways thought to be detrimental to cardiac function. Anti-IL-6 antibodies 
administered after T-H has been shown to improve cardiac function and also to reduce 
cardiac inflammation but the development of cardiomyocyte inflammation and injury is 
multifactorial and therefore although benefit has been seen with these antibodies, the precise 
mechanism of their action remains unknown (Yang et al 2007).  
1.7.5 General strengths and limitations of the therapeutic studies 
The therapeutic studies briefly discussed here have covered a wide range of 
pathophysiological factors contributing to the development of TISCI. General limitations of 
the therapeutic studies include the relative small number which combine both trauma and 
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haemorrhage. This would therefore reduce the overall physiological ‘burden’ of injury and 
make these studies less translatable to the most severely injured patients who experience the 
greatest organ dysfunction, mortality and morbidity. There have been a variety of methods 
used to assess cardiac performance, ranging from thermodilution techniques to assess cardiac 
output and organ blood flow (Coimbra et al 2004 and Angele et al 1998) to the insertion of 
left ventricular pressure transducers (Ba et al 2008). Study length and therefore the 
observation period was variable between studies, but generally studies were conducted to 
include at least a 2-hour observation period after trauma-haemorrhage, extending beyond 24 
hours in some cases (Gonzales et al 2006). There have been some encouraging advances 
made in the identification of novel therapeutics which could be used as adjuncts to 
resuscitation to improve cardiac outcomes. The emphasis needs to be on moving these studies 
out of the pre-clinical arena with the implementation of clinical trials of those with most 
promise. Carefully designed, robust pre-clinical models which reflect the human condition of 
TISCI will be vital in order to achieve this aim.  
 
1.8 The Quest for Novel Cardioplegic Agents and their Potential 
Application in Trauma Research 
Cardiac injury and dysfunction is well-recognised in the context of low out-put states other 
than that relating to haemorrhagic shock. In some cases (including some of the published 
work previously discussed) observations made in studies related to shock in the context of 
sepsis have led to the trial of the same agents for organ protection after trauma-haemorrhage. 
Innovations in trauma research therefore can come from an appreciation of advances being 
made in different fields where similar challenges relating to organ dysfunction and protection 
are being faced.  
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The early 21st century saw a drive to develop novel, more ‘myocardial friendly’ cardioplegic 
agents that could be used in complex cardiac bypass surgery, particularly with the challenges 
of an ageing patient group with multiple comorbidities. Observations made regarding the cell 
biology and electrophysiology of natural hibernators such as small rodents (and described by 
Geoffrey Dobson and Hayley Letson), gave rise to the idea of developing a ‘polarizing’ 
cardioplegic agent which would arrest the cell membrane at a more physiologically 
acceptable level for the duration of bypass. To this end, a solution containing a combination 
of drugs was produced which was associated with improved myocardial outcomes in terms of 
inflammation and function when compared to the older, more traditional high-potassium 
solutions.  
Adenosine, lidocaine and magnesium (ALM), three drugs used widely in clinical practice, 
were combined to produce a ‘polarizing’ cardioplegic agent. The rationale for this particular 
combination arises from the physiology of hibernating animals and a desire to mimic this by 
arresting the heart at its resting membrane potential of -80mV (Dobson & Letson 2016). No 
single agent would have the ability to achieve this, but it is possible using a combination of 
drugs each with different electrophysiological properties.  
Lidocaine blocks the movement of Na+ into cells, thereby inhibiting the sodium influx 
required to generate the upstroke of the action potential. Adenosine is a class V anti-
arrhythmic agent and acts on the atrio-ventricular (AV) node to induce a transient heart block 
and terminate AV-node dependent supraventricular tachycardia (SVT).  Adenosine exerts this 
effect by opening K+ATP channels and decreasing the length of the action potential and it 
was for this property that it was selected. Calcium entry into cells is observed during 
ischaemia-reperfusion. During ischaemia, intracellular ATP levels and pH drop and ion 
transport becomes disordered. Intracellular and mitochondrial calcium levels increase which 
can lead to cell swelling and eventual rupture (Kalogeris et al 2012). Magnesium was added 
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to adenosine and lidocaine in order to reduce calcium entry and limit cell injury mediated in 
this way and to prevent arrhythmia development (Dobson & Letson 2016).  
ALM was studied for this role in an isolated perfused rat heart model (Dobson & Jones 2004) 
and later in a canine model (Corvera et al 2005). These studies confirmed the drug to be safe 
to use and with improved cardiac outcomes when compared to alternative solutions. Three 
prospective, randomised controlled trials using the combination of adenosine and lignocaine 
in cardiac surgery (one of which was a paediatric study) have shown favourable outcomes, 
including improved haemodynamics, decreased cardiac biomarker levels and shorter in-
patient stay when compared to patients treated with high-potassium cardioplegia (Jin et al 
2008).  
Adenosine in combination with lidocaine +/- magnesium has also been reported as having 
cardiac benefits in a broad range of settings including sepsis (Griffin et al 2014 and Granfeldt 
et al 2014), preventing arrhythmia post cardiac arrest (Granfeldt 2013) and also in the context 
of haemorrhagic shock (Letson et al 2011). Table 1.3 gives the half-lives and 
cardioprotective mechanisms of adenosine, lidocaine and magnesium. 
1.8.1 Adenosine, Lidocaine and Magnesium in haemorrhage models 
Interest in the combination of ALM as a therapeutic agent in HS is relatively recent. A group 
of researchers who have since demonstrated its haemodynamic benefits in both rat (Griffin et 
al 2014) and porcine models of sepsis (Granfeldt et al 2014) and in reversing coagulopathy 
rat model of severe haemorrhage (Letson et al 2011) also observed that the use of ALM in a 
rat model of HS significantly improved the animals’ haemodynamic status, reduced the 
volume of fluid resuscitation required and also led to 100% survival compared to controls 





Table 1.3 Half-Lives and Proposed Mechanisms of Cardioprotection of Adenosine, 
Lidocaine and Magnesium. 
ICAM = intracellular adhesion molecule, VCAM = vascular cell adhesion molecule, eNOS = 
endothelial nitric oxide synthase, NFκB = nuclear factor kappa-light-chain enhancer of 
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Table 1.4 below gives examples of studies where adenosine, in combination with lidocaine 
and magnesium, has been shown to confer cardioprotection and survival benefit in animal 




Table 1.4 Adenosine, Lidocaine and Magnesium in Pre-Clinical THS Research. 
ATP = adenosine triphosphate, MgCL2 = magnesium chloride, NaCl = sodium chloride, MAP 
= mean arterial pressure, ALM = combined adenosine, lidocaine and magnesium, Mg = 
magnesium, A = adenosine, L = lidocaine, TH = trauma-haemorrhage.  
Author Year Model Agent/s Main findings 







Letson 2011 Rat    
Haemorrhage          
Crystalloid resuscitation 
NaCl/ALM 
&    
NaCl/Mg 
Improved MAP, reduced 
incidence of arrhythmia 
and 100% survival in 
ALM treated 
Letson  2011 Rat 
Haemorrhage 
Crystalloid resuscitation 
NaCl/ALM,   
NaCl/A/Mg,   
NaCl/Mg & 
NaCl/L/M   
Higher MAP in ALM 
treated 
Letson 2011 Rat 
Haemorrhage 
Crystalloid resuscitation 
NaCl/ALM Reversal of TH 
coagulopathy 
Granfeldt 2012 Pig 
Haemorrhage 




stability and cardiac and 
renal function 
Granfeldt 2014 Pig    
Haemorrhage 
Blood resuscitation 
NaCl/ALM Improved cardiovascular, 
metabolic, acid-base 
outcomes with improved 
renal function in ALM 
treated animals 
 
More recently, a rat-to-pig translational study was also performed whereby pigs were 
subjected to a 75% haemorrhage were treated with a bolus of ALM in normal saline 
(Granfeldt et al 2014). This study corroborated the beneficial haemodynamic effects of ALM 
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when used as part of the resuscitation fluid regimen in haemorrhagic shock. Mean arterial 
blood pressure, cardiac output and stroke volume were reported to increase significantly, 
along with a reduced heart rate, lower lactate and base excess when compared to a control 
group who had been resuscitated with blood and saline alone. The use of ALM in these 
haemorrhage models also favoured lower volume resuscitation; important for the avoidance 
of complications resulting from high volume clear fluid resuscitation including pulmonary 
complications and coagulopathy.  
Despite encouraging results being reported in haemorrhage models using rats and pigs, ALM 
has not, to the best of my knowledge, been investigated in the context of haemorrhagic shock 
accompanied by injury.   
 
1.9 Summary 
Severe trauma is associated with significant mortality and morbidity. As advances are made 
in the acute management of bleeding patients, research needs to keep pace with the new 
challenges related to the severe physiological derangement patients have suffered yet 
survived. There is growing clinical evidence for the development of a secondary cardiac 
injury after trauma-haemorrhage which is associated with myocardial dysfunction and worse 
clinical outcomes. 
 Pre-clinical research, predominantly in small animal models, supports the clinical data and is 
providing insights into mediators and mechanisms driving the development of cardiac injury. 
An acute onset cardiac injury characterised by an increase in systemic and cardiac 
inflammatory molecules, ROS generation and associated with impaired left ventricular 
performance has been described. The use of knock-out mouse strains and hormone agonists 
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and antagonists has provided insights into key molecular processes in both driving and 
preventing cardiac injury after trauma-haemorrhage. There is however a relative lack of 
studies assessing clinically-relevant cardiac biomarkers and their association with cardiac 
dysfunction.  
Robust, translatable animal models continue to be vital for the investigation of cardiac injury 
and dysfunction.  There are a number of well-designed pre-clinical models in the 
contemporary literature, but the focus has been largely on inflammation and less work has 
been undertaken which links the biomarker evidence with functional outcomes. There also 
needs to be a drive towards developing therapeutics which can be used acutely to limit the 
degree of cardiovascular dysfunction resulting from resuscitated trauma-haemorrhage. 
 
1.10 Project Aims and Objectives 
The overall aim was to investigate the functional consequences of trauma-induced secondary 
cardiac injury on the myocardium. The objectives were therefore as follows: 
1. Validate the use of H-FABP, a clinical cardiac biomarker of TISCI, in our existing in vivo 
model of trauma-haemorrhage and establish the nature of the relationship between H-FABP 
and severity of injury in the animal model.  
2. Characterise the acute functional myocardial response to trauma-haemorrhage in the 
animal model of H-FABP defined TISCI.  
3. Develop a resuscitated model of TISCI in which to assess the functional left ventricular 
response to resuscitation after antecedent trauma-haemorrhage and to quantify the biomarker 
response with restoration of baseline pre-load conditions.  
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4. Test the efficacy of ALM as an adjunct to fluid resuscitation in improving haemodynamic 










2 Materials and Methods 
The recurring materials and methods for all the experimental chapters to follow are outlined 
in this chapter.  
2.1 The Murine Model of Trauma-Haemorrhage 
All animal procedures described in this thesis are regulated under a specific animal project 
licence (Procedure Project Licence (PPL) – PC5F29685) approved by the Animal welfare and 
Ethical Review Body at Queen Mary University of London, and the UK Home Office, in 
accordance with the EU directive 2010/63/EU on the protection of animals used for scientific 
purposes. The PPL includes all the experimental procedures required for the pre-clinical 
studies, including the induction of haemorrhage and traumatic injury, imaging procedures, 
dosing substances and blood / tissue samplings. This PPL was renewed on December 2016 
and has been granted for 5 years (to December 2021). Previously to 2016, we used the PPL 
70/7348 which expired on the 30/11/2016.  
2.1.1 Mice 
Male C57BL/6 wild-type mice weighing 25 – 30 grams were supplied by Charles River 
Laboratories (Margate, UK). This strain was used in all experiments. Animals were housed in 
accordance with the UK Home Office Guidance in the Operation of Animals (Scientific 
Procedures) Act 1986 and received a standard diet and water ad libitum prior to undergoing 




Isoflurane (Abbott Labs ltd, Berkshire, UK) in combination with 100% medical oxygen was 
used for both induction and maintenance of general anaesthesia throughout the duration of 
the experiments which were all ‘non-recovery’. 100% oxygen was used due to the centre’s 
previous experience with injury and haemorrhage models and it has been deemed appropriate 
for a model of this severity with associated mortality.  
An animal was taken from their cage and transferred into a sealed anaesthetic induction 
chamber. Oxygen and isoflurane was delivered into the chamber and when the animal was 
anaesthetised, they were rapidly transferred to the scanner platform (or surgical table) where 
isoflurane and oxygen were delivered continuously via nose cone to maintain a surgical plane 
of anaesthesia. No surgery was commenced until a surgical plane of anaesthesia, assessed 
with reaction to paw pinch, was achieved and checks were performed intermittently 
throughout the experiment. “Depth” of anaesthesia was assessed with a combination of 
reaction to external stimulus such as paw pinch, and, after surgical placement of catheters, 
haemodynamic monitoring (if there was an unexpected increase in MAP during the 
experiment for example, reaction to stimulus was checked in order to assess adequacy of 
anaesthesia). Anaesthetic delivery was controlled with the titration of isoflurane as 
appropriate. All experiments were ‘terminal’ meaning that no animals were recovered from 
anaesthesia after surgery, and all were culled at the end of the experiment whilst still 
anaesthetised.  
2.1.3 Surgery 
After induction of anaesthesia and transfer to either the scanner platform or surgical table, a 
lubricated rectal probe was inserted and temperature maintained at 36.0 +/- 1oC with the use 
of heating pads under the platform (or surgical table) and heat lamps. 3 of the paws were 
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taped to maintain stability during surgery, with the 4th left free in order to monitor adequacy 
of anaesthesia. Prior to making the first incision, reaction to pain was assessed with a paw 
pinch on the unrestrained limb. No incision was made if the animal was not sufficiently 
anaesthetised (as discussed above).   
A neck dissection was performed and the left jugular vein was identified. A venotomy was 
performed and a length of polyethylene tubing (internal diameter 0.28mm, Portex. Smith’s 
Medical Int. Ltd. Kent, UK) which had been pre-flushed with heparinised saline (25 IU/mL) 
was inserted and secured with nylon suture. The right carotid artery was then cannulated in 
the same fashion. After carotid cannulation, a pressure transducer (Capto SP 844, AD 
Instruments. Chalgrove, UK) was connected to the line by way of a three-way connector. The 
neck wound was covered in a moistened gauze to prevent drying out of tissues and the wound 
was checked intermittently for evidence of line displacement and bleeding. If either of these 
situations developed, the animal was euthanised and removed from the experimental data. 
2.1.4 Haemorrhage 
The animals were allowed to stabilise for 5 minutes after cannulation and injury. A ‘baseline’ 
mean arterial blood pressure (MABP) was recorded at this point. Mice then underwent a 
pressure-controlled haemorrhage of arterial blood via the carotid catheter over 10 minutes to 
achieve a target MABP of 60 – 70mmHg or 30 – 40mmHg (depending upon the experimental 
group allocation). The target blood pressure was then maintained over a 60-minute period 
with removal of blood as required via the carotid cannula.  Shed blood was kept warm in a 
1mL syringe containing 0.05mL of heparinised saline (25 IU/mL) and occasionally agitated 
to prevent thrombus formation. This volume of heparinised saline was taken into account 




In models including an injury component, trauma took the form of bilateral hind limb 
fracture, laparotomy and rectus muscle crushing. Fractures were performed using a closed, 
manual 3-point bending technique. A 2cm midline laparotomy was performed, with internal 
inspection of the abdominal viscera in order to exclude inadvertent iatrogenic injury and / or 
bleeding. The rectus muscle was crushed using forceps in a systematic fashion in each 
animal. The laparotomy was then closed using 5.0 monofilament suture material (Ethicon, 
UK). Moist gauze was then applied to cover the neck and laparotomy wound sites.  
2.1.6 Observation periods 
After trauma-haemorrhage and resuscitation episodes, animals underwent a 60-minute 
observation period. During this time, core temperature was continuously monitored and 
maintained with the use of a heat mat and lamps. Temperature, MABP and % of inhaled 
anaesthetic required to maintain a surgical plane of anaesthesia were recorded at 10-minute 
intervals. In-dwelling vascular catheters were intermittently flushed with small volumes of 
heparinised saline and wound coverings were monitored and kept hydrated.  
(Refer to the experimental groups outlined for each chapter in tables 3.1, 4.1, 5.1 and 6.1 and 
experimental outlines for each experimental chapter given in figures 3.1, 4.1, 5.1and 6.1).  
2.2 Echocardiographic Assessment of the Left Ventricle 
Echocardiography was performed by a second investigator who had received relevant 
training in the techniques. This second investigator was the same person for each experiment 
and they were blinded to the experimental group the animal was assigned to. However, due to 
the nature of these experiments, the most severely shocked animals were easily identified on 
echocardiographic assessment (with obvious volume depletion of the left ventricle after 
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severe haemorrhage) and in this way, complete blinding of the second investigator was not 
possible. This was also true for the ALM experiments due to the immediate bradycardia 
induced by the drug which was visible during real-time imaging as the drug was delivered.  It 
was therefore obvious to the second investigator if ALM had been administered, but they 
were not able to distinguish between higher or lower dosage as the extent of the bradycardia 
was similar regardless of dose and were therefore blinded in this respect in the chapter six 
experiments.  
Imaging of the left ventricle was performed at baseline, and at defined time-points after 
trauma-haemorrhage and resuscitation, using the Vevo 770 high-resolution in vivo micro-
imaging system (Visualsonics Inc. Toronto, Canada). Animals were anaesthetised before any 
scanning was conducted as previously described. 
A lubricated rectal temperature probe was inserted and their paws were taped to 
electrocardiogram (ECG) pads which had been coated with a layer of conductance cream. 
The anterior thoracic wall was prepared with depilatory cream and warmed ultrasound 
transmission gel (Aquagel, Parker laboratories Inc., NJ, USA) was applied to the chest before 
applying the ultrasound probe. Modified parasternal long and short axis views were obtained. 
The short axis view was used to obtain an image of the left ventricle at the level of the 
papillary muscles. A 2-dimensional cine-loop was recorded. Scanning was converted to M-
mode at this point and an image of the left ventricle was acquired.  Continuous core 
temperature, EGC and heart rate monitoring was performed throughout the duration of the 
scanning procedure. Temperature was maintained at 36.0 +/- 1oC for the duration of the 
procedure.  
Qualitative and quantitative measurements were taken using analytical software 
(Visualsonics. Toronto, Canada). M-mode measurements were made using the programme 
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callipers. Measurements were taken in systole and diastole as follows; Intraventricular 
septum (IVSs, IVSd), left ventricle internal diameter (LVIDs and LVIDd) and left ventricle 
posterior wall (LVPWs and LVPWd). Using these measurements, the software automatically 
calculated stroke volume (SV), cardiac output (CO), ejection fraction (EF) and fractional 
shortening (FS). The measurements were carried out in triplicate and the average of these 
values calculated. 
 
Figure 2.1 Echocardiographic assessment of the left ventricle in B mode imaging.  
A shows the short axis view of the left ventricle (LV) and right ventricle (RV) at the level of 
the papillary muscles. B shows the long axis view (still in B mode imaging) of the LV, right 





2.3.1 Fluid resuscitation 
In experiments where fluid resuscitation was included in the protocol, fluid was administered 
via the jugular catheter over a 5 – 10 minute period. In the clinical setting of major trauma, 
blood products and other fluid is preferentially delivered through central veins (often the 
jugular or subclavian) during resuscitation and therefore administration via a larger vein in 
this model more closely resembles the clinical setting.  
The first resuscitation phase in all experiments saw the transfusion of whole blood which had 
been previously withdrawn during the haemorrhage phase. Shed blood was stored in a 1mL 
syringe and kept warm ex vivo before being administered as a bolus over 5 minutes via the 
jugular catheter. Haemodynamic parameters of heart rate and blood pressure were monitored 
closely to ensure a response to the blood resuscitation. If no response was seen, the neck 
structures and catheters were checked to ensure correct placement and to exclude 
extravasation of blood into the tissues. If the catheters were found to be dislodged, blocked or 
that blood was being lost into the tissues, the experiment was terminated and the animal 
replaced.  
If the return of shed blood was not adequate to resuscitate the animal to baseline parameters, 
small boluses of warmed crystalloid (Vetivex11. Dechra Veterinary Products, Shrewsbury, 
UK) were then administered. (Vetivex is a sterile, non-pyrogenic Hartmann’s solution and 
each 100mL contains sodium chloride 600mg, sodium lactate 317mg, potassium chloride 
40mg and calcium chloride dehydrate 27mg). Volumes of intravenous crystalloid 
administered were recorded in all experiments. In experiments where SV was used as an end-
point for resuscitation, real-time echocardiography was performed throughout the 
resuscitation phase in order to monitor the response to fluid boluses. In addition to the shed 
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blood, boluses of crystalloid solution were then administered in order to restore the SV to the 
baseline level which was taken to represent the completion of the resuscitation phase. 
Volumes of crystalloid administered to achieve the echocardiographically defined end-point 
in these experiments were recorded.  
In chapter six experiments, a second resuscitation phase was performed at the end of this 60-
minute monitoring period. During this time, which lasted 5 – 10 minutes, crystalloid alone 
was administered through the jugular line with the aim of restoring baseline SV once again. 
In some cases, the SV stopped incrementing in response to intravenous fluid. In this instance, 
if a previous increase in response to fluid had been witnessed and if satisfied that the jugular 
line remained appropriately sited, a failure to respond to a further fluid bolus was taken to 
represent the completion of this resuscitation phase and another period of monitoring was 
commenced with no further administration of fluid.   
2.3.2 End-points of fluid resuscitation 
The end-point of resuscitation was based either on MABP or on left ventricle volaemic status 
which was determined by means of echocardiography. When MABP was used as an end-
point, pressures within +/- 5mmHg of the baseline recording were accepted as indicating 
completion of the resuscitation phase. If the MABP was lower than the baseline and further 
fluid boluses were not leading to a positive increment in blood pressure, resuscitation was 
regarded as being completed.  
In all subsequent experiments, the end-point of resuscitation was based upon stroke volume 
recordings in response to fluid boluses.  In these experiments, the aim was to restore left 
ventricle stroke volume (SV) to baseline and resuscitation was deemed to be ‘completed’ 
when the SV was within +/- 5μL of baseline measurement. However, if SV plateaued at 
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lower than the baseline measurement and further fluid boluses were not increasing the SV, 
this point was accepted to represent the completion of the resuscitation phase.  
 
2.4 Adenosine, Lidocaine and Magnesium 
Prior to commencing the experiment, mice were assigned to either ALM or non-ALM 
resuscitation groups. Any animals that did not survive to complete the 60-minute TH phase 
were excluded and replaced to achieve the target N value.  
Animals in the non-ALM treated control group were resuscitated as outlined above with a 
combination of shed blood and crystalloid administered in order to achieve a target SV. 
ALM-treated mice received a combination of adenosine, lidocaine and magnesium in either a 
low or high dose “one-shot” regimen which was administered after the return of shed blood 
during the first resuscitation phase.  
The lower-dose administered comprised of adenosine 0.54mcg/g, lidocaine hydrochloride 
1.63mcg/g and magnesium sulphate 0.6mcg/g while the high dose group received a doubling 
of all the ALM components (adenosine 1.12mcg/g, lidocaine hydrochloride 3.26mcg/g and 
magnesium sulphate1.2mcg/g). The lower dose regimen mirrors that administered in the 
experiments of Granfeldt et al where this dose was used in a porcine haemorrhage model.  
Adenosine, lidocaine and magnesium doses were prepared according to weight and 
suspended in 0.5mL of warmed Hartmann’s solution (Vetivex). This solution was then 
administered after transfusion of shed blood in the first resuscitation phase and the 0.5mL 
volume included in the total volume of crystalloid administered during the first resuscitation 
phase. During intravenous infusion, blood pressure, heart rate and ECG were continuously 
monitored and echocardiographic assessment performed throughout.  The Hartmann’s 
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solution used to deliver the drugs was included in the volume of crystalloid administered to 
reach target SV during the first resuscitation phase. No ALM was administered during the 
second of the resuscitation phases in any of the experiments. 
2.4.1 Terminal blood sampling and storage of whole organs and samples 
At the end of the experiment, terminal exsanguination was performed via the carotid catheter. 
If the catheter has become dislodged, or had become blocked, blood was not taken from any 
other route. Cardiac puncture was avoided due to the requirement of these experiments to 
avoid direct cardiac injury which could impact upon biomarker assessment. In these 
circumstances, functional echocardiographic and haemodynamic data was included in the 
results but no serum biomarker analysis could be performed.  
Blood was dispensed into a 1.1ml Z-Gel microtube (Starstedt. Westphalia, Germany) before 
being centrifuged at room temperature for serum separation. The resulting serum was 
harvested and transferred into an Eppendorf tube (Eppendorf UK Ltd. Stevenage, UK) before 
being frozen at -80oC. Serum samples were stored at this temperature before being thawed in 
a water bath at 37oC for immediate assay. 
The hearts were removed immediately after the end of the experiment. The analysis of this 
cardiac tissue was performed in studies by Centre for Trauma Sciences PhD student, Sriveena 
Naganathar, and described in her thesis “Trauma Induced Secondary Cardiac Injury: clinical 




2.5 Assessment of Tissue Perfusion 
In addition to cardiovascular assessment in terms of MABP, heart rate and left ventricle 
functional parameters, the peripheral perfusion status of experimental animals was also 
performed with assessment of metabolic acidosis and cardiac index. 
2.5.1 Blood lactate measurement 
Blood lactate was measured and used as an index of shock and tissue perfusion. Lactate 
concentrations were assessed using the Accutrend Lactate monitor (Roche, Mannheim, 
Germany). In all of the experiments when a terminal blood sample could be taken, this blood 
was collected into a 1mL syringe and the first 0.05mL were discarded. A drop of blood was 
then immediately applied to the monitor according to the manufacturer’s instructions. Blood 
lactate was then recorded in mmol/L.  
In chapters 3 and 4, blood lactate measurements were recorded before the completion of the 
experiment. In these cases, in order to minimise the blood lost for sampling and therefore 
limit the haemodynamic instability resulting from further blood loss, a small volume of 
arterial blood was drawn back using the blood pressure transducer apparatus and a drop of 
blood was collected from the carotid catheter before the remaining blood in the line was 
flushed back into the animal. This blood was then analysed using the technique outlined 
above. 
2.5.2 Cardiac index 
In these experiments, cardiac index (CI) was calculated as an additional means to quantify 
tissue perfusion on an individual basis.  CI was calculated retrospectively after completion of 
the experimental work and was derived using echocardiographic readings (cardiac output) 
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and the weight of the individual animals which was determined prior to the induction of 
anaesthesia. Cardiac index was calculated using the following formula; 
                               CI (mL/min/Kg) = (CO (mL/min) / gram) x 1000 
 
2.6 Cardiac Biomarker Assessment 
2.6.1 Enzyme-linked immunosorbent assays 
Serum heart fatty acid-binding protein (H-FABP) and troponin I (TnI) were analysed using 
commercially available mouse specific enzyme-linked immunosorbent assay (ELISA) kits 
(supplied by Life Diagnostics Inc., West Chester, PA, USA.). ELISAs were performed in 
accordance with the manufacturer’s instructions. 
2.6.2 ELISA standard curves 
Standard curves for all ELISAs were plotted using Graphpad Prism software (version 6.0h) 
and unknown concentrations were interpolated from the standard curve. If readings fell 
outside of the standard curve, samples were diluted as appropriate and retested. Corrected 
biomarker concentrations were calculated by multiplying concentrations by the appropriate 
dilution factor. 
2.7 Statistical Analysis 
Haemodynamic and echocardiographic readouts and blood analysis results were stored on a 
database created using Microsoft Excel software for Macintosh. Data are expressed as mean 
+/- standard deviation of the mean (SD). Statistical analysis was performed using Graphpad 
Prism software for Macintosh (version 6.0h).  
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Parametric data was analysed using Student t test or one-way ANOVA. Non-parametric data 
was analysed with Kruskall-Wallis and Mann-Whitney U test analysis. 2-tailed P<0.05 was 
taken to represent significance in all statistical analysis. The strength of linear relationships 
(correlation assessment) was performed using Pearson’s correlation coefficient (for normally 
distributed data). Spearman’s rank correlation coefficient was used to assess the relationship 
between non-parametric variables. Derived r or rs values were interpreted as follows; 0 -0.19 
– ‘very weak’, 0.20 - 0.39 – ‘weak’, 0.40 - 0.59 – ‘moderate’, 0.60 - 0.79 – ‘strong’ and 0.80 
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3 Validation of Heart-Type fatty Acid Binding Protein (H-
FABP) as a Biomarker of TISCI in the 1 Hour Murine Model 
of Trauma-Haemorrhage 
3.1 Introduction 
The development of secondary cardiac injury is associated with worse outcomes in injured 
patients. A growing body of literature is suggestive of distinct biomarker profiles associated 
with trauma-induced secondary injury (TISCI) and the development of adverse cardiac events 
(ACEs) including tachyarrhythmia and cardiogenic shock. The development of TISCI has 
been found to be independent of pre-existing heart disease and can occur in the absence of 
direct thoracic trauma. De’Ath et al reported the findings of a retrospective study of 135 
patients admitted to a level one major trauma centre. 13.3% of patients recruited developed 
an ACE and these patients had significantly higher levels of cardiac specific biomarkers on 
admission when compared to patients who did not develop ACE over 28 days. Admission 
Heart fatty acid binding protein (H-FABP) concentrations were 3 times higher in those 
patients who went on to develop an ACE when compared to those who did not. Systolic 
blood pressure was found to be associated with the development of ACE with the likelihood 
increased if systolic blood pressure was below 100 mmHg on admission (De’Ath et al 2012).  
A prospective study conducted at the same centre and published in 2015 demonstrated that 
admission levels of H-FABP correlated with mortality. As well as an association with 
mortality after trauma, an elevated H-FABP on admission also appeared to have predictive 
value with respect to the development of ACE. Elevated serum levels of H-FABP were 
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therefore taken to represent the development of TISCI and when coupled with cardiac 
dysfunction, this resulted in increased mortality and morbidity (Naganathar et al 2015).  
The pathophysiology underlying the development of TISCI and associated cardiac 
dysfunction remain unclear. Mechanical trauma may instigate an inflammatory response, 
which is detrimental on cardiac function. Pro-inflammatory cytokines such as TNF-α and IL-
6 may be associated with admission cardiac biomarkers (De'Ath et al 2013) and associated 
with secondary cardiac injury and dysfunction (Yang et al 2004) Apoptotic pathways in 
cardiomyocytes were triggered when they were cultured with serum from injured animals but 
this was reduced with TNF-alpha blockade (Li et al 2007) These studies may point towards 
an inflammatory driver of TISCI as a result of injury and as part of a systemic inflammatory 
response, however, cardiac dysfunction has also been evident in haemorrhagic shock without 
concomitant mechanical injury (Horton et al 1989).   
Previous studies therefore support the existence of an indirect myocardial specific injury post 
trauma-haemorrhage. The release of proteins such as H-FABP into the blood from 
myocardial tissue may be an indication of occult cardiac damage that occurs soon after 
injury. What is less clear is the precise pathophysiological processes involved and the impact 
of this cellular injury on myocardial function. There is a need for clinically relevant in vivo 
models of TISCI in which to assess the translational relevance of H-FABP related to the 
pathophysiology of TISCI. The ideal animal model would demonstrate appropriate injury 
burden and severity of haemorrhagic shock and display biomarker profiles similar to those 
seen clinically in our patients.  
The relationship between acute trauma, with or without concomitant haemorrhagic shock and 
serum H-FABP levels has not previously been described in a pre-clinical TH model. In order 
to investigate the development of cardiac dysfunction as a consequence of TH, it will first be 
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important to demonstrate that H-FABP is an appropriate cardiac biomarker in this setting and 
does rise, reflecting cardiomyocyte injury, as quickly as 60 minutes after TH in the pre-
clinical model.  
 
3.2 Study Aims 
The overall aim of this study was to develop a mouse model of TISCI and characterise the 
acute cardiac response to trauma and/or haemorrhage. The principle objective was to confirm 
that TISCI, demonstrable by a rise in serum H-FABP concentration, occurred as soon as 60 
minutes after the onset of TH and that the magnitude of this rise was comparable to the 
clinical setting. 
 
3.3 Materials and Methods 
The broad materials and methods are discussed in Chapter 2. 
3.3.1 Experimental groups 
Before the start of the experiment, animals were randomly assigned to 1 of 5 experimental 
groups; Sham control (S), Trauma (T), Haemorrhage (H), Trauma-Haemorrhage at 60 – 









Table 3.1 Experimental Groups, interventions and final N number for the Chapter three 
studies.  




S T H TH 60-70 TH 30-40 












No Yes No Yes Yes 
Final N 
number 
6 6 6 6 6 
 
3.3.2 Experimental outline for Chapter three studies.  







Figure 3.1 Experimental outline for chapter three studies.  
Interventions, observations and the time-frame in which they occur are shown. TH60 refers to 
the 60th minute at target blood pressure in haemorrhage groups.   
 
The experimental period began after the traumatic injuries were inflicted in the T and TH 
groups. In the H and S groups, this was commenced 5 minutes after the carotid cannulation 
was completed thus allowing for the mean time taken to complete the traumatisation.  Mice in 
the H and TH groups underwent a pressure-dependent haemorrhage phase after cannulation 
and injury. Blood withdrawal via the carotid cannula was then performed over a 10-minute 
period to bring the MAP into target range of 30 – 40mmHg. Further blood withdrawals were 
performed throughout the remaining experimental period in order to keep the MAP within the 
target range. In order to investigate the effect of a less severe degree of haemorrhagic shock 




The experimental period was completed 60 minutes after the target MAP was reached in the 
H and TH groups. In the T and S groups, the experiment was completed after 70 minutes, 
allowing for the 10 minutes of bleeding phase in the H and TH groups.  
All animals were euthanized at the end of the experimental period with exsanguination via 
the carotid catheter. 
Blood was separated and stored as previously described. Cardiac tissue was harvested post 




3.4.1 Characterisation of the fixed-pressure TH model of TISCI 
A total of 41 mice were used in this study. There were no deaths in the S, T or TH 60-70 
groups. Due to vascular catheter issues such as blockage or dislodgement, 8 mice were 
excluded from the study. There were 2 deaths before the end of the experimental period in the 
TH 30-40 mmHg group and these were replaced in order to achieve N=6 mice in each of the 
5 experimental groups for final analysis.   
Mean arterial pressures after carotid catheter insertion were similar across the 5 groups (fig. 
3.1). (S = 86.83 ± 2.79 mmHg, T = 84.33 ± 8.91 mmHg, H = 81.33 ± 4.03 mmHg, TH 60-70 
= 86.33 ± 6.31 mmHg, TH 30-40 = 79.83 ± 7.57 mmHg; P>0.05 between all groups).  The 
mean arterial blood pressure of the H and TH 30-40 groups did not differ significantly at the 






Figure 3.2 Mean arterial blood pressure (MABP) trends over 60 minutes.  
Data is shown for the 5 groups throughout the experimental period. Dots represent the mean, 
vertical bars represent the standard deviations of the means.   
 
Venesection of 14.88 ± 2.79%, 32.75 ± 3.91% and 33.38 ± 3.03% of the estimated total blood 
volume (calculated based upon 0.07mL per gram of body weight) was required to achieve 
and maintain target mean arterial pressure in the TH 60-70, TH 30-40 and H groups 
respectively. There was no statistically significant difference in % blood loss between the TH 
30-40 and H groups (P>0.05) but the difference was significant when these 2 groups were 






































Figure 3.3 Blood loss in the fixed-pressure haemorrhage model. 
Box and whisker plots showing estimated blood loss as a percentage of total blood volume in 
the haemorrhaged groups. Median values (horizontal line within box), interquartile range 
(box) and range (error bars) are shown. *P<0.05, **P<0.01 versus TH 60-70. 
 
3.4.2 Blood lactate after 1 hour of trauma-haemorrhage 
Blood lactate measurements were made at the end of the 60 minute experimental period (S = 
0.93 ± 0.17 mmol/L, T = 0.92 ± 0.4 mmol/L, TH 60-70 = 1.9 ± 0.26 mmol/L, H = 4.47 ± 1.53 
and TH 30-40 = 4.45 ± 0.86 mmol/L).  There was no statistically significant difference 
(P>0.05) between the lactate concentrations of S, T and TH-60-70 groups but H 30-40 and 
TH 30-40 groups had significantly higher arterial lactate levels when compared to the S, T 
and TH 60-70 groups (P<0.01) (fig. 3.4). Trauma in the absence of haemorrhage did not 
produce a significantly higher lactate level when compared to sham controls but when trauma 
was coupled with the most severe haemorrhage (exceeding 30% of blood volume), 
significantly higher lactate levels were recorded (P<0.05). The most severe degree of fixed-
pressure haemorrhage alone resulted in similar levels of lactate to those seen when trauma 
and haemorrhage were combined. For the same target MAP over 60 minutes, the addition of 
trauma did not lead to significantly higher arterial lactate concentrations (P<0.05) (fig.3.4).  
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Figure 3.4 Arterial blood lactate concentrations in the fixed-pressure haemorrhage 
model.  
Box and whisker plots showing arterial blood lactate levels at 60 minutes. Median values 
(horizontal line within box), interquartile range (box) and range (error bars) are shown. 
*P<0.01 versus S, T and TH 60-70.  
 
3.4.3 The relationship between serum H-FABP and trauma-haemorrhage 
At the end of the 60 minute experimental period, blood was taken via the carotid catheter, 
serum isolated and this underwent batch analysis for H-FABP concentration (mean values 
and SDs were as follows; S = 3.54 ± 3.06ng/mL, T = 28.04 ± 21.10ng/mL, H = 64.50 ± 
38.17ng/mL, TH 60-70 = 80.04 ± 49.1ng/mL and TH 30-40 = 166.69 ± 38.64ng/mL). Serum 
H-FABP concentrations were significantly raised in T, H, TH 60-70 and TH 30-40 groups 
when compared to sham operated controls (P<0.05) (fig. 3.5). 
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Figure 3.5 Serum H-FABP concentrations in the 5 experimental groups.  
Box and whisker plots showing median values (horizontal lines within box), interquartile 
range (box) and range (error bars) are shown. *P<0.05, **P<0.01 and ***P<0.001 versus S.  
 
Post-hoc analysis revealed that H-FABP concentration in TH 30-40 group was significantly 
higher versus T (P<0.001), H (P<0.001) and TH 60-70 (P<0.01). Serum H-FABP is therefore 
elevated after 60 minutes of trauma and or haemorrhage with the highest serum 
concentrations being seen in the model combining injury with the more severe degree of 
blood loss.   
H-FABP level correlated positively with the estimated blood loss (r= 0.4812, 95 per cent 
confidence interval (C.I.) 0.00346 – 0.7801, p <0.05). Serum H-FABP negatively correlated 
with mean MAP over 60 minutes (r=-0.8092, C.I. -0.9075 to -0.6270, p<0.05).  
3.5 Discussion 
These experiments have shown that serum H-FABP concentrations are raised in response to 
trauma-haemorrhage as quickly as 60 minutes after the onset of TH. The highest 
concentrations were seen in the most severe form of trauma combined with haemorrhagic 
shock although levels were also significantly elevated when injured mice with a lesser degree 
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of shock were compared to non-injured or haemorrhaged controls. H-FABP concentration 
negatively correlated with MAP over the 60-minute TH phase and positively correlated with 
blood loss.   
The aim of these studies was to validate H-FABP as a biomarker of trauma-induced 
secondary cardiac injury and to develop a translatable model in which to investigate 
myocardial function acutely after TH.  
The mouse model developed in these studies successfully reproduces the biomarker profiles 
reported in clinical studies of TISCI. H-FABP levels have been shown to rise as quickly as 60 
minutes after TH in the absence of thoracic injury and the magnitude of this rise is similar to 
that seen in previous clinical studies of cardiac injury after trauma. The mean level of H-
FABP in TH30-40mmHg at 60 minutes was 166.69 ± 38.44 while De’Ath et al reported 
values of up to 200ng/ml on admission, in patients who later developed an ACE (De’Ath et al 
2012).  
H-FABP concentrations were significantly higher when TH animals were compared to sham 
controls. The H-FABP concentrations in the trauma group were numerically higher when 
compared to sham but his was not statistically significant. This is an interesting observation 
however as it may support previous work which has suggested a link between acute 
inflammation (systemic inflammatory response syndrome) and the development of 
myocardial dysfunction (De’Ath et al 2013) also IL-6 and cardio-depression after TH (Yang 
et al 2004). Mechanical trauma alone has been previously associated with cardiomyocyte 
apoptosis (Tao et al 2005). The injury inflicted in the absence of trauma may have 
precipitated inflammatory pathways, which drive TISCI and lead to the elevated H-FABP 
levels reported here. This finding needs to be interpreted with caution however, as the MABP 
in the T group by the end of the experiment was lower than that reported in the sham group 
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therefore there may have been a degree of hypotension in this group when compared to 
baseline blood pressure. Care was taken to ensure there were no sources of bleeding in the T 
group. Inspection of the abdomen post laparotomy was performed to exclude iatrogenic 
injury leading to internal haemorrhage and post-mortem analysis of the femoral fractures did 
not reveal gross haemorrhage into the hind limb. Mean lactate concentrations were similar 
between S and T groups and significantly lower than haemorrhage groups suggesting that 
although the T group had a lower MAP at the end of the experiment, there was no significant 
lactatemia, making the incidence of tissue ischaemia less likely. 
The highest H-FABP concentrations were seen in serum of animals experiencing a 
combination of trauma and haemorrhage. Haemorrhage alone to MAP 30-40 for 60 minutes 
however produced H-FABP levels which were significantly higher than controls, and higher 
(but not significantly) than TH 60-70. Blood loss as a percentage of total body weight was 
found to be in the region of 32 – 34% in the H and TH 30-40 group and the difference 
between the two groups was not significant. Lactate levels in these 2 groups were not 
significantly different with the H group actually having slightly higher mean values. This 
again supports the hypothesis that hypotension during a 60 minute period was perhaps not the 
only driver of TISCI and the higher H-FABP concentration.  
Reperfusion injury and associated myocardial inflammation has been reported as contributing 
to the cardiac injury seen after a period of ischaemia (Ashraf et al 1995 and Lefer et al 1993) 
I have presented here findings for an un-resuscitated model of TH and therefore the 
pathophysiological drivers of the TISCI in these animals are not dependent upon the 
reperfusion of the myocardium. Within 60 minutes of TH in patients, many may not have 
received intravenous fluid resuscitation, particularly if they are not hypotensive in the pre-
hospital setting. It may be that the higher H-FABP concentrations seen at 24 hours (De’Ath et 
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al 2012) may be due to ongoing cardiac ‘leak’ of H-FABP, or there may now be other 
processes involved now with fluid resuscitation and other interventions occurring.  
A pilot study was also conducted during the course of these studies to investigate troponin I 
(TnI) as a potential biomarker in this setting. TnI levels were not elevated (<0.05ng/ml) at 60 
minutes post TH when these animals were compared to sham (data not shown). This also 
supports the findings of De’Ath et al who reported admission levels of <0.05ng/ml in patients 
who went on to develop ACEs after trauma (De’Ath et al 2012). This pattern of biomarker 
release is likely to reflect the kinetics of H-FABP and TnI. H-FABP is released more quickly 
into the circulation in response to ischaemia when compared to troponin by virtue of its 
location within the cytoplasm. The low levels of TnI detected at 60 minutes of TH in the 
small study also supports the translational potential of this model to investigate TISCI as this 
reflects findings in the literature.  
These studies have therefore validated the use of H-FABP as a biomarker of TISCI in a 
murine model of TH. The results presented here also, for the first time, demonstrate the dose-
dependent nature of the H-FABP rise in response to TH at 60 minutes. No overt cardiac 
dysfunction was observed in these 60-minute experiments however and it is therefore unclear 
how the raised H-FABP levels correspond to the development of myocardial dysfunction at 
this acute stage and in the longer term.     
 
3.6 Limitations 
Trauma, in the clinical setting, represents a multi-factorial condition which poses many 
challenges when constructing a robust, translatable pre-clinical model. It is not possible to 
reproduce the uncontrolled haemorrhage seen clinically in small animal models of TH. Fixed-
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pressure haemorrhage as demonstrated here, therefore will not reflect the conditions seen in 
patients with uncontrolled blood loss. For example, the rate and depth of shock is controlled 
and may therefore limit the extent of tissue ischaemia and associated phenomena such as 
trauma-induced coagulopathy which can result (Frankel et al 2007). The benefit of the fixed-
pressure method used here however, has allowed for an assessment of the correlation between 
severity of blood loss and the resultant rise of H-FABP. Anaesthesia is induced before the 
onset of traumatization and bleeding and this obviously does not reflect the clinical setting. 
However, in order to limit the impact of anaesthesia choice in this experiment, isoflurane was 
specifically chosen as it is less cardio-depressant when compared to other anaesthetic agents 
available for in vivo studies using mice. Sham controls were anaesthetised in the same way as 
the other 3 groups and demonstrated the lowest lactate levels which suggests that anaesthesia 
was not negatively impacting upon cardiovascular reflexes or homeostatic mechanisms in 
these animals. This supports the use of isoflurane as the anaesthetic agent in these 
experiments. The sham animals also had the lowest H-FABP concentrations at the end of the 
experiment which indicates that the anaesthetic regimen was not causing direct myocardial 
injury under these conditions.  
Despite the limitations when performing this type of translational work, mice have proven 
valuable in cardiovascular research fields and the availability of micro-imaging systems has 
meant that these techniques have been successfully applied to this model of TH in order to 
discover more about myocardial function in the acute phase after injury and haemorrhage. 
Small animal models of TH are technically difficult to successfully master and reproduce. 
Another potential drawback is the small circulating volume and therefore limited blood 
available for biochemical analysis.  
This study has focussed on the first 60 minutes after trauma-haemorrhage. This is a very short 
window and the aim was to determine whether H-FABP would be significantly in the murine 
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model this quickly. The drawback of this however is that the very short study duration has 
not allowed for the development of overt adverse cardiac events. No comment can therefore 
me made between the association between myocardial cellular injury (diagnosed on the basis 
of H-FABP rise) and subsequent ACE development or the nature of the ACE that may arise 
on this background.  
 
3.7 Conclusions 
It has been possible to develop a murine model of trauma-induced secondary cardiac injury, 
which demonstrates biomarker profiles similar to those seen in clinical studies. Movement 
from ‘bedside-to-bench’ in this case has been invaluable in developing a translatable model 
in which to further investigate the functional implications of this cardiac injury after trauma 
haemorrhage. A dose-dependent increase in circulating H-FABP in response to TH has been 
shown here for the first time. 
The development of this pre-clinical model of TISCI, which mirrors the cardiac biomarker 
profiles of trauma patients at 60 minutes, provides an opportunity to investigate the functional 
cardiac outcomes associated with the development of the biomarker-proven insult. 
Characterisation of cardiac function in this small animal model of TISCI will prove 
invaluable in furthering our understanding of functional consequences of the acute damage 
inflicted upon a vitally important terminally differentiated cell population within the heart. 
There is a need therefore to characterise myocardial function in the context of elevated H-
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4 In-Vivo Assessment of the Myocardial Response to Trauma-
Haemorrhage using Non-Invasive Micro-Echocardiography 
4.1 Introduction 
The previous chapter of this thesis has demonstrated the presence of biomarker proven TISCI 
at 60 minutes post onset of trauma and haemorrhagic shock in the pre-clinical model. 
Circulating H-FABP levels have been shown to rise in-line with increasing severity of insult. 
This cardiac-specific biomarker can therefore be considered an indirect indicator of 
cardiomyocyte damage as a result of blood loss and remote injury. 
The application of in vivo functional assessment to the model described previously offers the 
potential to identify therapeutic targets which limit the extent of cardiac injury and 
dysfunction. This small animal model of TISCI has successfully demonstrated the presence 
of cardiomyocyte injury after just 60-minutes of trauma with haemorrhage; the impact of 
injury and severe blood loss with resultant H-FABP rise on myocardial function in vivo, 
remains to be elucidated. 
 
4.2 Important Considerations for the use of Echocardiography in 
Rodent Models of Cardiovascular Disease 
Echocardiography is a widely used non-invasive imaging tool with which to visualise cardiac 
structure and assess function in in vivo rodent models of cardiovascular disease. The 
development of high frequency (greater than 10MHz) probes for use specifically in small 
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animals has allowed for good quality imaging of the rapidly beating left ventricle in rats and 
mice. Genetically manipulated mouse strains have proven invaluable in the development of 
murine models of cardiovascular pathology and echocardiography has been a useful tool in 
the assessment of cardiac structure and function in these disease states (such as mouse models 
of cardiomyopathy and regional ischaemia), and in the development of therapeutics (Rottman 
et al 2007). 
 
Table 4.1 Baseline LV functional parameters and heart rate in conscious C57BL/6 mice.  
Mean values are given with standard deviations. (Data taken from Rottman et al 2007).  
LVID = left ventricular internal diameter, LVPW = left ventricular posterior wall, IVSd = 
interventricular septal, s = end systole, d = end diastole. HR = heart rate (beats per minute).  
 Systolic Measurements (cm) Diastolic Measurements (cm)  
Measurement LVIDs LVPWs IVSd LVIDd LVPWd HR 
Values (Mean 
and SD) 









An important consideration when using in-vivo imaging in rodent models is the impact of 
anaesthesia. Performing imaging in conscious animals would obviously be the most desirable 
scenario in order to limit the effect of sedatives and anaesthetic agents upon normal 
physiology, however, there are obvious logistical and humane barriers to doing this.  Physical 
restraint of conscious animals to facilitate scanning can be done but this in itself leads to 
physiological changes such as increased sympathetic tone, which will invariably have a 
bearing on readouts relating to cardiac performance such as heart rate (Yang et al 1999). 
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In order to minimise discomfort and distress, and allow reproducibility of good quality 
images, animals can be anaesthetised for the duration of the imaging procedure. The choice 
of anaesthetic agent in this case is of importance however as commonly used anaesthetics 
will vary in the associated degree of cardio-depression they induce (Rottman et al 2003). An 
agent with the least negative chronotropic and inotropic effects will therefore be favourable, 
particularly in the context of haemorrhage models where normal homeostatic mechanisms are 
vital in allowing physiological compensation and survival.  
Inhaled isoflurane is a sensible choice of agent for studying left ventricular function in mice 
due to its ease of titration and rapid reversibility. Isoflurane has also been reported to have 
fewer cardio-depressant effects when compared to other agents commonly used to 
anaesthetise rodents (Kohn. 1997). 
Body temperature will affect the transmission of ultrasound waves through tissues and 
therefore, to ensure consistent readouts, the animals’ temperature should be monitored and 
controlled throughout the duration of the scanning procedure (Lahoutte. 2007). 
Other cardiovascular imaging modalities are available for use in small animals. Computed 
tomography (CT), positron emission tomography (PET), magnetic resonance imaging (MRI) 
and micro-single photon emission computed tomography (microSPECT) have all been used 
to assess cardiac function in rodents but the need for sophisticated equipment and radioactive 
tracers mean that the successful application of these technologies is more complex and comes 
with additional costs (Golestani et al 2010). The pharmacokinetics of commonly used tracers, 
for example, dictates the time between scanning, as tracers need to be cleared before another 
scan can take place and this could therefore limit studies requiring serial evaluation.    
The advancement of ultrasound technology for use in animals coupled with the 
translational potential of this imaging modality means that echocardiography remains highly 
120 
 
popular in pre-clinical cardiovascular research to identify and monitor the progression of 
cardiac pathophysiology. The application of non-invasive cardiac ultrasonography in the 
model of TISCI will allow for rapid, serial assessment of the left ventricle before and after a 
period of trauma-haemorrhage. This will enable us to answer questions regarding cardiac 
function and the response of the left ventricle to the development of TISCI.  
 
4.3 Study Aims 
Determine the feasibility of using micro-imaging in the existing murine trauma-haemorrhage 
model. Assess the impact of 60 minutes of trauma and haemorrhage on systolic function of 
the left ventricle and correlate cardiac performance with severity of biomarker proven TISCI. 
 
4.4 Materials and Methods 











4.4.1 Experimental groups for Chapter Four studies 
Table 4.2 Experimental groups, interventions and final N number for the Chapter Four 
studies. 
 




S T TH 60-70 TH 30-40 










No Yes Yes Yes 
Baseline 
Echo 
Yes Yes Yes Yes 
60-minute 
Echo 
Yes Yes Yes Yes 
Final N 
number 




4.4.2 Experimental outline for Chapter Four studies.  
 
Figure 4.1 Experimental outline for the 1 hour echocardiography studies.  




A total of 28 mice were used in this study. Technical difficulties with carotid catheter (loss of 
patency and lack of reliable signal transduction) led to the exclusion of 2 animals. There were 
2 deaths in the TH 30-40 group before the end of the experimental period and these animals 
were replaced to give N=6 for all groups. There were no deaths in the S, T or TH 60-70 
groups before the end of the experiment.  
4.5.1 Haemodynamic characterisation of the trauma-haemorrhage model 
There was no significant difference between the MAPs after insertion of the carotid catheter 
(S = 89.33 ± 5.99 mmHg, T = 85.5 ± 4.72 mmHg, TH 60-70 = 86.5 ±4.42 mmHg and TH 30-
40 = 87.2 ± 7.69 mmHg). At the end of the experimental period, there was no statistically 
significant difference between the S and T group (P<0.05) whereas, the haemorrhaged groups 
were significantly more hypotensive when compared to S and T (P<0.001). Mice in the TH 
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30-40 group were significantly more hypotensive than TH 60-70 mice at 60 minutes 
(P<0.01). (S= 89.67 ± 10.61 mmHg, T= 90 ± 6.16 mmHg, TH 60-70 = 58.17 ± 13.3 mmHg 
and TH 30-40 = 32.4 ± 4.51 mmHg).  
. 
 
Figure 4.2 MABP trends during the 60 minute TH phase in 4 experimental groups.  
Line graph shows the trends in MABP across the experimental period of 60 minutes. P<0.05 
TH60-70 and TH30-40 compared to Sham and Trauma, P<0.01 Th30-40 compared to TH60-
70.  
 
Comparison of estimated blood loss (calculated as a percentage of total blood volume) in the 
2 haemorrhage groups revealed a significantly higher % blood loss in the TH 30-40 group 
(P<0.05) compared to those animals in the TH 60-70 group (Fig. 4.3).  
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Figure 4.3 Blood loss in the haemorrhaged groups.  
Estimated blood loss is shown as a percentage of the total blood volume (calculated based 
upon individual animal’s weight). Box and whisker plots showing median values (horizontal 
lines within box), interquartile range (box) and range (whiskers) are shown. *P<0.05 TH60-
70 versus TH 30-40.  
 
4.5.2 The functional myocardial response to non-resuscitated TH 
Echocardiography was performed at baseline and again after 60 minutes in each animal. 
Table 4.3 presents the mean and standard deviations (SD) for LV functional parameters 
(stroke volume (SV), cardiac output (CO), ejection fraction (EF) and fractional shortening 
(FS) and heart rate (HR) at baseline. There was no significant difference in SV, CO, EF, FS 









Table 4.3 Baseline LV outcomes.  
Mean values are given for stroke volume (SV), cardiac output (CO), ejection fraction (EF), 









































P value 0.4389 0.1499 0.4092 0.8494 0.0667 
 
Functional analysis at 60 minutes revealed a significantly lower SV and CO when the 
haemorrhage groups were compared to S and T groups (fig. 4.4 A-B). The greatest 









Table 4.4 Left ventricular outcomes at 60 minutes.  
Mean values are given for Stroke volume (SV), cardiac output (CO), Ejection fraction (EF), 
Fractional shortening (FS) and Heart rate (HR) with standard deviations also shown. P<0.05 





















Sham (n=6) 27.46 ± 7.14 12.57 ± 1.81 66.35 ± 10.43 36.04 ± 8.08 446.5 ± 
46.77 








3.46 ± 1.95 1.92 ± 0.95 71.16 ± 10.13 39.67 ± 8.16 573.6 ± 
76.56 
P value <0.0001 <0.0001 0.1232 0.3718 0.0157 
 
The reduction seen in CO was also significantly lower in the TH 30-40 group when compared 
to TH 60-70 (P<0.01). CO in the T group appeared to be higher than S (14.25 ± 3.50 mL/min 
and 12.57 ± 1.81 respectively) but this difference was not significantly significant (P>0.05) 





Figure 4.4 Left ventricular functional outcomes at 60 minutes.  
Box and whisker plot showing A Stroke Volume (SV), B Cardiac output (C.O), C Ejection 
fraction (E.F) and D Fractional shortening (F.S) at 60 minutes. Median values (horizontal 
lines within box), interquartile range (box) and range (whiskers) are shown *P<0.05, 
**P<0.001 versus sham or trauma. ***P<0.01 TH 60-70 versus TH 30-40. 
 
Ejection fraction and fractional shortening did not have any statistically significant difference 
across the 4 groups at 6o minutes (P>0.05).  
The heart rate tended to be numerically higher in the T versus S group but this was not 
statistically significant. HR was significantly higher in the haemorrhaged groups (P<0.05 and 













































Figure 4.5 Heart rate at 60 minutes.  
Box and whisker plot showing heart rate (HR) at 60 minutes. Median values (horizontal lines 
within box), interquartile range (box) and range (whiskers) are shown. *P<0.05 versus sham, 
**P<0.01 versus sham.  
 
4.5.3 Perfusion status after trauma-haemorrhage 
Cardiac index (calculated as litres per gram of body weight per minute) was derived as an 
indicator of perfusion using individual animal’s weight and cardiac output at specified time-
points. There was no statistically significant difference between the groups in terms of 
cardiac index at baseline (refer to table 4.5 below). Cardiac index was significantly lower in 
the TH 60-70 and TH 30-40 groups when compared to Sham and trauma groups. The TH 30-
40 group had significantly lower cardiac index when compared to the less severe TH 60-70 







Table 4.5 Cardiac index changes after 60 minutes of trauma-haemorrhage.  
Data is shown for the four experimental groups at baseline and then at the end of the 
experimental period. (Mean is given with standard deviation in parenthesis). P values are also 
given and calculated using unpaired t-test (comparison between baseline and 60 minutes) and 
one-way ANOVA (comparison between the 4 groups at baseline and 60 minutes). P<0.05 is 
considered significant.  
                                  Cardiac Index (L/g/min) 
Baseline 60 Minutes  P Value 
Sham 58.23 (± 11.30) 50.372 (± 4.74) 0.1472 
Trauma 67.76 (± 13.70) 51.974 (± 11.57) 0.0538 
TH 60-70 67.77 (± 11.078) 28.028 (± 12.79) 0.0002 
TH 30-40 66.97 (± 7.86) 8.386 (± 3.40) <0.0001 
P Value 0.3897 <0.0001  
 
The relationship between cardiac index at baseline and after 60-minutes of TH without 
resuscitation is illustrated in fig.4.6. Cardiac index will, by virtue of how it is derived, reflect 
the drop in cardiac output seen after TH but can be considered an indicator of how cardiac 
output is related to the size and therefore the perfusion status of the animal as a whole. For 
example, 2 animals may have similar cardiac output after an hour of hypotension, but a larger 
animal (with, by inference, a larger surface area) may be more compromised in terms of their 
peripheral perfusion status. In order to support this, blood lactate concentrations at the end of 
the experiments were recorded and a correlation analysis was performed to assess the 




A                                                                          B 
        
Figure 4.6 Cardiac index at baseline and at 60 minutes.  
Graphs show cardiac index at A) Baseline and B) 60 minutes. *P<0.01 when group is 
compared to Sham or Trauma groups. **P<0.01 when TH 60-70 versus TH 30-40.     
 
Blood lactate concentration was significantly higher at 60 minutes in the TH 30-40 animals 
(P<0.05) when compared to the other 3 experimental groups (fig.4.7). 
                                       
Figure 4.7 Blood lactate concentrations at 60 minutes.  
Median values (horizontal lines within box), interquartile range (box) and range (whiskers) 




4.5.4 The relationship between lactate and cardiac index 
There was a negative correlation between cardiac index and blood lactate concentration when 
all of the animals were assessed with the higher lactate concentrations being recorded in 
animals with lower cardiac index (fig. 4.8).  
 
                              
Figure 4.8 Correlation between lactate and cardiac index at 60 minutes.  
Scatter graph demonstrates the correlation between blood lactate concentration and cardiac 
index after 60 minutes of trauma-haemorrhage. Spearman r = -0.6206 (95% confidence 
interval -0.8231 – 0.2781. P value (2-tailed) = 0.0012). 
 
4.5.5 Serum H-FABP 
Serum H-FABP was highest in the TH 30-40 mice (fig. 4.9). This increase was significant 
when compared to sham controls. Serum concentrations of H-FABP were higher in the serum 
of T and TH 60-70 mice, but this was not statistically significant (P>0.05).  When assessed 
for a linear relationship between CO and Serum H-FABP, a negative correlation was found. 
As CO fell, H-FABP increased with Spearman r = -0.6959 (C.I. -0.8811 to -0.3259. Two-
tailed P value = 0.0013).  
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Figure 4.9 Serum H-FABP concentration at 60 minutes in the 4 experimental groups.  
Box and whisker plots showing serum H-FABP at 60 minutes. Median values (horizontal 
lines within box), interquartile range (box) and range (whiskers) are shown. *P<0.01 versus 
Sham, Trauma and TH 60-70.  
 
4.5.6 The correlation between perfusion and serum H-FABP 
Serum H-FABP analysis revealed that there was a tendency for higher H-FABP 
concentrations in animals subjected to increasing severity of insult. This biomarker rise was 
significant when TH 30-40 mice were compared to Sham, Trauma and TH 60-70 groups (fig. 
4.9). Correlation analysis performed to assess the relationship between H-FABP and cardiac 
index revealed that there was a statistically significant, strong negative relationship between 
the two with the highest H-FABP concentrations being seen in the animals with the lowest 




                           
Figure 4.10 Correlation between cardiac index and serum H-FABP concentration.  
Scatter plot shows the correlation between cardiac index and serum H-FABP at the end of the 
experiment. Spearman r = -0.7985, 95% confidence interval -0.9192 - -0.5406, P value (2 
tailed) <0.0001.  
 
4.6 Discussion 
Non-invasive echocardiography has been demonstrated to be a feasible cardiac imaging 
modality in this murine model of TH and has been used successfully in these experiments to 
assess left ventricular systolic function before and after trauma-haemorrhage with repeated 
imaging at specified time-points in the same animal. To the best of my knowledge, this is the 
first example of this imaging modality being used in a murine model of TISCI.  
Serum H-FABP levels at 1 hour reported here corroborate the data presented in the previous 
chapter with a dose-dependent increase in relation to severity of trauma and haemorrhagic 
shock at 60 minutes. This study confirms that serum H-FABP levels at 60 minutes correlate 
with cardiac output with the highest biomarker values reported for the animals experiencing 
the lowest cardiac output states as a direct result of blood loss. This finding is interesting and 
one can speculate that it provides an insight into the degree of cardiac output compromise 
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experienced by patients who present to the emergency department with hypotension and 
serum H-FABP level rises of a similar magnitude. 
There was no significant difference in baseline MAP between any of the groups. S and T 
groups did not differ significantly at the end of the 60 minute experimental period whereas 
the TH 30-40 group was significantly more hypotensive than S, T and TH 60-70 as expected. 
Blood loss as a percentage of body weight was significantly lower in the TH 60-70 group 
(mean 18.63 ± 3.50% compared to 35.83 ± 5.05% in TH 30-40).  Baseline analysis of the left 
ventricle revealed that there were no significant differences between the groups in terms of 
LV parameters SV, CO, EF and FS. We can therefore be more reassured that any differences 
seen at the end of the experimental period were not due to intrinsic differences in left 
ventricular function between the groups.  Heart rate at baseline tended to be higher in the 
trauma, TH 60-70 and TH 30-40 groups but this was not significant.  
At the end of the 60 minute period, SV and CO were significantly lower in the TH groups 
when compared to S and T with the greatest reduction being seen in the TH 30-40 mice. SV 
was comparable between the S and T mice. CO tended to be higher in T compared to S but 
this was found to be non-significant. The higher CO with similar SV seen in these non-
haemorrhage groups can be explained by the increased HR (446.5 ±46.77 bpm vs 504.33 ± 
43.12 bpm) in the injured mice. This increased heart rate may explain the difference in CO 
but was not statistically significant and likely reflects the expected physiological response to 
injury. Although there was a trend toward a higher heart rate in the more severe haemorrhage 
group, this was not significant when compared to TH 60-70. This may be regarded as 
somewhat surprising as a greater degree of tachycardia may be expected in those animals 
experiencing a greater percentage blood loss. A technical consideration here relates to 
acquisition of a signal from the peripherally placed ECG (and therefore HR) pads. In severe 
shock, it is possible that the resulting vasoconstriction resulted in poorer signal acquisition 
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and therefore an artefactual relatively reduced heart rate. Another important consideration 
however, relates to the phenomenon of bradycardia arising in rodents after haemorrhage. 
Severe haemorrhage in rats has been shown to be associated with a bradycardia response 
thought to be modulated via vagal efferent pathways. Furthermore, tissue injury has also been 
shown to modulate these reflex pathways (Little et al 1989). In this model of severe 
haemorrhage and tissue injury therefore, it is possible that these vagally-mediated pathways 
are upregulated and if not significantly lowering the HR, may be limiting the resultant 
tachycardia. Given that the only mortality that occurred during these experiments was in the 
most severe haemorrhage group, it may also be the case that the animals were so severely 
shocked that they were no longer able to compensate or mount a further tachycardia response 
and this physiological observation may hint at imminent decompensation. The cardiac output 
and stroke volume data in these animals would support this as it illustrates the severity of the 
fall in left ventricular outflow however at this stage in the experiment.  
The drop in CO and SV after trauma-haemorrhage is dramatic in the data presented here. 
Blood loss equating to approximately 19% of total blood volume in the TH 60-70 group 
resulted in a reduction of SV by 66.3% and CO by 58% while a 36% haemorrhage resulted in 
a percentage reduction of stroke volume of 90.39% and CO was reduced by 88.36% in the 
TH 30-40 mice. In this, and the preceding study, mortality during the TH phase was only 
seen in the TH 30-40 group and this may reflect the precarious cardiovascular situation at this 
degree of blood loss. (Post-mortem analysis of the laparotomy wound and the femoral 
fracture sites precluded the possibility of bleeding at these sites as a source of ongoing 
haemorrhage). 
Given that myocardial perfusion is dependent upon filling of the coronary arteries during 
diastole, this combination of reduced SV and shorter diastole as a result of the increased heart 
rate, may go some way to explaining the possible cardiac ischaemia and cardiac biomarker 
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rise seen in this model. Serum analysis revealed significantly higher H-FABP concentrations 
in the TH 30-40 mice when compared to all other groups with a numerical tendency for 
concentration to rise with severity of insult. Sympathetic drive in response to injury and 
blood loss may generate increased myocardial mechanical and metabolic activity that the 
coronary flow is not able to reconcile under these conditions. The resultant myocardial 
ischaemia, demonstrated by a rise in circulating H-FABP, may set in motion pathways which 
later lead to the development of overt cardiac dysfunction and, as referred to earlier, there is a 
need to perform longer term studies to evaluate myocardial function longer-term.   
Cardiac index has been used in previous animal models of trauma-haemorrhage as a 
haemodynamic outcome measure (Coimbra et al 2004) but tends to be measured using 
thermodilution techniques rather than in the way described here with echocardiographically 
derived cardiac output measurement.  Changes in cardiac index, used as a measure of cardiac 
performance and relates cardiac output to the size of the individual (in these experiments 
based upon weight) also serve to highlight the extent of the haemodynamic compromise 
experienced by the animals in the most severe haemorrhage group. Baseline measurements 
were similar throughout the 4 groups and although a small decline was seen in the sham and 
trauma groups at 60-minutes, this was not significant. Both haemorrhage groups had 
significantly lower cardiac index when compared to sham and trauma at 60-minutes and the 
TH 30-40 group animals had a significantly worse cardiac index at 60-minutes when 
compared to the less hypotensive group members. A limitation regarding the analysis of 
cardiac index however relates to the weight of animals used as experimental animals were 
only used if they were within the defined weight range. 
Fractional shortening and ejection fraction were also recorded before and after TH. There was 
no significant difference seen in these parameters when 60-minute data was compared to 
baseline. Fractional shortening assesses the degree of shortening of the diameter of the LV 
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between end-diastole and end-systole and therefore acts as an approximation of myocardial 
contractility. This 60-minute model of TH did not therefore demonstrate any significant acute 
change in myocardial contractility when using this systolic functional outcome. 
Haemorrhagic shock has previously been demonstrated to negatively impact upon myocardial 
contractility with or without accompanying mechanical injury. Mechanical cardiac 
dysfunction has previously been reported as soon as 30 minutes after trauma (Feng et al 
2013) but the dysfunction was not seen in vivo but rather within isolated heart systems and in 
preparations of isolated cardiac myocytes. In the majority of the studies, overt cardiac 
dysfunction, if seen, typically occurs beyond 1 hour (Remmers et al 1998 and Hsu et al 
2009), and in some cases up to 24 hours after initial TH. (Sambol et al 2009) Therefore, the 
duration of the studies reported here has demonstrated a significant rise in H-FABP over a 
60-minute period, but may not be long enough to allow for the development of overt 
myocardial dysfunction, as assessed with echocardiography. The omission of resuscitation in 
the model may also account for the apparent lack of overt cardiac dysfunction. The vast 
majority of small animal models in the contemporary literature regarding cardiac dysfunction 
after trauma-haemorrhage include resuscitation in their protocols. Reperfusion of previously 
ischaemic myocardial tissue may set in motion a number of pathophysiological pathways, 
both locally and distant, culminating in ventricular dysfunction. Inflammatory mediators 
generated in response to distant injury and hypoxia for example, may only impact upon the 
heart upon restoration of circulating volume and therefore in states of hypovolaemia, as in the 
un-resuscitated model presented here, the full impact of these factors may not be appreciable. 
Many studies have identified the presence of TISCI and there have been a number of 
different methods employed in order to assess cardiac function after trauma haemorrhage in 
animal models. The contemporary literature in this field (discussed previously) has however, 
generally focussed upon indirect techniques to explore changes in left ventricular function in 
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relation to TISCI such as the thermodilution methods. Methods such as the isolated perfused 
heart system have also been beneficial in providing a controlled circulatory system in which 
to assess therapeutics particularly. However, such ex vivo techniques have limitations, 
including removal of the heart from the ongoing exposure to circulating mediators 
constituting part of the milieu of haemorrhagic shock and inflammation.  
Imaging the in vivo model means that the cardiac function that we see here is within the 
context of the myriad of neuro-hormonal changes which are occurring in response to trauma 
and haemorrhagic shock and in this way, could be considered to be more translatable to the 
clinical scenario. These experiments have demonstrated that, despite technical constraints 
such as anaesthesia, the animals’ haemodynamic responses and compensatory mechanisms 
are still responsive and trends reflect those which we see in humans after significant 
haemorrhage i.e. tachycardia to maintain cardiac output in attempts to maintain adequate 
cardiac output and perfusion.  
The application of non-invasive imaging to the previously described small animal model of 
TISCI has allowed for the characterization of LV function in the acute stages after TH in the 
presence of biomarker proven cardiac injury. This un-resuscitated model has demonstrated 
the development of biomarker-proven TISCI in a 60 minute model of hypotension and 
trauma. Imaging the left ventricle in these studies has demonstrated the impact of 
haemorrhagic shock and injury on left ventricle functional parameters and has also allowed 
for the assessment of a ‘personalised’ marker of haemodynamic status in relation to habitus, 
reported as cardiac index.  
Clinical studies have highlighted the need for functional assessment of the myocardium in the 
presence of TISCI. However, many questions still remain about the underlying 
pathophysiology and functional consequences of TISCI. The development of this in vivo 
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model of TISCI will prove useful in the further characterization of the functional myocardial 
outcomes associated with this clinically important pathophysiology.  No overt myocardial 
dysfunction was demonstrated during these experiments at 60-minutes, even in the context of 
raised serum H-FABP concentrations. A longer-term model is therefore warranted in which 
to observe for the development of dysfunction beyond 60 minutes after initial severe TH.  
 
4.7 Limitations 
Some of the commonly encountered limitations when performing these types of studies in 
small animal models have already been discussed. Small animal work however is challenging 
and the small size and blood volumes means that there are restrictions on blood sampling 
frequency and monitoring. Despite these issues, I believe that these studies have 
demonstrated the feasibility of performing robust, reproducible in vivo cardiac imaging in a 
complex trauma-haemorrhage model. 
 
4.8 Conclusions 
Echocardiography is a non-invasive imaging modality, which provides the clinician with 
rapid, reproducible structural and functional information. Transthoracic echocardiography 
(TTE) has, in more recent years, been proposed as an adjunct to more traditional methods of 
assessing volume status and monitoring response to fluid therapy in adult trauma patients. 
(Porter et al 2015) Although there are no specific recommendations regarding its role in this 
aspect of trauma care at present, this serves to demonstrate the potential wide-ranging 
applications of cardiac ultrasound and how pre-clinical models will need to keep pace with 
developments in the clinical arena. 
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The application of this highly relevant and translatable imaging modality to this in vivo model 
of TISCI therefore represents a more sophisticated platform in which to further our 
knowledge regarding myocardial function in TISCI. The studies presented in this thesis thus 
far have focused upon the impact of trauma with hypoperfusion resulting from haemorrhage. 
Future work is needed to assess the impact of reperfusion on the myocardium. There is a need 
therefore to take the TH model described here forwards and develop a longer-term, 
resuscitated model of TISCI. The addition of echocardiography to the previously described 
TH model is feasible and has provided important insights into acute myocardial function and 
offers an opportunity to assess how the ventricle responds to changes in haemodynamic 
status. For these reasons, the next studies will include echocardiography as a means of 
assessing response of the left ventricle, and to monitor for the development of overt 
myocardial dysfunction, at later stages after TH and resuscitation. The clinical studies 
relating to TISCI (De’Ath et al 2012 and Naganathar et al 2015) observed biomarker rise and 
the development of adverse cardiac events in trauma-haemorrhage patients. For this reason, 
subsequent studies will focus on the TH pre-clinical model with combined injury and 
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5 Developing a Murine Model of Resuscitated Trauma-
Haemorrhage to Investigate the Longer Term Functional 
Consequences of TISCI 
5.1 Introduction 
The data previously presented in this thesis demonstrates the presence of biomarker-proven 
secondary cardiac injury after a 60-minute period of trauma and haemorrhagic shock. 
What remains less clear is the impact of this cellular injury upon myocardial function in the 
longer term and how the cardiac biomarker profile changes over time and with resuscitation. 
In order to investigate this, it is necessary to develop the existing murine model of TISCI and, 
using the non-invasive imaging techniques discussed previously, restore circulating volume 
guided by baseline pre-load conditions. Chapter four demonstrated the predictable nature of 
the decline in blood pressure, cardiac output, stroke volume and left ventricular end-diastolic 
pressure after 60-minutes of trauma haemorrhage and how these relate to cardiomyocyte 
injury as assessed by circulating H-FABP levels. This raises questions regarding how the left 
ventricle will function in the longer-term with this established secondary cardiac injury. The 
duration of the experiment could simply be prolonged until the inevitable demise of the 
animal, but the restoration of pre-load and sequential in vivo imaging would be more 
informative with regards to observing how the injured myocardium responds to resuscitation 




The addition of a resuscitation phase to the established in vivo model, will allow for 
functional assessment of the heart, in vivo, in real-time and at time-points further down the 
line from the initial TH. Replacement of intravascular volume, and therefore pre-load to the 
left ventricle, affords us the opportunity of characterising the myocardial response to 
resuscitation after an initial 60-minutes of reduced perfusion and subsequent cellular injury 
with the release of H-FABP. The addition of resuscitation to the existing model, introduces 
reperfusion to the myocardium thereby mirroring the clinical situation when intra-venous 
fluid is administered to a casualty after a preceding period of blood loss and reduced 
perfusion pressures. Resuscitating the existing murine model of TISCI in this way therefore 
more closely resembles the clinical setting. An hour of TH followed by fluid resuscitation 
with an increase in organ perfusion pressures, exposes the myocardium to both ischaemia and 
then subsequent reperfusion and renders it more translatable to the clinical scenario.  
 
Many models of resuscitated TH exist in the literature and these have been discussed 
previously in this thesis. Contemporary models of cardiac injury and dysfunction after TH 
however, demonstrate a variety of resuscitation strategies. The choice of resuscitation fluid 
may range from purely clear fluid solutions to blood only or in some instances, a combination 
of the two. Goals, or end-points, of resuscitation may be fixed for example, a pre-defined 
volume of fluid being delivered which signifies the completion of resuscitation or may be 
more dynamic, for example, titrating fluid in order to reach a pre-defined haemodynamic 
end-point such as arterial blood pressure. The route of fluid delivery may also vary although 




At low ventricular end-diastolic volumes, as demonstrated in the previous chapter in response 
to controlled haemorrhage, stroke volume can be quickly increased with the administration of 
an intravenous fluid bolus. Cardiac output will also rise in line with the stroke volume in the 
context of resuscitation with fluid. Perfusion to the tissues increases, along with the delivery 
of oxygen. Administration of resuscitative fluid will continue to elevate the stroke volume 
and cardiac output until a plateau point. Beyond this point, further fluid will not serve to 
increase these systolic parameters and further increase of preload may in fact prove to be 
detrimental, leading to complications including accumulation of pulmonary fluid 
(Weidemann et al 2006).  
It is therefore important when developing a model in which to investigate TISCI that the 
interventions performed are not contributing to the entity being investigated. Cardiac failure 
as a result of over exuberant fluid resuscitation for example, would not therefore truly 
represent dysfunction resulting from trauma and haemorrhage and the purposes of these 
experiments are not to investigate resuscitation strategies and resultant complications. The 
acquisition of a baseline scan in these experiments is therefore incredibly useful as it provides 
a target for tailored resuscitation in these studies which would, one hopes, avoid over-filling 
the heart and the complications that this may cause. The nature of echocardiography means 
that scanning can be performed to rapidly, reliably and reproducibly assess the filling status 
of the left ventricle and inform the decision regarding the requirement of further fluid 
boluses. Having the baseline data means that there can be greater confidence that the left 
ventricle is not being overfilled (although it is of course possible that a heart subject to TISCI 
may still be overfilled if subjected to restoration of baseline preload conditions). Other 
clinical parameters, such as blood lactate concentration can be used to determine the response 
to fluid administration. Urine output, arterial oxygenation, pH and conscious level are also 
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parameters which have value in determining adequacy of resuscitation, but the mouse model 
is not amenable to having these monitored due to practical considerations.  
In spite of the widespread use of echocardiography in pre-clinical cardiovascular research, to 
the best of my knowledge, none of the contemporary trauma-haemorrhage models use non-
invasive imaging of the heart in order to establish the extent and adequacy of resuscitation. 
One of the benefits of this novel approach is the ability to view, in real-time, the volume 
status of the left ventricle and therefore the pre-load conditions. The ability to scan animals 
before surgery and TH will establish individual baseline conditions of the left ventricle, 
which can then serve as an appropriate end-point in a goal-directed resuscitation strategy 
implemented in a model designed to investigate cardiac function in association with TISCI.   
5.2 Study Aims 
The overall aim of these studies is to introduce a resuscitation phase into the established 
model of TISCI and monitor left ventricle and biomarker response. 
This will be achieved by fulfilling the following objectives: 
1. Determine whether echocardiography can be used to assess fluid response. 
2. Compare MABP and stroke volume as end-points for completion of resuscitation. 
3. Conduct a 60-minute monitoring period after completion of resuscitation in which to  
observe the haemodynamic response to fluid and establish whether longer studies are 
feasible.  
4. Measure H-FABP levels 2 hours after TH to determine the response to resuscitation 




5.3 Materials and Methods 
 
The broad materials and methods have been previously described in Chapter Two.  
Animals were randomly allocated into either MABP or SV-directed resuscitation groups. 
Only animals that survived the 60-minute post trauma haemorrhage monitoring phase were 
included. Animals dying before the ‘TH60’ time-point were replaced.    
After completion of the 60-minute monitoring phase after trauma-haemorrhage, animals were 
resuscitated with blood and crystalloid according to their group allocation.  
5.3.1 Experimental groups for the Chapter Five studies 
There are two experimental groups for the following studies. The groups and the 












Table 5.1 Experimental groups, interventions and final N number for the Chapter Five 
studies. 







Stroke Volume Directed 
Resuscitation Group 













Shed blood & CSL via 
jugular catheter 











5.3.2 Blood pressure directed resuscitation 
Animals allocated to the blood-pressure end-point group received intravenous fluid boluses 
with the intention of restoring baseline MABP +/- 5mmHg. Fluid administration was 
conducted between 5 – 10 minutes and completion of the resuscitation period in this group 
was confirmed with reaching a MABP within the target range (or the failure of the MABP to 
increment appropriately despite earlier response and increase of MABP in absence of on-
going haemorrhage and delivery of appropriate percentage of isoflurane). After reaching the 
target MABP, a monitoring period was then commenced whereby temperature and MABP 
were continuously monitored, echocardiographic assessment was made at specific time-
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points but no further fluid boluses were administered. Total volumes of shed blood and 
crystalloid administered were recorded. 
 
5.3.3 Stroke volume directed resuscitation 
Baseline stroke volume (SV) of each mouse was calculated, as above, after anaesthesia but 
before surgery. The average stroke volume of 3 repeated measurements was recorded and 
used as the target for subsequent resuscitation. The resuscitation phase commenced as for the 
MABP group, with the intravenous infusion of shed blood, followed by a variable volume of 
crystalloid. Throughout the fluid administration procedure, imaging was performed 
continuously in order to monitor the response to fluid delivery and to guide the administration 
of further fluid boluses. Attainment of baseline SV indicated the completion of the 
resuscitation phase. In animals where the SV increased in response to fluid but the response 
reached a plateau and no further increment occurred in response to a bolus, this point was 
taken to represent the completion of the resuscitation phase.  Volumes of shed blood and 
crystalloid administered were recorded. Animals then began a period of monitoring with 
intermittent echocardiographic assessment and continuous temperature and MABP 




5.3.4 Experimental outline for Chapter Five studies.  
 
Figure 5.1 Experimental outline.  
Schematic representation of the experimental outline for the 2 hour resuscitation studies. The 
red arrow indicates the end of the 60 minute trauma-haemorrhage phase. The average time 
taken for echo, resuscitation and monitoring are shown. Echo = echocardiography, Resus = 
resuscitation, min = minute.  
 
5.4 Results 
A total of 26 mice were used in these experiments. All underwent anaesthesia and baseline 
scanning. 2 in the MABP-directed group died during the TH phase and another 2 were 
excluded due to technical issues with the jugular line (dislodged / blocked and therefore 
unable to use for resuscitation). In the SV-directed group, 2 died during the TH phase before 
receiving any resuscitation fluid. It was not possible to draw blood from the arterial catheter 
at the end of the experiment for one animal in the SV-directed resuscitation group making the 
N number for H-FABP and lactate analysis was therefore N=9 for the SV-directed 
resuscitation group but functional haemodynamic and echocardiographic data was available 
for all 10 animals in both groups.  
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5.4.1 Baseline haemodynamics and left ventricular function 
There was no statistically significant difference between the 2 groups in terms of MABP and 
heart rate at baseline (P>0.05) (table 5.2).   
Table 5.2 Haemodynamic outcomes in the 2 experimental groups at baseline.  
Averages are presented with standard deviations in parenthesis. MABP = mean arterial blood 
pressure, SV = stroke volume, BPM = beats per minute.  
Measurement MABP-guided 
(n=10) 
SV-guided  (n=10) P value (2-tailed) 
MABP (mmHg) 80 (± 4.14) 78.1 (± 4.13) 0.3306 
HR (BPM) 450.38 (± 65.13) 448.08 (± 39.67) 0.9934 
 
There was no statistically significant difference in LV functional parameters at baseline when 
the 2 experimental groups were compared (P>0.05) (see table 5.3). Cardiac index was 












Table 5.3 Baseline left ventricular systolic function.  
Descriptive numerical values for LV systolic function obtained in 2 experimental groups at 
baseline by means of high-frequency transthoracic echocardiography.  Mean values are 
presented with standard deviations in parenthesis. MABP = mean arterial blood pressure, SV 
= stroke volume, CO = cardiac output, EF = ejection fraction, FS = fractional shortening, 
LVEDV = left ventricular end diastolic volume. 2-tailed P values are also given.  
Measurement MABP-guided 
(n=10) 
SV-guided (n=10) P value (2-tailed) 
SV (μL) 44.19 (± 5.12) 45.68 (± 3.03) 0.4370 
CO (mL/min) 19.87 (± 3.73) 23.81 (± 7.71) 0.2837 
EF (%) 62.41 (± 7.16) 58.92 (± 7.32) 0.2954 
FS (%) 33.43 (± 5.19) 32.75 (± 5.51) 0.7769 
LVEDV* (μL) 72.81 (± 13.13) 79.51 (± 10.25) 0.2286 
*LVEDV calculated retrospectively using the formula (SV/EF) x 100. 
5.4.2 Haemodynamic Characterisation of the TH Model 
Figure 5.2 summarises the volume of blood drawn via the arterial catheter in order to achieve 
the target MABP of 30 – 40 mmHg. The volumes required to induce hypotension were 
slightly higher in the SV-directed group (mean 40.17%, SD 4.87% compared to mean 
36.80%, SD 4.42%), but were not significantly different between the 2 groups (P>0.05).  
The target MABP was reached over a 10-minute period in all animals and maintained 
throughout a 60-minute TH period. Figure 5.3 illustrates the MABP trends over this time in 
the 2 groups. There was no statistically significant difference seen between the 2 groups at 
any of the time-points (P>0.05). 
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Figure 5.2 Blood loss required to achieve target MABP in the 2 experimental groups.  
Blood loss is expressed as a percentage of total blood volume (calculated as body weight x 
0.07mL). P=0.1431. 
 
At the completion of the 60-minute TH phase, heart rate was recorded and there was no 
significant difference between the groups at this point (P>0.05). The MABP-directed group 





Figure 5.3 MABP trends across the 60 minute TH phase.  
Line graph shows the MABP at baseline and the trend in response to fixed-pressure 
haemorrhage. Dots represent the mean MABP for the group at a given time-point. Vertical 
bars represent the standard deviation of the mean.   
 
Functional LV parameters after 60 minutes of TH were assessed using echocardiography and 
Table 5.4 summarises the results obtained for the 2 groups. 
SV, CO, LVEDV and CI were significantly lower than baseline in each animal. Each group 
experienced a comparable reduction however, with no statistically significant differences 











Table 5.4 LV systolic functional outcomes and cardiac index at TH60.  
 Mean values are given with SDs in parenthesis for stroke volume (SV), cardiac output (CO), 
ejection fraction (EF), fractional shortening (FS) and left ventricular end diastolic volume 





P value (2-tailed) 
SV (μL) 5.82 ± (2.56) 6.75 ± (3.63) 0.7246 
CO (ml/min) 3.39 ± (1.15)  3.98 ± (1.82)  0.3936 
EF (%) 65.74 ± (11.83)  61.07 ± (17.21) 0.4885 
FS (%) 33.95 ± (7.51) 31.63 ± (11.10) 0.5906 
LVEDV (μL) 13.16 ± (9.76)  12.49 ± (11.68) 0.8940 
 
Animals were resuscitated as previously described immediately after completion of the TH60 
ultrasound scan. Warmed, shed blood was returned via the venous catheter and this was 











5.4.3 Fluid volumes required for resuscitation 
A                                                                                  B 
       
Figure 5.4 Fluid resuscitation volumes.  
Bar charts illustrate; A. Volumes of shed blood transfused and B. Crystalloid administered to 
achieve end-point of resuscitation. *P<0.001 versus MABP-guided group. 
 
Animals in the MABP-directed group received a mean blood volume of 0.74 ± 0.11mL whilst 
mice in the SV group received a mean of 0.78 ± 0.11mL. There was no significant difference 
between the groups in terms of the volume of blood infused at the commencement of the 
resuscitation phase (P>0.05).  However, the SV-guided resuscitation group received 
significantly higher volumes of crystalloid (mean 2.16, SD 0.64mL compared to mean 0.726, 






5.4.4 End-Points of Resuscitation 
A                                                                             B 
                                                                                                              
Figure 5.5 MABP and stroke volume at baseline and post resuscitation.  
Box and whisker plots show A. MABP at baseline and after resuscitation in the MABP-
directed group and B. SV at baseline and at completion of resuscitation in the SV-directed 
group. Whiskers represent range, box represents interquartile ranges and horizontal line the 
median value.  
 
There was no statistically significant difference in MABP at baseline and post-resuscitation in 
these animals (P>0.05) (fig.5A).There was no significant difference between baseline and 
post-resuscitation SV in this experimental group (P>0.05) (Fig. 5B).  
 
LVEDV was calculated at the end of the experiment using stroke volume and ejection 
fraction, and assessment of the strength of correlation between SV and LVEDV at baseline 
and after completion of resuscitation was calculated and a strong positive correlation between 
































































A                                                                                  B 
            
Figure 5.6 Correlation between SV and LVEDV in the SV-resuscitation group.  
Scatter plots show the correlation between SV and LVEDV at A. Baseline and B. Post 
resuscitation. Pearson r was calculated for both sets of data. Pearson r=0.6354 (95% C.I 
0.009699 – 0.9036, 2-tailed P value = 0.0483) at baseline and r=0.7319 (95% C.I 0.1897 – 
0.9320, 2-tailed P value = 0.0161) after resuscitation.  
 
5.4.5 Haemodynamic trends  
All animals reached their target MABP or SV with fluid resuscitation. Blood pressure 
increased in both groups after resuscitation and was then observed to decline in both groups 
throughout the following 60-minute monitoring period. The MABP tended to be higher in the 
SV-directed group during this phase of monitoring but this difference was not significantly 





Figure 5.7 Trends in MABP over 2 hours.   
Line graph showing trends in MABP in response to TH and resuscitation in the MAPB and 
SV-directed groups. Dots represent the mean for the group at a given time-point. Vertical 







Figure 5.8 Heart rate trends over 2 hours.  
Line graph shows trends in heart rate in response to TH and resuscitation in the MABP and 
SV-directed groups. Dots represent mean for the group at a given time-point. Vertical bars 
represent the standard deviations from the mean.  
 
In both of the groups, heart rate was higher after a 60-minute period of TH and fell after 
resuscitation. Heart rate tended to be lower throughout the experimental period in the SV-
directed group but this did not reach significance at any time-point (P>0.05) (Fig.5.8).  
Core body temperature was monitored throughout the experiment in both groups. Figure 5.9 
illustrates the changes in temperature over the course of the experiment and there was no 
statistically significant difference in temperature between the 2 groups at any of the time-
points (P>0.05). The SV-directed group however tend to show less variability in core 





Figure 5.9 Core temperature trends over 2 hours.  
Line graph showing the trends in temperature in both experimental groups over 2 hours. Dots 
represent the mean for the group at a given time-point. Vertical bars represent the standard 










5.4.6 Functional assessment of the left ventricle after resuscitated trauma-
haemorrhage  
Left ventricular systolic functional outcomes were assessed at pre-defined time-points in the 
2 groups. Tables 5.5 and 5.6 below show the data for LV systolic function and LVEDV after 
resuscitation and at 120 minutes respectively.  
Table 5.5 LV systolic functional outcomes and LVEDV post resuscitation.  
Mean values are given with SDs in parenthesis. *Indicates statistical significance when 
values of the 2 groups are compared.  
Measurement MABP-directed SV-directed P-value (2-tailed) 
SV (μL) 25.58 ± (8.57) 48.1 ± (9.77) <0.0001* 
CO (mL/min) 13.04 ± (3.85) 25.17 ± (5.62) <0.001* 
EF (%) 59.61 ± (11.69) 67.71 ± (8.13) 0.0887 
FS (%) 31.41 ± (7.84) 36.54 ± (8.60) 0.1798 
LVEDV (μL) 45.26 ± (13.36) 74.27 ± (15.96) 0.0005* 
 
Table 5.6 LV systolic functional outcomes and LVEDV at the end of the study.  
Means are given with SDs in parenthesis. *Indicates statistical significance when values form 
the 2 groups are compared.  
Measurement MABP-directed SV-directed P-value (2-tailed) 
SV (μL) 13.17 ± (3.81) 19.89 ± (9.31) 0.0617 
CO (mL/min) 7.41 ± (2.03) 11.27 ± (3.68) 0.0152* 
EF (%) 51.99 ± (13.32) 65.64 ± (17.63) 0.0820 
FS (%) 27.12 ± (8.41) 37.38 ± (14.65) 0.0868 





Figure 5.10 illustrates the trends in stroke volume, cardiac output, ejection fraction and 
fractional shortening over the 120-minute experimental period. There was no statistically 













Figure 5.10 LV systolic functional trends over 2 hours.  
Line graphs represent changes in A. SV, B. CO, C. EF and D. FS over time. Dots represent 
the mean for the group at a given time-point. Vertical bars represent the standard deviations 
from the mean.  
 
After resuscitation, the SV-directed animals had a numerically higher ejection fraction and 
fractional shortening when compared to the MABP-directed group but this did not reach 
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significance (see table 5.4). At the end of the experiment, the animals in the SV-directed 
group had significantly higher cardiac output when compared to MABP-directed group 
animals (refer to table 5.5).  
 
Left ventricular end-diastolic volume was calculated using stroke volume and ejection 
fraction for each animal and the data is given in figure 5.11. LVEDV was higher in the SV-
directed group animals at all time-points but this only reached significance at the post-
resuscitation time-point (P<0.05).   
 
 
Figure 5.11 LVEDV trends over 2 hours.  
Line graph shows changes in calculated LVEDV over the course of the experimental period. 
Dots represent the mean for the group at a given time-point. Vertical bars represent the 




5.4.7 Perfusion Indices after TH with Resuscitation 
Blood lactate concentrations were recorded at time-points throughout the experimental period 
as an indicator of tissue perfusion at TH60, after resuscitation and at the end of the 
experiment. 
Arterial blood lactate concentrations were seen to rise and fall in both groups in response to 
TH and subsequent fluid resuscitation and this data is shown in figure 5.12. The SV-directed 
group animals had significantly higher blood lactate levels after 60-minutes of TH. Although 
the lactate levels fell with subsequent resuscitation, they remained higher than in the MABP-
directed group at this point and at the end of the experiment, this group again had more 
severe lactatemia (although this was not significant at this time-point).  
Cardiac index was calculated (as previously described) in order to provide another 
measurement of an individual’s tissue perfusion status in response to TH with resuscitation. 
Trends in C.I are given for the entire experimental period in fig 5.13. As anticipated, C.I 
drops to a similar extent in both of the groups after TH. It then rises after fluid resuscitation. 
At 120 minutes, the cardiac index is significantly higher in the SV-directed group (P<0.05 
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Figure 5.12 Blood lactate concentrations.  
Column graphs show lactate concentrations in the 2 groups at 3 experimental time-points. 
*P<0.05 when the 2 groups are compared at TH60. Lactate concentrations after resuscitation 







Figure 5.13 Trends in cardiac index.  
Line graph showing the trends in calculated cardiac index across the 2 hours in the 2 
experimental groups. Dots represent the mean for the group at a given time-point. Vertical 
bars represent the standard deviations from the mean. *P<0.05.  
 
Table 5.7 Cardiac index results after resuscitation and at 120 minutes.  
Mean values are given with standard deviations in parenthesis. P values are also shown and * 
represents statistical significance (P<0.05) when the 2 groups are compared.  
Time-point MABP-directed SV-directed P value 
Baseline 692.8 (±121.6) 763.96 (±64.1) 0.1102 
TH60 118.40 (±37.81) 145.7 (± 63.06) 0.3150 
Post resuscitation 457.80 (±137.2) 545.52 (±148.1) 0.2799 




5.4.8 The relationship between cardiac index and blood lactate 
The nature and the degree of correlation between cardiac index and lactate, both used as 
indicators of perfusion, was assessed. There was a negative correlation between the 2 
parameters with the highest blood lactate being seen at the lowest cardiac index (Fig.5.14). 
There was therefore a relationship between C.I and lactate but the strength of this association 
was variable depending upon the experimental time-point with the strongest association seen 
at TH60. 
A                                                                                      
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Figure 5.14 Correlation between lactate and cardiac index.  
Scatter charts show the correlation between cardiac index and blood lactate concentration at 
A. TH60. Pearson r = -0.5211 (P<0.05), B. Post resuscitation. r = -0.2065 (P=0.3824) and C: 
At end of experiment r = -0.2817 (P=0.2574). 
 
5.4.9 Cardiac biomarkers 
Cardiac biomarkers were also analysed. H-FABP analysis revealed that both groups had 
elevated blood concentrations at 120 minutes. There was no significant difference between 
the 2 groups in terms of H-FABP concentration at the end of the experiment (P>0.05) 
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(Fig.5.15). There is a greater spread of H-FABP serum concentrations in this compared to the 
studies in preceding chapters three and four. The lowest concentrations were seen in the SV-
directed group with serum analysed from one animal yielding an H-FABP concentration of 
57.97ng/mL (all other animals recorded levels in excess of 150ng/mL). This individual had 
one of the highest % blood losses, but serial lactate measurements were the lowest within the 
group. This suggests that, despite comparable severity of haemorrhagic shock, 
haemodynamic compensation was better in this individual and this may go some way to 
explain the elevated, but relatively lower H-FABP in this case. Troponin T levels were also 
measured in the 2 groups but were not detectable in the vast majority at 120 minutes (data not 
shown). 
 
                                      
Figure 5.15 Serum H-FABP concentrations.  
Box and whisker plots show the serum H-FABP concentrations at the end of the study for the 
2 experimental groups. Whiskers represent the entire range, the box represents interquartile 





There were 4 deaths (2 in each experimental group) during the 60-minute TH phase before 
the commencement of resuscitation. This was comparable to the mortality seen during the 
same phase in chapters three and four, and demonstrates that the animals in these 
experiments are subject to a potentially lethal severity of trauma-haemorrhage.  
There was 1 death in the SV-directed group after resuscitation but before the end of the 
experiment. There were no deaths in the MABP-directed group but one animal was seen to 
have a period of haemodynamic instability which was associated with the onset of a cardiac 
arrhythmia during the final 10 minutes of the experiment (data not shown).  
5.5 Discussion 
The application of transthoracic echo in our mouse model of TH presented here, has been 
beneficial in two ways. Not only has it been demonstrated here as a useful tool in the 
development of a resuscitated model of TISCI, but it has also allowed for in vivo assessment 
of myocardial function after TH with resuscitation. The addition of a resuscitation phase has 
allowed for the studies in chapter three and four to be lengthened to 2 hours with good 
overall survival. Resuscitation to SV requires higher volumes of fluid when compared to the 
MABP-directed group but this was not associated with significantly higher blood pressure 
recordings but cardiac output and cardiac index at 2 hours was significantly higher in the SV-
directed resuscitation group suggesting that in terms of LVS function, this approach was 
favourable. H-FABP levels were high in all animals, irrespective of resuscitation strategy and 
there was no significant difference between the 2 groups.  
These studies have demonstrated that H-FABP concentrations continue to rise beyond the 1 
hour mark, and this supports clinical data also published by our group, where H-FABP 
continued to rise up until 24 hours after admission in severely injured patients who developed 
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adverse cardiac events (De'Ath et al 2012). In terms of cardiac events in these studies, 1 
animal in the MABP-directed group had a recorded period of arrhythmia towards the end of 
the experimental period.  
Baseline echocardiographic assessment, heart rate and MABP recordings showed that there 
was no significant difference between the animals in terms of haemodynamic parameters at 
baseline and after 60 minutes of trauma-haemorrhage. Both groups required a similar 
percentage blood loss to achieve the target MABP of 30-40mmHg and there was no 
significant difference in the MABP blood pressure between the groups for the maintained 
duration of the 60-minute TH phase.  
Given the comparable blood loss and blood pressure, it is interesting to note that the SV-
directed group did however have higher mean and median lactate concentrations at TH60. 
This suggests that this group, despite being haemorrhaged to the same target MABP range, 
were in a more severe shock state in terms of reduced peripheral perfusion and associated 
accumulation of lactic acid. This group had higher recorded lactate concentrations at every 
subsequent time-point compared to the MABP-directed group and the only post-resuscitation 
mortality was in this second group. This perhaps reflects that, despite the same degree of 
hypotension induced by controlled haemorrhage, some of these animals were more severely 
shocked and indeed, the animal with the highest recorded lactate at TH60 was the same 
animal that died before the end of the study.  
The end-point of resuscitation had a significant impact upon the volume of fluid required to 
adequately resuscitate the animal. Both groups received similar volumes of whole blood back 
at the commencement of the resuscitation period. Resuscitation targeted to restoration of 
baseline blood pressure was associated with lower volumes of crystalloid administration. In 
order to achieve baseline stroke volume however, animals required at least double the volume 
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of crystalloid be given after the return of shed blood (Fig.3B). This demonstrates that a 
regimen of fluid resuscitation guided by arterial blood pressure alone was not enough to 
restore intravascular volume measured by left ventricular volume. This is an important 
finding as this could have particular relevance when designing models in which to assess 
cardiac function after trauma-haemorrhage. Occult ‘under-filling’ (I.e. normotension but with 
significantly reduced LVEDV as reported here) could lead to ongoing physiological 
derangement, such as tachycardia, as the heart attempts to compensate and maintain cardiac 
output. A continuous tachycardia in response to fluid depletion, coupled with higher 
myocardial metabolic demand will lead to shortened diastolic filling times of the coronary 
arteries and may lead to myocardial ischaemia with resultant biomarker rise and dysfunction.  
The MABP in both groups was comparable after resuscitation but one could postulate that in 
the MABP-directed animals, a larger contribution was being made by neuro-hormonal 
mechanisms relating to blood pressure homeostasis, particularly after an antecedent period of 
shock. It could be suggested that these animals remain reliant upon peripheral 
vasoconstriction mediated by endogenous catecholamines to offset the continuing relative 
hypovolaemia. Although not significant, these animals also demonstrated higher heart rates 
throughout the experiment after resuscitation, a finding which supports a greater degree of 
compensation occurring in this group. Given the lack of other available physiological 
parameters however, this is difficult to confirm with certainty and the lactate data (with 
higher lactates recorded in the SV-directed group at the end of the experiment) would not be 
supportive of this.  
The fall in arterial lactate concentrations after resuscitation may reflect the relative 
hypovolaemia experienced by the MABP-directed group. Although the SV-group lactates 
were higher at each time-point, the fall in blood lactate between TH60 and 20-minutes after 
resuscitation was greater in the SV-directed group. Despite these animals having a higher 
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mean lactate concentration at the end of the TH phase, the extent of the drop in concentration 
suggests that these animals were able to correct the significantly higher lactate levels 
accumulated during the first 60 minutes.  
Despite the important differences seen in the physiology of the 2 groups, there are some 
similarities seen in haemodynamic trends across the experimental period. Irrespective of the 
method and relative ‘adequacy’ of the resuscitation, all animals demonstrated a decline in LV 
systolic parameters and blood pressure over the final 60 minutes of the experiment. Close 
monitoring of the surgical sites and post-mortem assessment was undertaken to ensure that 
there was no further uncontrolled blood loss which could account for this. Blood was drawn 
during the final 60 minutes for lactate measurement, but this was a very small volume and 
was followed by a small, compensatory bolus of crystalloid. Isoflurane, chosen in part due to 
its ease of titration, was adjusted throughout each experiment in order to minimise and 
standardise its impact upon haemodynamic outcomes. Isoflurane concentration were 
maintained between 0.5-1% in all animals during the final hour of the experiment (data not 
shown). The decline in blood pressure, stroke volume and cardiac output is therefore likely to 
reflect the redistribution of fluid occurring during this hour. Intravascular fluid depletion in 
the TH60 phase would have resulted in the shift of fluid from the interstitial into the vascular 
space in order to compensate and maintain perfusion as haemorrhage was occurring (evident 
during the haemorrhage phase with the need to draw small volumes of blood intermittently in 
order to maintain the blood pressure in the target range). Upon resuscitation, this fluid ‘debt’ 
generated during haemorrhage would have been repaid with the movement of fluid from the 
intravascular back to the interstitium. Although this could provide an explanation for the 
reported drop in MABP ad CO, this doesn’t explain why, after resuscitation, these parameters 
continue to decline beyond the baseline level. For example, in the SV-directed group, the 
mean CO at baseline was 21.39mL/min compared to 11.27mL/min at the end of the 
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experiment (refer to Fig.9B). The rebound in lactate with higher levels recorded at the end of 
the experiment compared to after resuscitation, also suggest that there is again a state of 
acidosis and worsening shock (Fig.12). Despite the administration of at least 2 times the 
original haemorrhage volume in both groups, haemodynamic and metabolic outcomes 
deteriorate in the final 60 minutes, in the absence of ongoing haemorrhage.  
The decline in haemodynamic performance after controlled haemorrhage and resuscitation 
seen here is not novel. A rodent haemorrhage study performed by Wang et al in 1991 
demonstrated that cardiac output (measured using an in vivo dilution method) normalised 
after resuscitation with up to 4 times the haemorrhage volume in Ringer’s lactate, but the CO 
was not sustained. (Wang & Chaudry 1991) Ongoing haemodynamic compromise despite 
resuscitation is likely to result from a complex interplay between neuro-hormonal 
homeostatic mechanisms. Haemorrhage and injury may also instigate an inflammatory 
response which leads to changes in the vasculature leading to third space fluid losses which 
has been well documented in sepsis and systemic inflammatory response syndrome. 
Resuscitation with crystalloids has been previously demonstrated to impair endothelial 
integrity and microvascular responsiveness (Torres et al 2013). The use of a combined shed 
blood and crystalloid regimen in these experiments therefore may have potentially allowed 
for the development of endothelial changes with resultant fluid extravasation and decline in 
intravascular filling status and elevated blood lactate concentration.  
Serum H-FABP concentrations were elevated in all of the animals in both of the experimental 
groups and support the findings of the earlier experiments. The serum H-FABP tended to be 
higher in the MABP-directed group but this was not statistically significant. The H-FABP 
concentration is not reduced using the SV-directed resuscitation protocol and the serum 
concentrations are higher than those seen in the earlier 1 hour experiments (chapter three and 
chapter four). This suggests that the cardiomyocyte injury leading to the release of this 
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cardiac-specific biomarker is ongoing and not reduced with either resuscitation protocol.  
Higher levels of H-FABP in these 2 hour experiments may indicate that, despite restoration 
of pre-load, there is continuing cardiomyocyte damage. The results may have been different 
with a more ‘clinical’ resuscitation protocol with further fluid boluses administered in 
response to declining haemodynamic parameters. For the purposes of these mechanistic 
studies, a protocol of restoring baseline conditions (MABP or SV) was chosen in order to 
monitor the LV response to initial hypovolaemia and then subsequent resuscitation with 
standardised resuscitation at defined intervals rather than administering intermittent boluses 
of fluid for the duration of the study. This approach clearly deviates from the clinical practice 
of hypotensive resuscitation and therefore limits the translational potential of these 
experiments in that regard. Bolus resuscitation as employed here may allow for TISCI to 
worsen in the intervening periods as MABP declines. However, if hypotensive resuscitation 
had been used with intermittent fluid boluses administered to keep MABP above a defined 
level throughout, TISCI may not be prevented or reduced as the LV remains relatively, 
persistently under-filled. Both approaches therefore have their pitfalls when considering 
mechanistic studies.  
Echocardiography has proven a useful guide to resuscitation in these studies. It did not 
however, identify any acute structural abnormalities or regional wall motion abnormalities 
resulting from a period of TH. A single episode of arrhythmia was captured on the ECG trace 
and then confirmed with imaging. In terms of left ventricular systolic function, these studies 
did not identify any significant loss of contractile function (regarded in terms of fractional 
shortening). The SV-directed group tended to have a slightly higher fractional shortening at 
the end of the experiment, while the MABP-directed group showed a steady decline over the 
120 minutes but this was not statistically significant (Fig.9D). According to Starling’s law, 
the force of contraction is related to the volume of blood in the LV at the end of diastole; 
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given that there was no significant difference in LVEDV between the 2 groups at 120 
minutes, perhaps this is to be expected. There is a difference between the 2 groups in terms of 
the temporal trend of FS over 120 minute (Fig. 9C) with a persistent decline in FS seen in the 
MABP-directed group over time. The reason for this is unclear.  
Apart from the isolated case of arrhythmia, the heart appears to respond as expected to 
resuscitation in these studies and the decline in SV, CO and CI appears to be a result of fluid 
redistribution rather than an intrinsic contractile failure. Despite this, there is biomarker 
evidence of increasing cardiomyocyte injury. It may be that the 2 hour timeframe of these 
experiments was not adequate to allow for the development of overt LV dysfunction and 
longer studies would be needed to test this hypothesis.  
 
5.6 Limitations 
The aims of these studies were met but the development of this resuscitated model of trauma-
haemorrhage was complex and required the accomplishment of a number of new skills. 
Vessel cannulation in itself is difficult and needs to be performed in a consistent way. Having 
previous experience with arterial cannulation meant that I was able to become proficient at 
jugular cannulation relatively quickly and without having to sacrifice animals in order to 
practice but there were cases where loss of lines led to removal of animals from the data and 
necessitated the use of another animal to replace them. Adding a second line did however 
lengthen the anaesthetic and surgical time and the initial experiments were inevitably a little 
longer than the last because of this.  
As well as the technical challenges of siting and manipulating an animal with additional lines, 
there are considerations related to the overall small size of the animal. Relatively small total 
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blood volume has obvious limitations on the number and frequency of blood tests that can be 
performed without further compromising survival, particularly in TH models where animals 
have lost significant circulating volume prior to resuscitation. For example, it would have 
been useful to perform biomarker analysis at a number of time-points but the serum volumes 
required for assay made this impracticable. The emphasis was on establishing cardiac 
biomarker levels at the end of the experiment and there was therefore no blood available for 
performing other analysis. Assessment of acid-base, haemoglobin levels for example could 
have been a useful means by which to ensure standardisation of the haemorrhage phase and 
modes of resuscitation but this was not possible.  
  
Questions remain regarding fluid redistribution after resuscitation and assessment of 
inflammation and vascular permeability may have provided insights into this, but were 
beyond the remit of these studies.  
 
5.7 Conclusions 
Echocardiography is a reproducible, non-invasive, quick imaging technique which has 
already shown promise as a tool for fluid management in critically ill patients (Boyd et al 
2016). These studies have demonstrated that micro-echocardiography, a highly translatable 
imaging modality, can be robustly applied to our existing murine model of TH. Not only can 
it be used as a method of assessing cardiac structure and function, but it has also provided an 
insight into the volumetric status of animals after TH and subsequent resuscitation. A major 
benefit of this approach is that we can accurately guide restoration of baseline pre-load 
conditions to the LV.  This also gives confidence that we are appropriately restoring 
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intravascular volume the before going on to assess cardiac function and dysfunction as a 
consequence of TH. Resuscitation is carried out with the intention of restoring normal 
physiology. It could be viewed as particularly relevant in the case of TH models of cardiac 
injury as the organ of interest is particularly susceptible to the impact of inadequate 
resuscitation as it struggles to compensate to maintain cardiac output and jeopardises its own 
perfusion further as it mounts and maintains tachycardia and increases contractility.  
The studies presented here have demonstrated cardiomyocyte injury in the resuscitated model 
of TH regardless of resuscitation protocol. H-FABP concentrations were elevated despite 
fluid resuscitation and were generally higher than those recorded in the 60-minute studies in 
chapter three and four so one can speculate that the cardiomyocyte damage is worsening with 
time and despite fluid administration (this cannot be said with absolute certainty due to the 
lack of serial H-FABP measurements in these experiments). An adverse cardiac events (in the 
form of arrhythmia) was recorded, but only in a single animal. This suggests that whereas 
ACEs were not detected in the 60-minute studies, a longer time-frame has been required to 
assess for myocardial dysfunction. There is therefore a need to implement longer 
experimental periods to assess for the development of overt cardiac dysfunction in more 
animals. The addition of resuscitation to the original 1 hour model discussed in chapter three 
allows for longer studies with acceptable survival rates in which to carry out such studies and 
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6 Investigating Adenosine, Lignocaine and Magnesium as a 
Cardiovascular ‘Rescue’ Agent in the Murine Model of TISCI 
6.1 Introduction 
The previous chapters of this thesis have demonstrated a predictable decline in MABP and 
LV systolic functional outcomes despite resuscitation. This observation is by no means novel. 
Well-characterised physiological responses to haemorrhage have outlined the nature of fluid 
redistribution acutely during haemorrhage, and in the acute, intermediate and longer term 
after resuscitation. Starling forces acting across capillary beds during haemorrhage, for 
example, result in fluid movement from the interstitium into the vascular compartment in an 
attempt to compensate for blood loss. The interstitium therefore can be viewed as 
representing a reservoir of further fluid to sacrifice to the intravascular space if the losses 
continue (this phenomenon of the ‘internal transfusion’ (Levick 2000) is evidenced in animal 
models of haemorrhage with the need to intermittently draw blood after initial haemorrhage 
in order to maintain a target MABP). Upon fluid resuscitation, pre- and post-capillary 
pressures are subject to change again, this time to favour fluid movement from the 
intravascular space to the interstitum and intracellular compartment thereby repaying the 
fluid ‘debt’ accrued during the haemorrhagic shock phase.  
It is well known therefore that THS and HS models require a higher volume fluid 
resuscitation compared to the shed blood volume. Simply returning the same volume of shed 
blood will initially restore MABP for example, but as fluid redistributes, intravascular 
volume will begin to decrease once again. A 1991 study using a rat model of trauma-
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haemorrhage reported that crystalloid resuscitation with 4x the volume of the initial blood 
loss, was enough to initially restore CO and total peripheral resistance, but CO was not 
maintained (Wang et al 1991). This observations made by this group is likely to have led to 
the adoption of the 4x volume of blood loss fluid replacement strategy in multiple studies 
published by the same authors. 
Ongoing haemodynamic impairment post TH with resuscitation is not new to the intensivist 
or anaesthetist either. A point is usually reached after severe shock where vasoactive 
substances are required in an attempt to improve haemodynamic status. Choice of agent and 
timing of implementation is controversial (Mongarden et al 2009) and  the use of more 
commonly used vasoactive substances such as noradrenaline in humans usually requires 
invasive monitoring, titration and central vein cannulation which usually limits their use to 
the theatre and critical care setting.  
There is a need to identify novel therapeutic agents which can be used in the acute phase after 
TH which can a) prevent or ameliorate this cardiovascular decline and eventual 
cardiovascular collapse (‘buying time’ during initial resuscitation and transfer to a place of 
definitive care) and b) limit the extent of the cardiac injury and dysfunction and facilitate 
cardiac recovery. A cardioplegic agent comprising of adenosine, lidocaine and magnesium 
(“ALM”) has been previously investigated and has shown promise as an adjunct to small-
volume, hypotensive resuscitation in rats (Letson & Dobson 2011) and pigs (Granfeldt et al 
2012) subjected to haemorrhagic shock. The use of this combination of drugs has been 
demonstrated to dramatically improve survival and haemodynamic outcomes in treatment 
animals compared to controls in these studies. What remains unclear however, is whether this 
drug combination has efficacy in a model where severe haemorrhage is combined with 
trauma, and what, if any, impact it has upon H-FABP levels and LV systolic function in a 




6.2 Study Aim 
The principle aim of this study is to investigate the use of ALM, when given as an adjunct to 
blood and crystalloid resuscitation, as a potential cardiovascular ‘rescue’ agent with the 
ability to improve survival and limit / prevent the haemodynamic deterioration previously 
characterised in the murine model of TISCI. The impact of the addition of ALM to 
resuscitation protocol on H-FABP levels and LV systolic function will also be investigated.  
6.3 Materials and Methods 
The broad materials and methods have been previously discussed in Chapter Two.  
 
6.3.1 Experimental design 
Prior to commencing the experiment, mice were randomly assigned to either ALM or non-
ALM resuscitation groups (refer to table 6.1 for experimental groups). Animals that did not 
survive the 60-minute TH phase at 30-40mmHg were excluded and replaced. Animals in the 
non-ALM group were resuscitated as outlined above. ALM-treated mice received a 
combination of adenosine, lidocaine and magnesium in either a low or high dose “one-shot” 
regimen. The lower-dose administered comprised adenosine 0.54mcg/g, lidocaine 
hydrochloride 1.63mcg/g and magnesium sulphate 0.6mcg/g (based on the previous work in 
the porcine model of HS as described by Granfeldt et al in 2012) while the high dose group 
received a doubling of all the ALM components (adenosine 1.12mcg/g, lidocaine 




Adenosine, lidocaine and magnesium doses were prepared according to weight and 
suspended in 0.5mL of crystalloid. This solution was then administered after transfusion of 
shed blood in the first resuscitation phase. During intravenous infusion, blood pressure, heart 
rate and ECG were continuously monitored and echocardiographic assessment performed 
throughout.  The Hartmann’s solution (Vetivex) used to deliver the drugs was included in the 
volume of crystalloid administered to reach target SV during the first resuscitation phase. No 
ALM was administered during the second of the resuscitation phases and crystalloid alone 
(entire shed blood volume having been returned during the first resuscitation phase) was 
administered to resuscitate the animals to achieve baseline stroke volume. 
Table 6.1 Experimental groups, interventions and final N number for the Chapter Six 
studies. 
MABP = Mean arterial blood pressure, Echo = Echocardiography, CSL= Crystalloid, SV = 




Control ALM ALM Double-Dose 




Yes. 30-40mmHg Yes. 30-40mmHg Yes. 30-40mmHg 
Laparotomy 
& Fractures 
Yes Yes Yes 
Baseline 
Echo? 
Yes Yes Yes 
Resus Fluid 
(Resus 1) 
Shed blood & CSL 
via jugular catheter 
Shed blood & CSL & 
ALM via jugular catheter 
Shed blood & CSL & 
ALM via jugular 
catheter 
ALM dose N/A Adenosine 0.54mcg/g, 
lidocaine hydrochloride 























CSL only CSL only CSL only 
Final N 
number 
10 10 10 
 
 
6.3.2 Experimental outline for chapter six studies.  
 
Figure 6.1 Experimental outline for the ALM treatment studies.  
Schematic showing the experimental outline for the 3 hour ALM studies. The red arrow 
represents the end of the 60 minute TH phase. Interventions and observations and their 
average timings are given. 
 
6.4 Results 
A total of 37 animals were used in these experiments. Any animal that survived to receive the 
1st resuscitation fluid +/- ALM was included. Any animal that died at any time before this 
point was replaced in order to achieve n=10 in all groups. 2 animals had an abnormal 
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appearance of the left ventricle at baseline assessment and were therefore removed from the 
study.  
Echocardiographic assessment of the left ventricle was performed at baseline and SV, CO, 


















6.4.1 Baseline left ventricular systolic function 
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Figure 6.2 Left ventricular systolic functional outcomes at baseline.  
Box and whisker plots show the LVS functional outcomes in the three experimental groups. 
Data is shown for A. Cardiac output (CO), B. Stroke volume (SV), C. Ejection fraction (EF) 
and D. Fractional shortening (FS). Box and whisker plots show the median (horizontal line), 




Although there was greater variability between control group animals, there were no 
significant differences between the 3 groups at baseline in terms of LVS function assessed 
with echocardiography (fig.6.2). 2 animals assigned to the control group did demonstrate a 
structurally abnormal LV appearance on baseline echo and these were excluded and replaced, 
however, no animals were excluded from the final analysis based on non-significant baseline 
LVS functional variability. LVEDV was calculated for each animal at baseline (using SV and 
EF) and no statistically significant differences were observed (fig.6.3) between the animals in 
the 3 groups.  
 





















L V E D V











Figure 6.3 LVEDV at baseline.  
Box and whisker plots represent the calculated LVEDV at baseline in the 3 groups. Box and 
whisker plots show median (horizontal line), interquartile ranges (box) and range (whiskers).     
 
6.4.2 Haemodynamic characterisation of the TH model 
Animals in the three experimental groups underwent a similar percentage blood loss in order 
to achieve the target MABP of 30-40mmHg (fig.6.4). Estimated total blood volume was 
calculated as 0.07 x grams of total body weight. Mean percentage blood loss was 39.71 
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(±3.88) %, 37.44 (±3.27) % and 40.41 (±2.40) % in the control, ALM and ALMx2 groups 
respectively.  
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Figure 6.4 Blood loss required to achieve target MABP in the 3 groups.  
Colum graphs show the blood loss as a percentage of total blood volume (derived from body 
weight) for control and ALM treated groups.  
  
              
Figure 6.5 MABP trends across the 60 minute TH phase.  
Line graph showing the MABP trends in the 3 groups at baseline and then at 10-minute 
intervals until reaching the TH60 time-point. Dots represent the mean value, vertical lines 




Figure 6.5 above shows the trend in MABP at 10-minute intervals over the 1 hour TH phase. 
There was no significant difference between the groups in terms of MABP at baseline and at 
every subsequent time-point over the first hour of the experiment. All animals were kept 
within the target MABP range of 30-40mmHg for the duration of the haemorrhage phase.  
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Figure 6.6 Heart rate at completion of TH60.  
Box and whisker plots show heart rates in the 3 groups at the end of the TH60 phase. Plots 
represent the median (horizontal line), interquartile ranges (box) and range (whiskers). 
*P<0.05 when compared to control and lower dose ALM group.   
 
All animals mounted a relative tachycardia in response to haemorrhage (data not shown). At 
the point of completion of the 60-minute TH phase, despite a similar percentage blood loss 
and blood pressure in the 3 groups, the higher dose ALM group demonstrated significantly 




6.4.3 Left ventricular Systolic Function after Trauma-Haemorrhage 
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Figure 6.7 Left ventricular systolic function after TH60.  
Box and whisker plots show the A. Cardiac output (CO), B. Stroke volume (SV), C. Ejection 
fraction (EF) and D. Fractional shortening (FS) at the completion of TH60 for the 3 groups. 





Echocardiographic assessment was performed at the end of the 60-minute TH period. All 
animals showed a reduction in CO and SV compared to baseline. There was no significant 
difference in CO, SV, EF or FS at TH60 when the 3 groups were compared. LVEDV was 
calculated after 60-minutes of TH and there was no significant difference seen when the 3 
groups were compared (P>0.05) (fig.6.8).  
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Figure 6.8 LVEDV at completion of TH60.  
Box and whisker plots show the calculated LVEDV after 60 minutes of TH for the 3 groups.  
Plots show the median (horizontal line), interquartile ranges (box) and range (whiskers). 
 
6.4.4 Resuscitation 1 Fluid Requirement  
Animals that survived the initial 60-minute TH period underwent echocardiographic 
assessment and were then resuscitated. Echocardiographic assessment of SV was performed 
during resuscitation and resuscitation was deemed ‘complete’ when baseline SV+/- 5µL was 
achieved (or the SV stopped incrementing in response to further fluid boluses). All animals 
positively incremented their SV in response to fluid and target SV was achieved.  
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Animals treated with ALM required significantly less intravenous crystalloid for resuscitation 
(P<0.05) when compared to control animals. Animals treated with higher dose ALM tended 
to require less fluid than the lower dose group but this difference was not statistically 
significant (Fig.6.9).  
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Figure 6.9 Volumes of fluid administered during resuscitation 1.  
Box and whisker plots show the volumes of fluid resuscitation required to achieve SV.  A. 
Shed blood and B. crystalloid administered during the first resuscitation to achieve target SV 
are shown.  Box and whisker plots show median (horizontal line), interquartile ranges (box) 
and range (whiskers). *P<0.05 when controls compared to ALM and high dose ALM.   
 
6.4.5 The left ventricular functional response to ALM resuscitation 
After completion of resuscitation, echocardiography was used to assess LVS function. All 
animals, irrespective of experimental group, showed improvement in CO, SV and LVEDV 
when compared to TH60 outcomes. The left ventricle had filled in response to fluid 
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Figure 6.10 Left ventricular systolic function in response to ALM resuscitation.  
Box and whisker plots show the response of the LV to ALM resuscitation in addition to blood 
and CSL. A. CO, B. SV, C. EF and D. FS after completion of resuscitation 1 are shown. Box 
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Figure 6.11 LVEDV after resuscitation with, and without, ALM.  
Box and whisker plots showing the calculated LVEDV in the 3 groups.  Plots show median 
(horizontal line), interquartile ranges (box) and range (whiskers). 
 
There was no significant difference in the response to fluid in terms of LVS function and 
LVEDV among the 3 groups (figs. 6.10 and 6.11) after completion of resuscitation with 
blood and crystalloid (P>0.05).  
Resuscitation was guided by stroke volume. Table 6.2 below gives the mean and standard 
deviations for SV at baseline and after resuscitation 1 and 2.  
Table 6.2 Stroke volume changes from baseline in response to resuscitation.  
The table gives the figures for stroke volume and how these change in response to fluid 
resuscitation with, and without ALM. Mean values are given along with standard deviations 
in parenthesis. ALMx2= ‘double-dose’ ALM.  
Time-point Stroke Volume (μL) 
Baseline Resuscitation 1 Resuscitation 2  
Control (N=10) 47.07 ± (5.28) 47.87 ± (5.00) 47.87 ± (8.53) 
ALM (N=10)  52.44 ± (5.59) 53.65 ± (5.90) 51.16 ± (5.88) 
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ALM x 2 (N=10) 46.75 ± (3.63) 48.00 ± (3.90) 43.39 ± (4.75) 
 
Resuscitation titrated to baseline SV (as a surrogate for LVEDV and therefore pre-load) was 
therefore achieved in all animals at resuscitation 1. The volume of fluid required however to 
achieve this was highly variable with control animals requiring significantly higher volumes 
compared to the treatment groups (P>0.05) (fig.6.9). 
After completion of SV-directed resuscitation, animals were monitored for 60 minutes with 
no further fluid administration performed. Echo was then performed at the end of this 
monitoring phase (the ‘120-minute’ point) to assess LVS function and assess LVEDV and 
Cardiac index.  
6.4.6 Left ventricular function at 120 minutes 
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Figure 6.12 Left ventricular systolic functional outcomes at 120 minutes.  
Box and whisker plots show A. CO, B. SV, C. EF and D. FS at 120-minutes. Plots show 
median (horizontal line), interquartile ranges (box) and range (whiskers). CO *P<0.05 when 
ALMx2 compared to control and lower dose ALM, **P<0.01 when controls compared to 
ALM and ALMx2. SV *P<0.01 when controls compared to both ALM and ALMx2 groups.  
 
At 120 minutes, CO was significantly higher in treatment animals, at either dose when 
compared to controls (P<0.05). The double-dose (ALMx2) animals also had significantly 
higher CO when compared to the lower dose ALM group (P<0.05) (fig.6.12).  
Stroke volume and LVEDV was significantly lower in the control animals when compared to 
the treatment groups (P<0.05) but there was no difference between the 2 ALM-treated groups 
(fig.6.12 & 6.13).   
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Figure 6.13 LVEDV at 120 minutes.  
Box and whisker plots show calculated LVEDV at 120 minutes in the 3 groups. Plots show 
the median (horizontal line), interquartile ranges (box) and range (whiskers).  *P<0.05 when 
controls were compared to ALM and ALMx2 groups.  
 
6.4.7 Resuscitation 2 fluid requirement 
All animals in each of the groups survived to receive a second resuscitation. Animals in the 
control group required significantly higher volumes of CSL during this resuscitation to reach 
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Figure 6.14 Volumes of crystalloid administered during resuscitation 2.  
Box and whisker plots show the CSL volumes required to achieve target SV in the 3 groups. 
Plots show the median (horizontal line), interquartile ranges (box) and range (whiskers). 
*P<0.01 when controls were compared to both ALM and ALMx2 groups.  
 
After completion of resuscitation (i.e. with the restoration of baseline SV), echo assessment 
was performed in order to assess function. Figure 6.15 gives SV, CO, EF and FS outcomes 
for the groups after resuscitation. There was no significant differences seen when the groups 
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Figure 6.15 Left ventricular systolic functional outcomes after resuscitation 2.  
Box and whisker plots show left ventricular systolic function A. CO, B. SV, C. EF and D. FS 
after completion of the 2nd resuscitation. Plots show median (horizontal line), interquartile 
ranges (box) and range (whiskers). 
 
LVEDV was calculated after completion of fluid resuscitation. There was no difference 
between the groups in terms of LVEDV after resuscitation 2 (fig.6.16).                       
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Figure 6.16 LVEDV after completion of resuscitation 2.  
Box and whisker plots show the calculated LVEDV at the end of resuscitation phase 2 in the 
3 groups. Plots show the median (horizontal line), interquartile ranges (box) and range 
(whiskers).  
 
6.4.8 The relationship between LVEDV and resuscitation 
Due to the need for real-time imaging and technical limitations, SV was employed as a 
surrogate indicator of LVEDV and therefore pre-load. 
Table 6.3 LVEDV changes from baseline in response to resuscitation.  
The table gives the values for calculated LVEDV at different time-points throughout the 3 
hour studies. Mean values are given along with standard deviations in parenthesis. * denotes 
P<0.05 when compared to baseline.  
Time-point Left ventricle end-diastolic volume (μL) 
Baseline Resuscitation 1 Resuscitation 2  
Control (N=10) 76.17 ± (10.15) 73.74 ± (11.85) 66.18 ± (13.62) 
ALM (N=10)  79.89 ±(9.76) 73.31 (±8.37) 67.86 ± (10.07)* 




All animals positively incremented SV at both resuscitation points, however the LVEDV, 
calculated retrospectively, did indeed decrease from baseline levels at both resuscitation 
points (table 6.3).  
There was no significant difference in LVEDV between the groups after resuscitation. There 
was however a trend, across all groups, for the LVEDV to fall and it was lower at 
resuscitation 2 compared to baseline in all groups. The LVEDV at resuscitation 1 was 
significantly lower in the ALMx2 group and was also significantly lower when compared to 
baseline LVEDV in the ALM and ALMx2 groups at resuscitation 2 (P<0.05).  
After completion of a second resuscitation, animals were monitored for a further 60-minute 
period without administration of any further fluid boluses. During this second period of post-
resuscitation monitoring, 4 of the 10 control animals died and therefore did not undergo 
echocardiographic assessment of LVS function at the 180-minute time-point. 1 animal in the 
control group decompensated during the 180-minute scan and died after image acquisition. 
This animal was therefore included in the data analysis for 180-minute LVS function and 
blood was available for end-experiment H-FABP and lactate analysis. It was however classed 









6.4.9 Left ventricular function at 180 Minutes 
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Figure 6.17 Left ventricular systolic function at 180 minutes.  
Box and whisker plots show LVS outcomes at 180 minutes in the 3 groups.  A. CO, B. SV, 
C. EF and D. FS at 180 minutes are all shown. Box and whisker plots show median 
(horizontal line), interquartile ranges (box) and range (whiskers).  *P<0.0001 when controls 
compared to ALM treated groups. SV *P<0.0001 when controls were compared to ALM 




Echo assessment at 180 minutes revealed a significantly lower CO and SV in controls 
compared to the treated animals. EF and FS were similar for the 3 groups (fig.6.17). LVEDV 
was significantly lower in the control animals at 180 minutes (P<0.0001) (fig.6.18).  
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Figure 6.18 LVEDV at 180 minutes.  
Box and whisker plots show calculated LVEDV at 180 minutes in the 3 groups. Plots show 
the median (horizontal line), interquartile ranges (box) and range (whiskers).  *P<0.0001 
















6.4.10 Haemodynamic & temperature trends over the entire study period 
 
                        
Figure 6.19 MABP trends across 180 minutes.  
Line graph shows the MABP trends across the study period of 180 minutes in the 3 groups. 
Dots represent the mean for the group, vertical lines represent standard deviations from the 
mean. *P<0.01 controls versus ALM and ALMx2 groups. N=6 for control group at 180min 
time-point.  
 
Figure 6.19 above illustrates the trend in MABP from baseline to the end of the experiment at 
180 minutes. There was no significant difference between the groups at baseline, TH60 and 
after completion of the resuscitation 1. However, control animals tended to have lower 
MABPs at this point forwards at the 120-minute and 180-minute time-points, the blood 
pressure in these animals was significantly lower when compared to ALM and ALMx2 
groups (P<0.01). The higher dose ALM group animals tended to do the best in terms of blood 
pressure maintenance and stability, but this improvement did not reach significance when 
compared to the lower dose group.  
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Figure 6.20 Heart rate trends across 180 minutes.  
Line graph shows the trends in heart rates across the study period of 180 minutes in the 3 
groups. Markers represent mean cardiac index value at specific time-points. Vertical lines 
represent standard deviations. *P<0.05 ALMx2 versus ALM and controls. N=6 for control 
group at 180 min time-point.  
 
Significantly higher heart rates were recorded for the ALMx2 group at TH 60 (P<0.05) but 
there was no statistically significant difference seen when the groups were compared at any 
time-point over the remainder of the experiment (fig.6.20). As would be expected, heart rates 
were seen to increase relative to baseline in response to haemorrhage. 
Importantly, ALM treated animals, although experiencing a transient, self-limiting 
bradycardia lasting a couple of seconds, in response to the bolus of ALM (data not shown), 
these treated animals did not develop any sustained relative bradycardia when compared to 
controls.  
The temperature of each animal was monitored for the duration of the experiment and 
regulated with the use of heat lamps. Warmed blood and crystalloid was administered at each 
resuscitation point in order to limit the drop in temperature but despite these measures, a drop 
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in temperature was observed at these points. Generally, ALM and ALMx2 treated animals 
were easier to regulate and the control group became relatively hypothermic in the final 60-
minute monitoring phase, and technically required more intensive temperature monitoring 





Figure 6.21 Core temperature trends across 180 minutes.  
Line graph shows temperature trends in the 3 groups over the 180 minute study period. Dots 





6.4.11 Trends in left ventricle function 
LVS functional parameters were collated and line graphs represent the temporal changes in 
CO, SV, EF and FS at baseline and over the course of the experiment.  
CO was significantly different when ALMx2 animals were compared to both controls and the 
lower dose ALM group at 120-minutes (P<0.05) (fig.6.22). CO was significantly lower in the 
control group compared to ALM (at any dose) at 180 minutes (P<0.01). At 180 minutes, 
there was no significant difference between the two treatment groups (P>0.05).  
                    
Figure 6.22 Trends in cardiac output across 180 minutes.  
Line graph shows the trends in CO in response to TH with subsequent resuscitation in the 3 
groups. Dots represent the mean, vertical bars represent standard deviations. *P<0.01 controls 
versus ALM treated (any dose), **P<0.05 ALM versus ALMx2. N=6 for control group at 





                    
Figure 6.23 Trends in stroke volume across 180 minutes.  
Line graph shows the trends in SV in response to TH with subsequent resuscitation in the 3 
groups. Dots represent the mean, vertical bars represent standard deviations. *P<0.01 controls 
versus ALM (at either dose). N=6 for control group at 180 min time-point.  
 
SV was significantly lower in the control group when compared to both ALM groups at 120 
and 180-minute time-points (P<0.01). There was no statistically significant difference 




          
Figure 6.24 Trends in ejection fraction across 180 minutes.  
Line graph shows the trends in EF in response to TH with subsequent resuscitation in the 3 
groups. Dots represent the mean, vertical bars represent standard deviations. N=6 for control 
group at 180 min time-point. 
 
Ejection fraction varied across the course of the 180-minutes but there were no significant 
differences between the groups at any of the time-points analysed (fig.6.24).  
There was no statistically significant difference at any time-point between the 3 groups when 
fractional shortening was analysed over the 180-minute period. 
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Figure 6.25 Trends in fractional shortening across 180 minutes.  
Line graph shows the trends in FS in response to TH with subsequent resuscitation in the 3 
groups. Dots represent the mean, vertical bars represent standard deviations. N=6 for control 
group at 180 min time-point. 
 
Control animals tended to have lower percentage FS from TH60 onwards, but this did not 
reach significance at any of the time-points analysed (fig.6.25).  
LVEDV was calculated using SV and EF. LVEDV was taken as the pre-load to the left 
ventricle and, as expected, fell dramatically in all of the animals as a consequence of 
haemorrhage and rose in response to fluid resuscitation (titrated to SV). LVEDV fell in the 
animals during the 2 post-resuscitation monitoring periods, regardless of group allocation 
however, the LVEDV in the control animals was significantly lower than the ALM and 
ALMx2 groups at 120 and 180 minutes (P<0.05 and P<0.01 respectively). At the end of the 
experiment, the LVEDVs of control animals was approaching that of the TH60 value, despite 




               
Figure 6.26 Trends in LVEDV across 180 minutes.  
Line graph shows the trends in calculated LVEDV in response to TH with subsequent 
resuscitation in the 3 groups. Dots represent the mean, vertical bars represent standard 
deviations. *P<0.05 controls versus ALM (either dose) at 120 minutes, *P<0.01 controls 
versus ALM at 180 minutes. N=6 for control group at 180 min time-point. 
 
6.4.12 Perfusion indices 
Blood lactate was measured at the end of the experiment with blood drawn for terminal 
exsanguination. In animals who were dying before the 180 minute time-point, if blood was 
available, this was withdrawn and analysed prior to death and recorded as ‘end experiment 
lactate’.  
Figure 6.27 shows the end experiment lactate concentrations with the highest being recorded 
in the control group. These levels were significantly higher in the controls when compared to 
the ALM group (P<0.05). Blood was taken and lactate recorded for animals who died before 
the 180 minute time-point in the control group meaning that pre-morbid lactates were 
included in the analysis. These levels were the higher than for survivors at 180 minutes and 
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therefore increased the mean level for the control group. ALMx2 group tended to have lower 
lactate concentrations at 180-minutes, but this was not significant when compared to controls.  
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Figure 6.27 Blood lactate concentrations.  
Box and whisker plots show the blood lactate concentrations at the end of the experiment in 
the 3 groups. Plots show median (horizontal line), interquartile ranges (box) and range 
(whiskers).  *P<0.05 when compared to control group. N=8 for ALMx2 group at the end of 
the experiment due to inability to draw blood via the catheter. N=10 for the ALM and Control 
groups.  
 
Cardiac index was calculated using CO and individual body weight as a way to quantify 
individual animal’s perfusion status relative to body surface area. CI, and by extrapolation, 
peripheral perfusion, was similar at baseline, TH60 and at both resuscitation phases. Only 6 
of the control animals survived to complete the experiment and undergo LVS functional 
assessment and CI analysis. Means and standard deviations are shown in table 6.4 below, 






Table 6.4 Cardiac index changes over time.  
The table gives the calculated cardiac index values for the 3 groups at different time-points.  
N=6 for control group at 180 min time-point. Mean values are given with standard deviations 
in parenthesis.  P values are shown.  
Resus = resuscitation. 
Group Experimental Time-Point 
Baseline TH60 Resus 1 120 
minutes 







































0.2091 0.1772 0.0896 <0.0001 0.3310 <0.0001 
 
Cardiac index was significantly lower in the control group at 120 and 180-minutes when 
compared to the ALM treated animals (at any dosage, P<0.0001). Similarly to the trend seen 
in LVEDV, CI was approaching TH60 levels in the control group at the end of the 
experiment. The CI in ALMx2 animals tended to be highest at these time-points, but this was 
not significantly higher than the lower-dose group animals (P>0.05).  
The results suggest that animals receiving a bolus of ALM, of either dose, during the first 
resuscitation, maintain higher cardiac index levels. In the control group, by the end of the 




                   
Figure 6.28 Cardiac index trends across 180 minutes.  
Line graph shows the trends in calculated cardiac index over 180 minutes and in response to 
TH and subsequent resuscitation. Dots represent mean cardiac index value at specific time-
points. Vertical lines represent standard deviations. * P<0.0001 when controls are compared 
to ALM and ALMx2.  N=6 for control group at 180 min time-point. 
 
In contrast, the ALM treated animals at 180 minutes had at least double the cardiac index 
seen in control mice. ALM treated animals therefore had significantly improved perfusion at 
120 and 180 minutes when compared to controls. This is somewhat supported by the lactate 
data with control animals having significantly higher blood concentrations of lactate at 180 
minutes when compared to treatment groups. However. ALM treated animals still had lactate 
concentrations above the normal range and data for the control group includes lactates 
recorded in non-survivors and these pre-terminal blood lactate levels in non-survivors were 
the highest recorded resulting in an elevated mean value for this group. There was no 
statistically significant difference in the lactate concentrations when lower dose ALM 
treatment was compared to the higher dose treatment group (fig.6.28).  
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6.4.13 Observed cardiac dysfunction 
ECG monitoring was performed while the animals were on the echo scanning platform. ECG 
analysis was performed therefore for the duration of any imaging, and also was prompted 
when there was any unexpected change or unexplained variation in MABP. 5 of the 10 
control animals did not survive the 180-minutes and ECG traces recorded showed evidence 
of atrial fibrillation which was coupled with labile blood pressure before the onset of 
profound hypotension which occurred as a pre-terminal event.  
There were no observed cases of arrhythmia in the lower dose ALM group, however, 4 
animals who received the higher dose preparation had witnessed episodes of arrhythmia with 
accompanying haemodynamic instability. In all cases, this was recorded in the second 60-
minute monitoring phase after resuscitation 2. In 3 out of the 4 animals, this persisted until 








6.4.14 Cardiac Biomarkers 














































Figure 6.29 Serum H-FABP at 180 minutes.  
Box and whisker plots show the serum H-FABP concentrations at the end of the study in the 
3 groups. Plots show median (horizontal line), interquartile ranges (box) and range 
(whiskers). N=8 for the ALMx2 group at the end of the experiment.  
 
Serum H-FABP concentrations were assessed for each animal where blood was available at 
the end of the experiment. In animals that died before the end of the experiment, a sample 
was taken in the agonal phase. This however was not possible in a number (due to low 
MABP and therefore technically unable to draw blood from the carotid catheter). In 2 of the 
ALMx2 animals, the line was not patent at the very end of the experiment and therefore no 
blood could be drawn.  
Mean H-FABP concentrations were 339.81 (±106.72) ng/mL, 313.09 (±109.71) ng/mL and 
273.74 (±97.04) ng/mL in the controls, ALM and ALMx2 groups respectively.  All groups 
demonstrated abnormally high levels of the cardiac specific biomarker. There was a trend for 
the ALM groups to have lower H-FABP concentrations when compared to controls, but this 






                          
Figure 6.30 Kaplan-Meier survival analysis for the ALM studies.  
Kaplan–Meier survival analysis shows the proportion of animals alive at 60, 120 and 180 
minutes in control and ALM (at any dose) treated groups. P=0.01 (Log-rank (Mantel-Cox 
test)). 
 
100% of the treated animals (single and double dose) survived the 3 hours (fig.6.30). 50% of 
the control animals did not survive the 180 minute experimental period and were observed to 
have arrhythmia as a pre-terminal event. 4 of the ALMx2 group developed arrhythmia in the 
final 60 minutes of the experiment, but all survived to undergo final echo assessment and 
terminal blood sampling.  
 
6.4.16 Six-hour studies  
Given the encouraging results of the 3 hour studies with lower dose ALM in terms of 
improved haemodynamics, smaller fluid required for resuscitation and 100% survival, a 
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smaller pilot study was conducted in order to investigate whether the beneficial responses 
persist beyond the 3 hour experimental period. The lower dose regimen was chosen due to the 
better survival outcome compared to that of the double-dose. 5 animals were treated with 
ALM at the lower dose (as previously described), 5 control animals were resuscitated with 
shed blood and crystalloid alone (as outlined above). The methodology was the same as for 
the shorter experiments, apart from the final monitoring period after the second resuscitation, 
which lasted for 4 hours rather than 1. No further fluid boluses were administered during this 
phase as the aim was to determine the trends in MABP, HR and LVS function. H-FABP, 
lactate were also assessed at the end of the experiment as previously described.    
Baseline MABP and LVS functional parameters were similar for treatment and controls at 
baseline and after 60-minutes of TH (data not shown). Mean blood loss was 39.82 ±2.49% 







Figure 6.31 MABP trends across 6 hours.  
Line graph shows MABP trends over the 6-hour experimental period and in response to TH 
with subsequent resuscitation in ALM-treated and control animals. Dots represent the means, 
vertical lines the standard deviation.  
 
Fluid volumes administered, MABP, HR and LVS trends up until 180 minutes mirrored those 
seen in the initial 3-hour studies with significantly less fluid and significantly improved LVS 
function at 180 minutes compared to controls. At the end of the experiment (this referred to 
blood taken immediately prior to death if the animal did not survive), the controls tended to 
have higher lactate concentrations, but this did not reach significance (mean concentrations 




Figure 6.32 Trends in left ventricular systolic function across 6 hours.  
Line graph shows the trends in LV systolic function over 6 hours in response to TH with 
subsequent resuscitation in ALM treated animals. Dots represent the mean, vertical bars 
standard deviation.  
 
The trends in MABP and LV systolic function for the ALM treated animals are given in 
figures 6.31 and 6.32. The trends seen in the 3 hour studies are repeated here up until 180 
minutes. Beyond 3 hours, CO and SV decline before showing a slight increase between 300 
and 360 minutes.  
At the 240 minute time-point, 2 of the control animals had died. Only 1 survived until 300 
minutes, and subsequently died at 330 minutes, 30 minutes before the 6-hour point. No 
control animals therefore survived the entire experiment and all developed arrhythmia as a 
pre-terminal event. The 100% survival rate previously seen in the shorter studies was not 
seen at 6 hours with 1 of the ALM group dying at 280 minutes (fig.6.33).  
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Figure 6.33 Kaplan-Meier survival analysis for the 6 hour studies.  
Kaplan-Meier survival analysis shows the proportion of animals alive at 60,120,180,240,300 
and 360 minutes in the control and ALM treated group. P=0.01 (Log-rank (Mantel-Cox test)). 
N=5 for ALM and control groups.  
 
Blood sampling was performed at the end of the experiment. Serum was analysed, as 
previously described, for H-FABP and concentrations shown in figure 6.33. In the single 
ALM-treated animal that did not survive, no blood could be drawn during the agonal phase 












































Figure 6.34 Serum H-FABP concentrations at 6 hours.  
 Box and whisker plots show serum H-FABP concentrations at the end of the 6 hour studies 
(or at point of death if the animal did not survive). Plots show the median (horizontal line), 
interquartile ranges (box) and range (whiskers). 
 
All animals had elevated H-FABP concentrations at the end of the experiment (fig.6.33), but 
there was no statistically significant difference in the H-FABP levels between the two groups 
(means were 327.06 ± 114.06ng/mL and 270.15 ±144.94ng/mL in controls and ALM animals 
respectively). It is important to note when interpreting these results that the longest a control 
animal survived for was 330 minutes, with the other deaths at 280 minutes (2 mice), 170 and 
140 minutes. Where available, blood was analysed for H-FABP in non-survivors with blood 
taken just prior to death and individual H-FABP concentrations were higher in the control 
animals than the treatment group but this is likely to reflect the severity of the physiological 
derangement pre-mortem. Numerically lower H-FABP levels in the ALM group may not 
therefore reflect a direct protective effect of ALM on cardiomyocytes but rather an indirect 
effect due to improved haemodynamics and / or longer term survival allowing for clearance 





This study supports the findings of previous studies by other groups using haemorrhage-only 
models, with a 100% survival rate seen in the animals treated with a single intravenous dose 
of ALM during resuscitation after shock (Letson et al 2011). 50% of the controls died, the 
earliest occurring before the 120 minute scan. Those control animals who survived the 120-
minutes did so with LV systolic parameters and MABP approaching values seen after the 
initial TH phase, such was the extent of their haemodynamic decline. ALM treated animals 
however survived the 3-hour studies and did so with improved haemodynamic parameters 
when compared to controls. This study has shown that ALM, when used as an adjunct to 
blood and crystalloid resuscitation fluid has efficacy in a rodent model combining trauma 
with severe haemorrhage.  
Baseline MABP, HR and LV systolic functional parameters were similar in controls and 
treatment groups. All animals experienced a similar percentage blood loss during the TH 
phase of the experiment in order to achieve the target MABP of 30-40mmHg.  There was no 
significant difference between the groups in terms of MABP or echo outcomes at completion 
of the TH phase of the experiment. One could reasonably expect therefore, that animals had 
experienced a similar degree of physiological derangement up until this point before 
commencement of resuscitation. However, the ALMx2 animals had a significantly higher HR 
prior to resuscitation. Given the similar degree of blood loss and plane of anaesthesia, the 
reason for this is not immediately clear. This difference was seen before commencement of 
resuscitation and was therefore not related to ALM treatment.  
Resuscitation with crystalloid alone has been previously shown not to fully restore or 
maintain microvascular blood flow or cardiac output (Robinson 1997). Previous chapters of 
this thesis also echo some of these observations. The inclusion of blood in the resuscitation 
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regimen in this study discussed here has also been shown to be inadequate in terms of 
restoring baseline pre-load and haemodynamics and crystalloid was required in all animals in 
order to restore baseline SV and CO.  
There was no significant difference between the groups in terms of the volume of blood 
delivered but there was a striking difference in the volume of crystalloid needed to restore 
SV. ALM-treated animals required significantly less fluid than controls. Control animals 
required up to 3-times more crystalloid. This is an interesting observation as this suggests that 
ALM has an immediate effect upon the haemodynamic status of treatment animals. 
Delivering the ALM as a rapid bolus dose therefore has enabled an appreciation of the 
rapidity of onset of its action.  
The observations here regarding fluid resuscitation volumes support some previous work 
(Letson et al 2011) but some important differences are noted. Letson et al report an upward 
trend in MAP seen in the 60 minutes following ALM treatment in their rat model. They were 
however, investigating NaCl/ALM as an ‘ultra-small’ bolus for early resuscitation after 
haemorrhage alone and as such, they used 7.5% (hypertonic) saline in their studies whereas 
Hartmann’s was the crystalloid used here. The addition of injury in our model also sets into 
motion the cascade of systemic responses to trauma which will contribute to cardiovascular 
dysfunction.  
After completion of the resuscitation phases, a 60-minute period of monitoring was 
undertaken and no further fluid boluses were delivered. This strategy has allowed us to 
appreciate a predictable decline in MABP and LV systolic functional outcomes despite 
previous resuscitation which had restored pre-load. In these studies, ALM-treatment did not 
arrest this decline completely, but the animals treated with ALM, at either dose, did not 
deteriorate as far or as rapidly as controls. MABP, cardiac output and stroke volume were 
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significantly higher in treatment animals at 120 minutes and this was despite significantly 
lower volumes of resuscitation fluid being given to these animals. Ejection fraction and 
fractional shortening were not significantly different when the three groups were compared. 
FS tended to be higher in the ALMx2 group but this did not reach significance.  Given that 
FS is an indicator of myocardial contractility, this finding suggests that ALM was not having 
an impact upon the force of contraction and the heart was not ‘working harder’ as a 
consequence of the drug. This is an important observation as, given what we already know 
regarding cardiomyocyte injury in TH, any therapeutic that caused further ‘stress’ on the 
myocardium may not be favourable in this context. This observation is only speculation 
however as, due to technical limitations, shock index could not be calculated and used as an 
indirect indicator for LV stroke work in this model. Published work using ALM in 
haemorrhagic shock does not include data relating to this aspect of cardiac function so this 
question remains unanswered.  
All animals survived the 60-minute post resuscitation monitoring phase but controls had 
experienced significant cardiovascular deterioration by the 120-minute time-point and were 
in worse physiological condition than the ALM-treated animals upon entering the second 
resuscitation phase. Control animals required significantly higher volumes of crystalloid in 
order to restore SV at this point. Although not significant, ALM-treated animals required 
even less fluid than they did in the first resuscitation and ALM high dose animals required the 
smallest volumes. This reflects the improved SV of the ALM treated animals at the time of 
reaching 120 minutes; less fluid was required to push this up to baseline levels again.  
This second resuscitation was again targeted to the baseline SV. The rationale for this 
decision was that SV provided a rapidly assessable surrogate for LVEDV and the aim was to 
restore pre-load. At both resuscitation points, SV was successfully restored to within target 
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range to all animals. However, when LVEDV was later calculated, it was found to fall at each 
resuscitation point, in each group, despite restoration of the SV to within the target range.  
The decline in LVEDV was not significant when baseline was compared to resuscitation 2 in 
the control group but there was a significant drop from baseline in the ALM and ALMx2 
groups and it is also interesting to note that in the higher dosage group, the fall in LVEDV 
between baseline and resuscitation 1 was significant whereas the fall in LVEDV in the single-
dose group did not reach significance until the baseline and resuscitation 2 values were 
compared. 
It is possible that ALM has an impact upon the pre-load conditions of the heart, independent 
of the volaemic status of the animal, which has been shown to be improved with ALM 
treatment at either dose. Cardiac output and index was improved in the treatment animals and 
it may be the case therefore, that peripheral perfusion was improved and a lower LVEDV 
reflects improved micro-circulation in the periphery rather than a truly reduced intravascular 
volume and LVEDV in the case of the ALM treated animals. This may also be supported by 
the temperature trend data with treated animals appearing to maintain thermoregulatory 
capability and maintain stable temperature whereas controls were less able to maintain 
temperature in the latter stages of the experiment and were more dependent upon external 
heat sources. Metabolic acidosis (reflected by higher lactates in the control animals) is known 
to instigate a peripheral vasodilatation in decompensated shock (Levick). Control animals 
therefore may have entered the decompensation phase with peripheral vasodilatation feeding 
into a fatal spiral of falling central pressures and this was the reason for the drop in LVEDV 
in this group.  
Isoflurane was titrated against response to MABP and stimuli throughout the experiments 
(data not shown). Control animals required lower levels of isoflurane and in the final 60-
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minutes, many were receiving only 0.5%. In comparison, ALM animals often required the 
dose to be increased (above 1.5% in some cases) in the final 60 minutes as they showed signs 
of regaining consciousness. This observation may reflect improved cerebral perfusion in the 
treatment-groups at this late stage but this is of course difficult to quantify with accuracy. It 
can also be suggested that ALM has a direct action on the CNS. Adenosine and lignocaine 
have been previously shown to cross the blood brain barrier (Partridge 1994, Dobson 2016). 
Although an interesting observation, any further comment on this however is beyond the 
limitations of this study.  
Arrhythmia was seen in control animals as a pre-terminal event. Arrhythmia was however 
also seen in the ALM animals, but only in those receiving higher dose treatment. 4 of the 10 
ALMx2 animals developed an arrhythmia in the final 60 minutes of the experiment and this 
was not in the context of a sudden decline in MABP (although the MABP was noted to 
become labile in these animals with arrhythmia onset). The development of arrhythmia in 
these animals differed from the controls as the onset did not appear to be related to 
physiological extremis, in fact the animals had been stable with satisfactory blood pressure 
prior to onset.  
The higher lactate levels seen in the ALMx2 animals, although not significant, may possibly 
reflect the haemodynamic instability associated with the onset of arrhythmia which was 
intermittent but persisted for the remainder of the experiment in these animals.  
A possible explanation lies with the doubling of the lignocaine dose in this group as the drug 
is known to induce arrhythmia at toxic levels (Brown 1980). Magnesium is known to stabilise 
the myocyte membranes. Adenosine has been used to prevent the development of arrhythmia, 
in a variety of settings across a range of doses in the literature but its role in the development 
of the arrhythmias seen in these studies is unclear.  
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As demonstrated in the previous chapters of this thesis, HFABP is elevated after 60-minutes 
of trauma-haemorrhage and the biomarker is a well characterised marker of myocyte 
ischaemia and necrosis. Other studies have demonstrated that adenosine has the ability reduce 
the extent of necrosis in regional ischaemia (Canyon et al 2004) and troponin levels post 
cardiac surgery in clinical trials when adenosine-lignocaine cardioplegia (Jin et al 2008). In 
our model, myocardial injury has been demonstrated with HFABP rise as a consequence of 
TH. In chapter 5, resuscitated 2 hour models demonstrated HFABP levels of a similar 
magnitude seen here at 3 hours. It is encouraging that the biomarker levels do not rise in 
response to ALM treatment and, although not significant, levels tended to be lower in ALM 
treated mice (the limited numbers having HFABP analysed for the reasons given earlier, 
means that there may be a power issue when interpreting this data). This may be seen as 
evidence for a reduction in the ongoing myocyte injury suggested in previous chapters, but it 
could also be related to improved renal perfusion pressures as a consequence of enhanced CO 
in the treatment groups. HFABP is renally excreted and therefore the lower levels may reflect 
improved renal perfusion and excretion of the molecule after its initial release during the TH 
phase.   
 
6-hour experiments 
The principle aim for conducting these longer experiments was to assess the feasibility of 
performing longer studies and to investigate whether the beneficial haemodynamic effect and 
survival outcomes previously seen with ALM treatment persisted.  
Statistical analysis is limited due to the small numbers used in this study. This was a study 
designed to gain a better understanding of the longer-term consequences of using a single 
bolus of ALM. Initially an N of 10 for each group was planned but logistical reasons meant 
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that greater numbers were not achievable within the time available. However, the limited 
results are useful and provide some informative data regarding survival and longer-term 
functional outcomes and this data has therefore been included here.  
The animals did not show any significant differences in terms of baseline MABP, HR or LVS 
function. They were haemorrhaged to a similar extent. Trends in fluid requirement, MABP, 
temperature and LVS function were similar to those in the 3-hour studies at the 3 hour time-
point. In the 3 hours beyond the 3 hour time-point, the gradual decline in MABP continued in 
controls and ALM group. CO and SV declined past the 180 minute point but in the final 60 
minutes of the experiment appeared to plateau and then a slight increase in these parameters 
was seen. EF and FS also show little change in the final 60 minutes.  
At the 360 minute time-point, the MABP for the 4 survivors was 53.25 ± 9.52mmHg. No 
control animals survived the 6 hours and 1 ALM treated animal died at 280 minutes. The 
small number of controls surviving beyond 180 minutes makes comparison difficult and 
would require a larger study. The practical considerations of running these 6 hour 
experiments make them incredibly time-consuming and challenging. Previous rodent H 
models with ALM treatment have not continued as long as 6 hours and therefore, although 
limited by small group size,  this study has provided some additional insights into the longer 




This is a complex, technically challenging model involving multiple phases which subjects 
animals to extreme physiological derangement. There are some notable limitations regarding 
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the design and practical aspects of this study. Limitations relating to species and method of 
haemorrhage have been discussed in previous chapters.  
ALM has been identified as novel therapeutic agent for the acute management of the shocked 
patient. In these studies, bleeding had been arrested by the time of ALM administration. It is 
not possible therefore to comment on its efficacy in a situation of on-going bleeding.  
Mice have a limited circulating volume and this limits the investigations that can be 
performed, particularly in a model with a 40% blood loss. Further blood taking can lead to 
death due to the precarious haemodynamic state of the animal. Temporal patterns of cardiac 
biomarkers such as H-FABP may have addressed some of the questions raised in this study, 
but blood volume is a limiting factor. Blood analysis of the drug doses may have helped to 
investigate the cause for arrhythmias in the double dose group but again, blood volume is 
prohibitive.  
A major limitation of the 6 hour studies is that these are underpowered, reflecting logistical 
issues which arose. The aim was to gauge the longer-term response to ALM and therefore the 
data from these studies is of interest but must be interpreted cautiously.  
 
6.7 Conclusions 
ALM has been shown to be beneficial when used as an adjunct to blood and crystalloid 
resuscitation after 60 minutes of TH. There is also some limited evidence for a dose-
dependent response. This study used a bolus rather than infusion but despite the short half-
life of adenosine in particular, we have seen lasting effects in terms of improved 
haemodynamics and LV systolic outcomes.  
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Single agent studies would be of value in determining additive / synergistic contributions of 
the three drugs. A single agent study may also help identify the cause of the arrhythmia seen 
in the high dose group; this being a major limitation to the use of the combination drug at this 
dose.     
The mechanisms of action of ALM are still unclear but they are likely to be multiple and to 
include cardio-specific and systemic pathways. An advantage of having this model 
established in mice is that it would allow for the use of genetically-modified strains with 
which to further our understanding of the actions of adenosine in particular. For example, the 
availability of adenosine receptor knock-out strains may yield insights into the pathways 
involved in protective effects of ALM in TISCI.  
This is the first time this combination drug has been used in the context of both trauma and 
haemorrhage. Studies in rats and pigs have been in the context of haemorrhagic shock 
without concomitant injury and therefore, lack the sequelae of combined TH.  
These studies are also, to the best of my knowledge, the first example of echocardiography 













7.1 Summary of Project Findings 
The aims of this project, as laid out in chapter one, were all met. The movement from 
“bedside-to –bench” to validate H-FABP as a marker of TISCI in our previous model of TH 
was successful. H-FABP was detected at significant concentrations as early as 60-minutes 
after trauma haemorrhage, in a time frame and magnitude that supports the clinical data. This 
research has also, for the first time, demonstrated the dose-dependent nature of the cardiac-
specific biomarker rise in response to different severities of trauma + / or haemorrhage. The 
validation of the use of H-FABP as a biomarker of TISCI in the murine model was an 
important first step in this project as it confirmed established cardiomyocyte injury after 60-
minutes, before going on to investigate the functional implications of this injury.  
 
Chapter four demonstrated the successful application of non-invasive micro-imaging to 
characterise the functional systolic response of the left ventricle to TH. The novel use of this 
modality in a small animal model of trauma-haemorrhage has yielded insights into the LV 
performance in the acute phase after injury and blood loss and highlighted the dramatic 
reduction in cardiac output and stroke volume seen in response to severe blood loss. This 
emphasises the precarious state of the haemodynamic system at this point and helps to clarify 
why H-FABP levels are significantly raised at 60-minutes. Severely reduced cardiac output 
coupled with elevated heart rate will compromise filling of the coronary circulation during a 
shortened diastole. The left ventricular myocardium however is subject to increased 
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physiological demands however and the elevated H-FABP levels are likely to represent the 
resultant cardiomyocyte ischaemia. The H-FABP levels seen after 60-minutes of MABP of 
30-40mmHg in chapters three and four are similar and therefore support that this is a 
reproducible model which demonstrates a H-FABP rise comparable to that seen in the 
clinical studies.  
The model of TH presented here includes a severe form of haemorrhage which was fatal in 
some cases and associated with a mortality of approximately 25% during the initial 60-
minute TH period. The mortality rate increased with time and the 3-hour studies in chapter 
six were associated with 50% mortality in non-ALM treated animals that had survived to 
receive resuscitation fluid.  
A resuscitation model was developed so that the effects of the initial 60-minutes of severe TH 
could be assessed in the longer-term and the functional response of the myocardium, 
previously shown to have developed TISCI, could be assessed. In order to limit 
cardiomyocyte injury resulting from ‘under-resuscitation’, a decision was made to utilise the 
in-vivo imaging system to ensure ‘adequate’ re-filling of the left ventricle. Using this 
approach ensured that cardiac injury, and associated elevations in H-FABP concentration, 
was predominantly a consequence of the initial 60-minute insult and not due to either under 
or overfilling of the ventricle. A comparison of SV-guided and MABP-guided resuscitation 
was therefore conducted.   
 
Additional intravascular catheters, the need to transfer the animals and the repeated use of 
scanning made for a complex, technically challenging model. Echocardiographic assessment 
of the filling status of the LV was used as a targeted end-point of resuscitation and to 
facilitate restoration of adequate, pre-load. Comparison of two resuscitation strategies 
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usefully demonstrated the relative inadequacy (in terms of LV volumetric status) of 
resuscitation targeted to MABP. Many of the contemporary models address the need for more 
fluid resuscitation relative to blood loss, but this project highlights, in more precise 
physiological terms, the potential pitfalls of using a less direct marker of intravascular 
volumetric filling status. The techniques used in these studies were robust and reproducible 
and trends in haemodynamic decline were predictable in animals resuscitated by either 
means.  
 
The data presented here supports that of other researchers who have identified the 
development of an acute cardiac injury associated with cardiovascular dysfunction after THS 
(Hsieh et al 2006, Kuebler et al 2003, Kapoor et al, 1997). Having identified this 
consequence of TH, there has been an acknowledgement that therapeutic agents need to be 
identified which could treat TISCI.  
 
The results of the ALM studies presented in chapter six are very exciting in that regard. The 
hypothesis was that the use of this drug, as an adjunct to fluid resuscitation, would improve 
haemodynamic stability after TH as suggested by previous authors (Dobson et al 2016, 
Granfeldt et al 2014). These studies were the first to use this combination drug in a mouse 
model of haemorrhage and trauma, and the assessment of the LVS response by means of echo 
added a functional assessment to the haemodynamic, lactate and biomarker data. ALM, used 
at 2 different doses as a single bolus, was shown to confer haemodynamic stability as well as 
a survival benefit (also demonstrated in 2011 by Letson and Dobson with the rat haemorrhage 
model) at 3 and 6 hours. Together, these studies have shown that ALM has great potential as 
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a treatment for haemodynamic instability which was shown to be associated with biomarker 
proven TISCI in this mouse model.   
 
7.2 Limitations and Strengths of the Project 
 
7.2.1 Limitations of the project 
Some limitations have discussed in the previous chapters and here I will summarise the 
general limitations that need to be considered and also discuss study specific limitations 
relating to specific methodologies used.   
Technical limitations 
There are significant challenges associated with the use of a small animal such as a mouse for 
studies of this nature. This may also go some way to explaining the predominance of rat 
models within the contemporary literature.  
Vessel cannulation is difficult and time consuming, especially in the early stages of mastering 
the techniques. Despite steps taken to prevent lumen occlusion, blockage of lines in some 
cases resulted in a lack of blood available for lactate and biomarker analysis at the end of the 
experiment. Despite this, cardiac and haemodynamic assessment is still valid in these animals 
and the decision was made to include this data despite a lack in accompanying blood results 
in a small number of cases.  
A fixed-pressure haemorrhage protocol was used in all of the studies presented here. This is 
currently the only practical way to induce haemorrhagic shock in mice due to their size. Steps 
were taken to attempt to keep the rate of onset and the depth of shock the same for all animals 
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but, as has been demonstrated by these studies, markers of impaired perfusion status, such as 
lactate, were variable amongst animals in the same experimental group. This may indicate 
that the severity of shock was not identical in each animal in a particular group. Some may 
have been bled more quickly in the first few minutes for example leading to a more rapid 
onset of shock.  
Small animals only possess small blood volumes and this has obvious implications for the 
number of samples that can be taken and often precludes repeated sampling in the same 
animal due to resultant haemodynamic instability. Analysis of H-FABP, for example, would 
have been useful at different points in the same experiment but the volumes of blood required 
to generate enough serum for the assay made this impossible.  
Young, male mice were used for all of the studies. This therefore limits the translational 
potential when considering older trauma patients and those with pre-existing cardiovascular 
disease – an important and clinically very challenging patient group.  
Limitations of the echocardiography studies.  
With the appropriate training, echocardiography is rapid and reproducible. Imaging the left 
ventricle in a haemorrhaged animal however is more difficult due to the profound loss of 
volume from the LV and the tachycardia that results from haemorrhage. This is therefore not 
a straightforward undertaking in this model and acquisition of images and the derived LV 
outcomes are difficult and subject to a potential loss of accuracy when placing callipers on 
the M mode images. A second investigator with considerable experience in micro-imaging 
conducted all of the scans for these studies in an attempt to limit inaccuracy and to avoid 
inter-observer bias. Three sets of measurements were taken at each point and the mean of 
these calculated to improve accuracy.  
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Performing the imaging required transfer of the animal and in a couple of instances, lines 
became dislodged resulting in exsangination if the carotid catheter was lost, or inability to 
resuscitate according to protocol if the jugular line became misplaced. Due to loss of lines in 
this way in the first experiments, additional anchoring sutures were placed to prevent this and 
a small transfer ‘scoop’ was made which facilitated transfer of the animal to the scanner after 
surgery and line insertion. These measures led to a reduction in the number of lines dislodged 
in subsequent experiments.  
Limitations of the resuscitation studies. 
Stroke volume was used as a surrogate for LVEDV due to practical considerations. Real-time 
calculation of the LVEDV was not possible with the scanner used and therefore SV served as 
a rapid way to determine filling status during resuscitation. This has limitations however as 
SV doesn’t necessarily directly reflect the volumetric status of the LV alone and subject to 
other influences.  
Shed, and therefore whole, blood was used to resuscitate animals during the first resuscitation 
phase. If a second resuscitation was included, this was by means of administration of 
Hartmann’s, a crystalloid solution. Such a resuscitation strategy has considerable differences 
when compared to clinical approaches. There is no possibility of transfusing individual 
components such as packed red cells in studies of this kind, reinfusion of the shed blood 
meant that there was no further blood available at the next resuscitation point. This is a 
potential drawback in the use of mouse models in THS research generally.  
Limitations of the ALM studies. 
The addition of ALM to resuscitation fluid has been shown in this project to have benefits 
related to haemodynamic outcomes, fluid requirements and survival. This project has not 
elucidated the mechanisms responsible for these findings and one can only speculate.  
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This model is not one of on-going bleeding and no further blood was drawn after the initial 
60 minute TH phase. This means that although the benefits of ALM are convincing in this 
model, it is in the absence of on-going haemorrhage.   
In the course of this project, I have developed a robust, reproducible small animal model of 
biomarker-proven TISCI. The contemporary pre-clinical models of trauma-haemorrhage 
were reviewed and drawn upon in order to develop a model capable of addressing questions 
regarding TISCI and cardiac dysfunction.  
The model is incredibly complex involves both trauma and severe haemorrhage.  The 
combination of injury with haemorrhage was important in terms of improving the 
translational potential of the model.  TISCI has been demonstrated clinically to be associated 
with haemorrhage and trauma of high severity. The addition of injury to haemorrhage will 
instigate inflammation and therefore is more likely to represent the clinical scenario however, 
the chapter three studies demonstrated that H-FABP was elevated above normal in the mice 
subjected to haemorrhage alone. The use of a haemorrhage only murine model therefore may 
still represent the clinical condition and would likely prove less technically challenging and 
would also allow for a recovery model to be more easily developed. Echocardiography could 
then potentially be performed in the days and even weeks following haemorrhagic shock in 
order to monitor for the development of overt cardiac dysfunction after resuscitated 
haemorrhagic shock. More work on this haemorrhage only model of TISCI is therefore 
warranted.  
Rodent models of trauma and haemorrhage are challenging. This project has demonstrated 
that the challenges are not insurmountable however and there is still a role for these models in 




7.2.2 Strengths of the Project 
Trauma is a complex, multifactorial disease and therefore the development of robust, 
translatable animal models is a significant challenge.  
The centre for trauma sciences have previously used a mouse model of trauma haemorrhage 
to investigate conditions such as acute traumatic coagulopathy (Frith et al 2010). This project 
has therefore benefitted from the availability of a previously validated murine model of injury 
and haemorrhage in which to conduct these studies and I was trained by co-workers with 
significant expertise in the field of pre-clinical research and trauma research in particular.  
Considering that haemodynamic function was to be assessed in this project, close attention 
was paid to the design of the model, for example, inhaled isoflurane was selected as the 
anaesthetic agent due to ease of titration, rapid elimination and the fact that it is one of the 
least cardio-depressive agents amongst the variety available for pre-clinical work. A degree 
of hypotension was inevitable with anaesthesia, but isoflurane was used in an attempt to limit 
this and therefore minimise the impact of anaesthesia on cardiovascular function.  
This project has, for the first time, demonstrated a dose dependent rise in H-FABP with 
increasing severity of trauma-haemorrhage. The magnitude of the biomarker rise is similar to 
that seen in clinical studies at 1 hour making H-FABP a valid biomarker of TISCI in this 
animal model. The studies in chapter three were important as establishing the presence and 
magnitude of this biomarker rise was vital in determining that cardiac injury was present 
within the model at the degree of haemorrhagic shock induced, before proceeding to assess 
haemodynamic outcomes in the hours after injury onset.  
This project took the existing mouse TH model and developed it to include venous 
cannulation and a resuscitation phase and in vivo myocardial imaging. A sophisticated model 
has therefore been developed which is complex yet benefits from good reproducibility. The 
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ability to image the left ventricle in real-time has allowed for multiple images to be acquired 
at different experimental time-points with resuscitation tailored to the individual animal 
rather than a ‘one-size fits all’ approach to fluid resuscitation. Mice do not require ventilation 
and as such, effects of positive pressure ventilation on cardiac blood flow and function were 
not an issue in this model.  
A second investigator with considerable in-vivo imaging expertise carried out the 
echocardiographic assessment of the LV. There was therefore no potential for inter-observer 
variability. His expertise also allowed for rapid, reproducible assessment of the left ventricle 
meaning that animals weren’t subjected to lengthy scan times and frequent re-positioning. 
This investigator was not involved in the surgery and haemorrhage aspect of the studies and 
was therefore not generally aware of the blood pressure prior to performing the imaging. In 
some cases, if the animal was particularly unstable prior to transferring to the scan bed for 
example, it was necessary to discuss this but this was the case in only a minority of the severe 
haemorrhage animals.  
Echocardiography is of huge clinical relevance and the ability to quantitatively assess the left 
ventricle under TH conditions makes this project highly translatable and relevant. As 
previously discussed, ultrasound imaging is cheap, reproducible and already used in the 
resuscitation bay as an adjunct to resuscitation. It is portable and images of the heart can be 
acquired quickly without the need to transfer unstable patients for more lengthy cardiac 
imaging studies. These features make echocardiography, as applied in this project, a realistic 
and attractive option for future clinical studies of TISCI. Echocardiography is a frequently 
used clinical imaging modality. It is already used in the resuscitation bay and there is some 
suggestion that its use should be broadened and it could have utility in volumetric assessment 
of trauma patients and used to assist in fluid resuscitation. This project has demonstrated the 
disparity between MABP and LV volumetric status as markers of the ‘adequacy’ of fluid 
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administration and therefore, could also support the argument for a role for echocardiography 
in guiding resuscitation of shocked trauma patients.  
Mouse models are ideal for mechanistic studies and are widely used in cardiovascular 
research. The creation of this TH model serves as a great platform for future studies. Using 
genetically modified mouse strains in this setting could address outstanding questions 
regarding the inflammatory aspects of TISCI development and may be useful in determining 
the mechanisms underlying the cardio-protective effects of ALM therapy that have been 
reported here. The techniques and protocols used for this project could also easily be adapted 
for a rat model of TH in which to assess myocardial function. This may have additional 
benefits including higher blood volume available for more frequent testing and the 
opportunity to catheterise the urinary bladder for urine output assessment. 
This project is the first to demonstrate the haemodynamic and survival benefits of ALM in a 
mouse model of trauma with haemorrhagic shock. The use of echocardiography to assess LV 
function before, during and after ALM therapy is another strength of this project. There is a 
real need to identify therapeutics for use in trauma patients in both the civilian and military 
settings. The findings of this project lend support to the use of this drug combination to 
maintain haemodynamic function, reduce the need for high-volume fluid resuscitation and 
favour survival in a setting where there has been blood loss resulting in hypotension with 
severe decline of LV function and a dramatic fall in cardiac index. The decision was made to 
deliver the ALM bolus after reinfusion of shed blood and this was taken in order to optimise 
the translational potential of these studies as any therapeutic delivered clinically is likely to 
be administered after initial blood product based resuscitation. The findings of this project 
regarding the haemodynamic benefits of ALM are incredibly exciting as this project has 
identified a drug which is potentially life-saving and warrants further attention in clinical 






7.3 Future Work 
The development of this model offers exciting opportunities for further research into TISCI. 
The sophisticated model, combining bony and soft tissue injury, pressure-controlled 
haemorrhagic shock, blood and crystalloid resuscitation and in vivo cardiac imaging, 
represents a complex, but achievable, pre-clinical platform in which to advance our 
knowledge of the pathophysiology of TISCI.  
This project has addressed some of the functional questions surrounding TISCI but there are 
opportunities to further our knowledge. For example, this project has not included an 
assessment of the contribution of inflammation to the development of TISCI and this is an 
incredible important aspect in the development of cardiac complications after TH and as 
such, has been the focus of work by many research teams. The methodology described in 
these studies however, could be applied to knock-out mice to investigate the roles of specific 
immune signalling pathways in the development of, or protection from TISCI. The use of 
knock-out mice in such studies however would not be without its own limitations. One of the 
most important, but frequently overlooked, considerations relates to the persistence of regions 
of genetic material neighbouring the ‘knock-out’ gene. These “flanking regions” can be 
transferred onto the selected genetic background and have implications for observed 
phenotype. Knock-out mice may also have differences that have not been specifically 
selected for such as altered motor function and behavioural changes (Eisener-Dorman et al 
2009).  
As more sophisticated imaging techniques and miniaturisation become available, these could 
add a fresh perspective to pre-clinical TISCI research. More advanced ultrasound imaging 
could provide a more accurate quantitative determination of myocardial contractility in 
response to TH and resuscitation. For example, speckle-tracking (or ‘myocardial deformation 
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imaging’) echocardiography is a more recently developed technique allowing for direct 
quantification of myocardial contractile function rather than relying on the LVEF which 
provides an indirect estimate. This technique ‘tracks’ changes in myocardial segment length 
and the rate at which this is occurring. It can therefore detect more subtle changes in 
contractile function compared to older techniques (Bansal & Kasliwal, 2013).  
Nuclear imaging modalities such as cardiac single-photon emission computed tomography 
(SPECT) could also be employed to characterise perfusion and metabolic demands of the left 
ventricle in THS. Left ventricular pressure-transducer catheters (used in some rat models of 
THS) are available for murine work and this could also be explored as a method of assessing 
LV systolic function in mouse studies.  
Although ALM has shown promise in these studies to slow the rate of haemodynamic decline 
and prevent early mortality, the precise mechanisms of action remain unclear. Again, 
genetically-modified mice with adenosine receptor mutations may provide a way of 
investigating its action further, as would the use of this model with receptor agonists / 
antagonists.  
TISCI in this project has been modelled in young, male mice, presumed to be free from 
cardiovascular disease. As more research is carried out relating to older trauma patients, and 
those with pre-existing cardiac disease, the strain of mouse selected could be tailored in order 
to address questions about the pathophysiology of TISCI in older people with pre-existing 
vascular disease, and the efficacy of novel therapeutics in this case. 
Clinical studies of TISCI have identified biomarker rises in TH patients which are associated 
with the development of ACE (De’Ath et al 2013, Naganathar et al 2015). There is still much 
to learn regarding the long term cardiac outcomes in TH survivors and clinical studies are 
needed to investigate the longer term impact of TISCI. For example, do survivors with high 
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admission H-FABP levels have a higher risk for ACE in the longer term? Should we be 
monitoring survivors in the months / years after discharge for the onset of a ‘trauma-related 
cardiomyopathy’? Would follow-up echocardiography identify structural and / or functional 
changes beyond discharge? These are the type of questions that could usefully be addressed 
with clinical studies in the future. 
There is a need for therapeutic agents which can be used clinically to prevent death and limit 
the organ dysfunction resulting from major trauma. The work presented in this thesis has 
identified a therapeutic agent which shows efficacy in trauma with haemorrhagic shock in the 
pre-clinical model. The use of ALM as an adjunct to fluid resuscitation has shown dramatic 
effects on survival, fluid requirement and haemodynamics. A clinical study is therefore 












This thesis has successfully completed all of the study aims. It has demonstrated, for the first 
time, a dose-dependent cardiac-specific biomarker rise with increasing severity of injury in 
the murine model of THS, on a magnitude similar to that reported in clinical studies of 
TISCI. The use of echocardiography has provided important insights into in vivo myocardial 
function in the minutes and hours after trauma-haemorrhage with cardiac injury.  
The development of a robust resuscitated model of TISCI has enabled us to perform longer 
studies in which to observe changes in cardiac function up to 6 hours after haemorrhage and 
also to investigate the functional implications of 60-minutes of TH followed by restoration of 
volume to the left ventricle. Trends in haemodynamic decline and myocardial functional 
outcomes after TH with, and without resuscitation, have been identified.  The project also 
highlights the impact of resuscitation guided by MABP which resulted in persistent relative 
hypovolaemia of the left ventricle when compared to the individual’s baseline conditions and 
the SV-guided resuscitation approach. 
Improved haemodynamic outcomes and survival were seen with the addition of ALM to 
resuscitation fluid. ALM has therefore been shown here to have great promise as a 
cardiovascular rescue agent after acute injury and blood loss and consideration should be 
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